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Abstract  
Treatment of Crohn's disease (CD) is challenging. The use of enteral nutrition 
(EN) as primary therapy in adult patients with CD is not yet supported by high quality 
evidence. The fat composition of EN has been suggested to be a key factor in 
controlling the inflammation in CD. Moreover, deep understanding of disease 
pathogenesis is lacking. In CD, the mesentery attached to the inflamed intestine is 
often focally thickened: the phenomenon known as “fat-wrapping”, but the reasons 
for this are unknown. Additionally, the alteration in tissue remodelling of intestinal 
epithelium by high fat intake is a newly suggested cellular mechanism for intestinal 
diseases. It is predicted that improved patient outcomes will come from novel 
nutritional therapies resulting from an improved understanding of the disease 
pathogenesis.  
The aims of my PhD research were to investigate novel mechanisms of action 
of dietary fatty acids in CD patients’ mesenteric pre-adipocytes and epithelial cells 
which could benefit the development of optimized lipid formulation of enteral feeds.  
 
Here, in a systematic review of previous clinical trials in CD, we demonstrated 
that high remission rate is significantly associated with the intake of exclusive enteral 
nutrition (EEN) feeds that have a high n-6:n-3 ratio. The amount of medium chain 
triglyceride (MCT) in the feeds was also positively correlated with the remission rate 
but without statistical significance. lower remission rates were non-significantly 
associated with higher intakes of feeds enriched with long chain triglycerides (LCTs) 
or monounsaturated fatty acids (MUFA). 
 
In CD mesenteric adipose tissue (MAT) I have identified several abnormalities 
in their gene expression profile. Unlike typical adipose tissue, MAT in CD was 
associated with defective adipogenesis via reduced expression of leptin and CEBPa, 
and was associated with a low anti-inflammatory profile via decreased expression of 
M2 macrophage markers. Moreover, in in-vitro study I showed that mesenteric pre-
adipocytes have an increased adipogenic response to oleic acid, linoleic acid, and a-
linolenic acid, which was predominantly modulated via CEBPa. Finally, in cell 
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culture study I have shown that low concentration of lipids can modulate the 
physiology of the gut epithelium by reducing colonic crypt proliferation. 
In conclusion, my data indicate that the fatty acid composition of EEN can 
play a key role in improving clinical outcomes in CD. According to my findings, the 
mechanism of this action can be mediated via MAT function and possibly through 
intestinal stem cell function. Overall, the findings of this PhD research provide 
important insights into a new mechanism of action which can be exploited to target 
future therapeutic approaches in CD and to help optimize the lipid formulation of 
enteral feeds used in its treatment. 
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1 Chapter 1. Introduction: Crohn’s disease, therapeutic lipids, the 
fat-wrapping phenomenon, and intestinal epithelium healing 
 
 
1.1 Background of Crohn’s disease 
CD is a chronic inflammatory bowel disease (IBD). Unlike ulcerative colitis 
(UC), CD can affect any segment of the gastrointestinal tract (GIT) from mouth to 
anus, and usually in a discontinuous and transmural pattern of inflammation, affecting 
all layers of the gut from mucosa to serosa. Therefore, the disease is associated with 
the development of fistula and intestinal perforation. The terminal ileum and colon are 
typically affected in CD. Patients with CD usually experience unpredictable events of 
relapse and remission. Thus, the main goal of disease management is to induce clinical 
remission and to maintain it using drug therapy. However, when the disease becomes 
complicated and drug resistance develops, most CD patients will require surgical 
intervention. The prevalence of CD varies across the world. The incidence rate is 
greater in the north and west of Europe and North America, while it is low in Asia, 
Africa, and South America (Hart and Ng, 2015). CD can present at any stage of life, 
but is usually diagnosed between the age of 10 and 40 years (Hart and Ng, 2015). 
However, the number of cases is currently increasing, particularly in younger and non-
western populations.  
Until recently, CD was considered to be an idiopathic disorder. However, it is 
now believed that CD may be caused by a combination of genetic and environmental 
factors. The role of different risk factors in modulating the chronic inflammatory 
response of CD is complex, and there are gaps in the existing knowledge of disease 
aetiology and pathogenesis. Future medical therapies targeting new plausible 
mechanisms are currently under investigation. 
1.2 Epidemiology 
CD incidence varies according to geographical location. Generally, the 
incidence rate of the disease is high in North America, northern regions of Europe, 
and United Kingdom (Vind et al., 2006, Yapp et al., 2000, Loftus Jr et al., 1998). 
Nevertheless, the incidence and prevalence rate of CD have changed over the last 
decades; it started to increase not only in the western countries but also in eastern 
countries like Japan, Hong Kong, and Korea (Thia et al., 2008). Epidemiological 
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studies across eight countries in Asia and Australia found that the incidence of CD 
was 0.54 per 100,000 individuals which is significantly lower than in western 
countries (Ng et al., 2013). The disease is still considered uncommon in African and 
South American countries, however, recent studies suggest a rising number of new 
cases in these regions (Archampong and Nkrumah, 2013, Ukwenya et al., 2011). An 
increasing number of CD cases have been reported in Saudi Arabia, with similar 
morbidity as in the western countries (Al-Mofarreh and Al-Mofleh, 2013). 
Furthermore, the role of environmental risk factors in increasing the incidence of CD 
is supported by studies on migrants, which aim to monitor disease incidence and 
behavior in migrant populations and their offspring, during their transition from 
developing countries to developed countries. Data from studies in Sweden suggested 
that the incidence of the disease in migrants coming from West or South Asia 
increased in second generation migrants while it was low in first generation migrants 
(Li et al., 2011). While another Canadian study comparing the incidence of the disease 
between migrants and their Canadian-born children, with the Canadian population 
found that the lower the age of migrants coming to Canada, the higher the risk of 
developing the disease; furthermore, children of migrants (coming from selected 
countries) who were born in Canada had a higher incidence of the disease, suggesting 
that disease risk factors could be influenced by earlier exposure in life to 
environmental triggers (Benchimol et al., 2015). Overall, such studies have provided 
a deeper understanding of the relationship between environmental factors and disease 
characteristics.  
CD is more commonly diagnosed at a younger age; the disease is considered 
a disease of the youth. Data from population-based studies have shown that the median 
age of patients at the time of diagnosis is between 29.5 and 31years (Ramadas et al., 
2010, Vind et al., 2006, Loftus Jr et al., 1998). The majority of the studies have also 
shown that CD predominates in females, unlike UC, which is slightly more prevalent 
in males (Forbes, 2001, Loftus Jr, 2004). However, the CD incidence can be also vary 
by race and ethnicity. For instance, the risk of the disease is higher in Jewish 
populations from America and Europe, while it is low in African-American and 
Hispanic populations (Ananthakrishnan, 2015). 
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1.3 Aetiology and pathogenesis 
Over the past years, CD has been considered as an idiopathic disease. Several 
risk factors are implicated in its pathogenesis but with unclear mechanisms of action. 
The combination of genetic predisposition, environmental factors, changes in gut 
microbiome, and the resulting host immune response have been suggested to trigger 
chronic inflammation in the gut, causing the disease. 
1.3.1 Genetic factors 
Convincing evidence from family and twin studies have supported the derived 
heritability in CD before genetic confirmation existed; the risk of IBD is greater in 
first degree relatives of patients with CD (Halme et al., 2006) and is approximately 
50% in identical twins. The genome-wide association studies (GWAS) have identified 
many susceptibility genes and loci for IBD, which greatly help in understanding the 
molecular mechanism of the disease (McGovern et al., 2015). Most of these genes are 
involved in the maintenance of intestinal barrier function, immune responses, 
autophagy, tissue repair, and in immune reactions to foreign microorganisms and 
antigens (Chan et al., 2015, Ananthakrishnan, 2015). However, several of the 
identified genes could be influenced by the presence of certain environmental triggers 
(Guerreiro et al., 2009). Most of the identified genes are associated with both UC and 
CD with similar outcomes; however, the expression of the NOD2 and ATG16L1 genes 
is considered to be more specific to CD only, while other genes are associated with 
UC (Jostins et al., 2012). 
1.3.2 Environmental factors 
The rising incidence rate of CD in countries adopting a western lifestyle, and 
among migrants living in western countries strongly support the association between 
environmental factors and disease pathogenesis (Chan et al., 2015). Over the past 
years, several risk factors have been identified by epidemiological studies. Some 
were found to occur consistently between the studies, while other risk factors were 
debated with inconclusive evidence and lack of certainty about their effect.  
Smoking has been consistently recognized as a risk factor for CD. According 
to a systematic review, the estimated rise in CD risk among smokers was found to be 
twofold (OR 1.76, 95% CI 1.40–2.22) (Mahid et al., 2006). However, the effect of 
smoking on CD risk seems to be dose dependent, and the earlier the exposure to 
smoking in life, the higher the disease risk (Ko et al., 2014). Smoking was also found 
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to be correlated with early onset of the disease and with a high dependency on 
immunosuppressive drugs, particularly in females (Cosnes et al., 2004). It is also 
associated with disease worsening and poor prognosis, as the requirement for surgical 
resection, and the rate of disease relapse and recurrence increased significantly in CD 
patients who smoke (Hovde and Moum, 2012). The mechanism of action of smoking 
on disease pathogenesis is not completely understood. Nevertheless, studies have 
shown that smoking could play a role in changing the smooth muscles that stimulate 
endothelial function, in reducing intestinal epithelial integrity, in increasing the level 
of oxidative stress, and impacting the gut microbiome (McGilligan et al., 2007). 
The association of diet and early life feeding patterns with CD risk has been 
supported by many epidemiological studies. A protective effect of breastfeeding 
against CD development has been reported by several studies. An earlier meta-
analysis founded that breastfeeding is associated with lower risk of CD, however, only 
few of the included studies were graded as high quality (Klement et al., 2004). 
Moreover, the evidence also seems to be contradictory, as a recent large prospective 
cohort study of U.S. women did not find a significant correlation between early life 
factors, including being breastfed, and the risk of CD (Khalili et al., 2013). Further 
studies of a higher methodological quality are needed for clarifying this association. 
Studies have found that the risk of CD is usually high in people following a 
western diet, which is high in refined and processed foods that are high in fat and 
protein, but low in fruit and vegetable. Scientists have explained the association 
between diet and CD risk using several theories. For example, the presence of 
antigens, alteration in gut microbiota, over nutrition, and changes in prostaglandin 
levels are proposed as possible biological mechanisms behind this association (Hou et 
al., 2011). However, the evidence for these mechanisms is contradictory. For instance, 
the practice of excluding food antigens from diet (exclusion diet) is not supported by 
adequate evidence, as there has been an apparent similarity of the efficacy of the 
elemental enteral diet and the polymeric enteral diet in patients with active CD, which 
will be highlighted later in this report (Zachos et al., 2007b). 
The effect of macronutrients intake on increasing the risk of the disease has 
been investigated by many case-control and large cohort studies, which can be 
associated with several limitations. The effect of excessive carbohydrate intake is 
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suggested to be relevant to inducing the development of CD by either affecting gut 
microbiota composition or by leading to obesity, which could influence the expression 
of markers predisposed to intestinal inflammation (Chan et al., 2014b). However, 
limited findings from earlier studies have shown inconsistent results, and a recent large 
prospective cohort study has found no association between total carbohydrate and total 
sugar intake with CD, suggesting that future epidemiological studies should address 
the individual effects of each type of carbohydrate that could be considered an actual 
risk factor (Chan et al., 2014b). For the effect of protein intake, it is mostly limited to 
the intake of animal protein, as studies have shown a positive correlation between the 
rising incidence of CD and increased meat intake in Japan and European countries 
(Shoda et al., 1996, Jantchou et al., 2010). High meat consumption was suggested to 
increase CD risk due to an increase in toxic, metabolic end product production in the 
colon by the local microbiota (e.g. hydrogen sulphide) (Jantchou et al., 2010). 
Out of all the macronutrients, fat has been the most interesting dietary factor 
to investigate in CD, mostly because of the suggested involvement of some types of 
fat in the inflammation process, consequently augmenting the risk of CD. A resent 
systematic review of case-control and cohort studies has shown that the risk of  both 
types of IBD is greater in individuals with a history of high total fat, polyunsaturated 
fatty acid (PUFA) and meat intake; whereas high intake of dietary fibre and fruits were 
correlated with lower CD risk, and high vegetable intake was associated with lower 
UC incidence (Hou et al., 2011). In this systematic review, there was a great level of 
heterogeneity between the included studies and the retrospective nature of many case-
control studies that may have further limited the quality of the results, due to the 
possibility of a recall bias of dietary intake. Nevertheless, a large prospective study 
from the Nurse Health Study has shown inconsistent findings; insignificant correlation 
was found between the intakes of total fat, saturated/unsaturated fatty acids, or specific 
polyunsaturated fatty acids (PUFAs) with the risk of CD (Ananthakrishnan et al., 
2014). However, only a significant association was found between high, long-term 
intake of n-3 fatty acid and reduced risk of UC, and between the excessive intake of 
trans-fatty acids and increased incidence of UC. Although, the second study has many 
strengths with regard to its design, it is still limited by the inclusion of only white 
women who might have specific traits for later disease onset; thus, we cannot 
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generalize its findings (Chan et al., 2015). As current evidence in the literature is 
limited and contradictory, future epidemiological studies with better design are still 
needed to clearly understand the role of various dietary components in triggering CD. 
The effect of selected micronutrients on CD risk have been reported by several 
studies. Vitamin D was found to be linked to CD pathogenesis. Vitamin D deficiency 
was found to be highly prevalent in patients diagnosed with IBD (Abraham et al., 
2014). Yet, it is not clear whether low vitamin D levels are a result of the disease itself 
or if it is a causative factor in disease onset. Current evidence from observational 
studies is inconclusive and contradictory in supporting the association between 
vitamin D deficiency and CD risk (Del Pinto et al., 2015). However, the evidence 
associating vitamin D deficiency with disease outcomes and progression is more 
convincing. Vitamin D deficiency in CD patients is considered multifactorial; it could 
be related to low level of sun exposure, low intake, malabsorption secondary to small 
intestinal resection, altered enterohepatic circulation, and increased intestinal vitamin 
losses as a result of protein-losing enteropathy (Ulitsky et al., 2011). Additionally, 
iron intake has been linked to CD risk. Iron could stimulate intestinal inflammation 
via specific signaling pathways, via oxidative stress, and by altering the composition 
of gut microbiota  (Carrier et al., 2001, Khalili et al., 2017). One epidemiological study 
has shown a relationship between iron enriched drinking water and higher CD risk 
(Aamodt et al., 2008). However, findings from cohort studies have shown no 
association between dietary iron intake (i.e. total and heme iron) and CD risk (Khalili 
et al., 2017). Yet, the association between iron and disease onset and pathogenesis 
needs further validation. Moreover, zinc intake might be related to CD risk by its 
impact on autophagy, innate and adaptive immunity, and on the regulation of the gut 
barrier function. According to one epidemiological study, dietary zinc was inversely 
correlated with CD risk (Ananthakrishnan et al., 2015). 
The level of exposure to infections, antibiotic use, and the use of drugs such 
as aspirin, non-steroidal anti-inflammatory drugs (NSAIDs), and oral contraceptive 
pills (OCP) are other identified environmental factors that could trigger the 
development of CD. The use of antibiotics, especially during the first year of life, was 
highly associated with CD incidence rate. According to a cohort study, 58% of IBD 
diagnosed pediatric patients had received antibiotics in the first year of life, while only 
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39% did not receive antibiotics (Shaw et al., 2010). The relationship between NSAID 
use and IBD risk was found to be stronger with larger doses and longer duration of 
use, and was the same for both types of IBD (Ananthakrishnan et al., 2012). In 
addition, results from a meta-analysis showed that OCP use raised the incidence rate 
of CD in a dose-response manner, while OCP withdrawal decreased the risk of disease 
development (Cornish et al., 2008).  
1.3.3 Immunological factors 
Disturbed immune response to the normal intestinal microbiota, and the 
irregular balance of pro-inflammatory and anti-inflammatory cytokines are both 
considered contributing factors in CD pathogenesis. The inflammatory responses in 
CD are characterized by the high expression of pro-inflammatory markers like 
Tumour necrosis factor-a (TNF-a), Interleukin-6 (IL-6), IL-8, and adhesion 
molecules, such as intercellular adhesion molecule-1 (ICAM-1) and vascular cell 
adhesion molecule-1 (VCAM-1). Overall, maintenance of gut homeostasis needs an 
adequate balance between pro-inflammatory and anti-inflammatory cytokines, which 
are controlled by T-cells. An imbalance in these pathways may result in an interrupted 
immune response to intestinal bacteria leading to CD development (Round and 
Mazmanian, 2009). 
1.4 Clinical symptoms and complications 
The symptoms for CD are dependent on the location and the severity of the 
inflammation. Generally, the clinical symptoms for patients diagnosed with CD 
usually involve: diarrhea, abdominal pain, thickening of the intestinal wall, which 
causes intestinal stricture and obstruction, abscess formation, and fistula development 
between the skin and internal organs. Progressive disease can lead to nutrient 
malabsorption and steatorrhea. 
Other extraintestinal manifestations of the CD inflammatory response include: 
low-grade fever, weight loss (because of reduced food intake and malabsorption), 
delayed growth in children, large joint arthritis, eye complications (e.g. uveitis, iritis, 
and episcleritis), and skin lesions (e.g. erythema nodosum and pyoderma 
gangrenosum) (Gajendran et al., 2018). 
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1.5 Diagnosis 
CD is associated with transmural inflammation, where all layers of the 
intestinal wall can be affected. CD can affect any part of the GIT starting from the 
mouth to the anus. Gajendran et al. have reported the prevalence of colonic, ileal and 
colonic-ileal CD at about 25%, 25% and 50%, respectively. (Gajendran et al., 2018). 
Overall, the key aspects of CD diagnosis depend on an evaluation of clinical 
symptoms and also on laboratory, radiographic, endoscopic, and pathological findings 
which indicate focal, asymmetric, transmural or granulomatous characteristics. 
Computed tomography scanning (CT scan) of the intestine is the most commonly used 
radiographic method for assessing CD, while magnetic resonance imaging (MRI) is 
also used, and is associated with reduced exposure to ionizing radiation. Nevertheless, 
endoscopies remain the gold standard for assessing disease activity and progress, and 
also for measuring the degree of mucosal healing, particularly in clinical studies. 
1.6 Assessment of disease activity 
 Several scoring systems have been established for the clinical assessment of 
disease activity in CD patients. This include the Crohn’s Disease Activity Index 
(CDAI) which is the most commonly used criteria, the Harvey-Bradshaw index (HBI), 
the Montreal classification system, the Short Inflammatory Bowel Disease 
Questionnaire (SIBDQ), and the Lehmann score (Gajendran et al., 2018). Most of 
these criteria will assess disease activity based on: subjective measures, such as the 
disease’s affect on the patient’s life (e.g. symptoms, quality of life, and fatigue), 
objective or quantifiable measures (e.g. C-reactive protein (CRP) level), and disease 
severity measures (e.g. history of bowel resection, number of relapses, or presence of 
any extraintestinal disease features) (Peyrin-Biroulet et al., 2016). 
1.7 Management  
1.7.1 Medical therapy 
The primary goal of medical therapy in CD patients is to induce and maintain 
remission, restore the damaged mucosa, and to improve the patient’s overall quality 
of life. The choice of therapy usually depends on the severity and the location of the 
disease. Several therapeutic agents have been used over the past years. The use of 
corticosteroids is now disputed as it is probably only effective in reducing symptoms, 
while it is inefficient in maintaining remission (Dignass et al., 2010, Forbes et al., 
2011). 5-aminosalicylic containing drugs are not effective in maintaining remission 
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and their use in CD has been controversial (Akobeng and Gardener, 2005). 
Immunomodulators are, nevertheless, effective in acute intervention and as a 
maintenance therapy. Other emerging therapies that modulate key aspects of the 
different inflammatory processes in CD have been investigated for their efficacy. 
Although, there is strong evidence supporting the benefit of using these medications, 
the number of associated side effects cannot be overlooked. In situations where the 
disease becomes more complicated or when there is resistance to drug therapy, 
surgical intervention will be required. This kind of intervention is more common when 
the disease involves the ileum. It has been estimated that about 50% of CD patients 
will undergo at least one operation during the first 10 years of diagnosis, while 40% 
of patients will need additional surgery in the first 10 years of diagnosis (Hart and Ng, 
2015).  
1.7.2 Nutritional therapy 
Poor nutritional status is commonly seen in CD patients, especially in 
individuals with affected small bowel. The prevalence of malnutrition in CD are 
attributed to the following reasons: the malabsorption of nutrients, intestinal losses, 
anorexia, vitamin deficiencies, catabolic effects of inflammation, poor appetite as a 
result of gastrointestinal symptoms (abdominal pain and diarrhoea), and the side effect 
of certain drugs. Therapeutic approaches in CD should also target disease-related 
malnutrition, which would eventually improve the overall patient prognosis. Artificial 
nutrition support has been more favoured over the past years in CD. The rational for 
using tube feeding or parenteral nutrition (PN) in CD is basically two-fold; first, it can 
treat malnutrition, secondly, it can modify the underlying disease pathogenesis aiming 
to achieve a high rate of remission, via controlled delivery of exogenous dietary 
substances to the gut (Forbes et al., 2011). 
Several dietary therapies have been identified for managing patient symptoms 
and prolonging remission. For example, a gluten-free diet, a diet low in fermentable 
oligosaccharides, disaccharides, monosaccharides, and polyols (the low FODMAP 
diet), or following a diet rich in n-3 PUFAs, have been increasingly recommended 
over the past few decades. Nevertheless, clinical trials are limited and the evidence is 
yet inconclusive in showing the potential benefits of such dietary modifications in CD 
patients. According to a recent IBD guideline published by the European Society for 
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Clinical Nutrition and Metabolism (ESPEN), no specific diet can be generally 
recommended for inducing disease remission.  
1.8 Enteral nutrition in the treatment of Crohn’s disease 
The efficacy of nutritional support, especially that of EN in adult patients, has 
only been supported by limited evidence, which provided limited assumptions about 
its mechanism of action. Therefore, the current published guidelines state that EN in 
adults is less efficient than steroids in inducing remission, but it might be 
recommended in special situations, such as when other primary therapies become 
unfeasible, or when patients refuse the use of medication (Lomer, 2014, Narula et al., 
2018). Contrarily, evidence from paediatric studies are relatively consistent in 
recommending EN as a primary therapy; such a practice originates from the 
observation that EN administration resulted in a significant improvement in growth, 
while growth failure and poor bone health occurred with the continuous use of 
steroids.  
The effect of EN in CD has been observed by different types of formulations: 
whole protein-based feeds with high fat (polymeric feeds), glucose and amino acid-
based feeds with low fat (elemental feeds), and peptide-based feeds (semi-elemental 
feeds). The low antigenic profile of elemental formulae was initially proposed as a 
reason for why these feeds are preferable. However, this idea was later challenged by 
the findings of an updated meta-analysis of clinical trials, that found similar effects of 
polymeric and elemental feeds in CD patients (Zachos et al., 2007b, Narula et al., 
2018). Due to the proposed role of lipids in manipulating the inflammatory response, 
some trials have specifically compared the effect of different feeds consisting of 
differing fat compositions, in CD patients, which generated inconsistent 
interpretations of the effect of lipids. 
1.9 The role of lipids in Crohn’s disease 
1.9.1 Lipid classes 
Generally, lipids are classified into fatty acids, triacylglycerol, phospholipid, 
glycerol, steroid and wax groups. Fatty acids are considered the building blocks of 
lipids. The chemical structure of fatty acids consist of long hydrocarbon chains ending 
with carboxyl group. Fatty acid chains can be either short (< 6 carbon atoms), medium 
(between 6 and 12 carbon atoms), or long (> 14 carbon atoms). Another classification 
of fatty acids is based on the presence of double-
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fatty acids contain double bonds in the carbon chain, while saturated of fatty acids do 
not. 
Fatty acids are important for human health, and include essential fatty acids 
that cannot be synthesised by the human body, therefore needing to be obtained 
through one’s diet. This includes n-6 PUFA (linoleic acid) and n-3 PUFA (a-linolenic 
acid), both of which have at least two double bonds and are vital for maintaining 
health. The metabolism of a-linolenic acid results in the production of two essential 
unsaturated fatty acids, which are eicosapentaenoic acid (EPA) and decosahexaenoic 
acid (DHA) (Figure 1). The main dietary source for EPA and DHA is fish and fish 
oils. Over the past decades, several health benefits have been suggested to be 
associated with the high intake of EPA and DHA. 
 
 
Figure 1: The conversion of plant-derived essential n-6 and n-3 PUFA to their 
longer chain, more unsaturated derivatives.  
DHA, docosahexaenoic acid; EPA, eicosapentaenoic acid. 
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1.9.2 Lipids as pro-inflammatory mediators 
n-3 PUFAs have several anti-inflammatory functions. They have the ability to 
reduce leucocyte chemotaxis, the degree of adhesion molecule expression and 
leucocyte-endothelial adhesive interactions, the release of eicosanoids (i.e. 
prostaglandins and leukotrienes) from the n-6 PUFA metabolism, the release of 
inflammatory cytokines, and the proliferation of T-cells (Calder, 2013). On the other 
hand, n-6 PUFA has been associated with many inflammatory effects, where its 
derivative, “arachidonic acid” is considered a precursor for key pro-inflammatory 
mediators. (Innes and Calder, 2018). However, current evidence is still inconclusive 
in confirming the inflammatory effect of n-6 PUFA. Also, the balance between n-3 
and n-6 PUFAs, and the communication between their lipid mediators during 
inflammation is complex and unclear.  
1.9.3 Role of dietary and therapeutic lipids 
Due to the proposed role of lipids in controlling the inflammatory response, 
several studies have examined the effect of different fat compositions in nutritional 
feeds that have been prescribed for CD patients as EN. Polymeric, protein-based feeds 
with high fat content have been compared with low fat, glucose and amino acid-based 
feeds, and with oligomeric peptide-based feeds (Fernandez-Banares et al., 1995, 
Griffiths et al., 1995, Messori et al., 1996, Zachos et al., 2007a), but without 
compelling evidence that one is better than another (Zachos et al., 2007a). One meta-
analysis found a negative correlation between long chain triglyceride (LCT) content 
and remission rate (RR) (Middleton et al., 1995), and a second found comparable, but 
non-significant trends favouring low LCT and low overall fat content (Zachos et al., 
2007a). Regarding the effect of feeds high in medium chain triglyceride (MCT) on 
modulating the inflammatory response in CD, the evidence is yet not conclusive. An 
earlier meta-analysis of randomized clinical trials (RCTs) has shown a significant 
reduction in the levels of inflammatory markers observed with MCT-rich feed, 
suggesting that there is an anti-inflammatory effect of MCT oil, while a later study 
found no significant difference between low MCT feed and high MCT feed (70% 
MCT) on the clinical RR in CD patients (Middleton et al., 1995, Sakurai et al., 2002). 
Given the potential aetiopathogenic relevance of lipids to CD (due to a higher disease 
prevalence in populations on high fat Western diets) and the curious phenomenon of 
fat-wrapping (almost pathognomonic of CD), further investigation in this area is 
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warranted, partly because of the inability of the other meta-analyses to provide a 
verdict on this issue. 
The anti-inflammatory effect of n-3 in CD has been strongly supported by 
animal and in-vitro studies, while the currently available clinical trials provide 
conflicting results. Most of the available trials assessed the effect of n-3 PUFA in CD 
patients by using fish oil dietary supplements, while only few studies assessed its 
effect within therapeutic EN feeds. A recent systematic review of RCTs did not show 
any positive effect of using n-3 PUFA in maintaining remission in CD patients (Lev-
Tzion et al., 2014). The major limitation of this review was the heterogeneity of the 
included clinical trials, such as variations in n-3 PUFA formulations and in routes of 
delivery. Although supplementation with n-3 PUFA has always been considered safe, 
an analysis from this review has shown that adverse events of gastrointestinal 
symptoms, like diarrhoea, are more prevalent in the intervention group than in the 
control group. Several mechanisms have been proposed for the role of n-3 PUFA in 
treating CD patients. A high intake of n-3 PUFA can reduce the availability of 
arachidonic acid, leading to a lower production of eicosanoids, and consequently, a 
decreased expression of pro-inflammatory markers. It also can reduce the synthesis of 
pro-inflammatory cytokines, such as TNF-a (Gorard, 2003). 
1.10 Mesenteric adipose tissues in Crohn’s disease 
1.10.1 Fat-wrapping: a characteristic feature in Crohn’s disease 
In 1932, the fat-wrapping phenomenon in CD was first identified and was 
characterized by a hypertrophy of the MAT adjacent to the inflamed intestines (Crohn 
et al., 1932). It is considered a specific feature to CD. However, only few studies have 
speculated the effect of fat-wrapping on disease activity (i.e. the degree of ulceration, 
transmural inflammation, and inflammatory response), suggesting that it could be a 
predictor of more chronic disease (Sheehan et al., 1992, Desreumaux et al., 1999). 
Nonetheless, later studies have started to focus on the pathogenic mechanism behind 
this phenomenon, proposing a potential role of MAT in CD pathogenesis (Zulian et 
al., 2012, Peyrin-Biroulet et al., 2012). 
1.10.2 Histology  
Only a few studies have tried to investigate the morphology and the cellular 
compartment of fat-wrapping in CD. Histological findings from earlier studies found 
that morphological features of the MAT of CD patients differ from other patients. The 
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size of adipocytes in the MAT of CD patients was found to be significantly smaller, 
but higher in number compared to mesenteric adipocytes derived from control cases 
(Peyrin-Biroulet et al., 2007). Conversely, hypertrophied MAT is caused by an 
increase in adipocyte size in obesity. Moreover, the inflamed mesenteric fat in CD is 
significantly infiltrated with inflammatory cells. Compared to non-inflamed MAT, the 
expression of macrophages and T lymphocyte markers (i.e. CD68 and CD3 positive 
cells) were found to be significantly higher in hypertrophied MAT in CD (Yamamoto 
et al., 2005). The evidence is still inconclusive in determining whether adipocyte 
hyperplasia is primarily responsible for activating inflammation in the hypertrophied 
fat in CD, or whether this is a secondary outcome resulting from the transmural 
inflammation of the diseased intestine. 
1.10.3 Expression of inflammatory adipocytokines in mesenteric fat  
Adipocytes are considered important factors in adipose tissue inflammation, 
as inflammatory mediators are synthesized by these cells. In mesenteric adipocytes, 
alteration in the balance of pro-inflammatory and anti-inflammatory adipocytokines 
was reported (Paul et al., 2006). Smaller adipocytes tend to secret higher amounts of 
adiponectin than larger adipocytes (Yamamoto et al., 2005). The secretion of other 
adipocytokines including leptin, resistin, IL-6, and Monocyte chemoattractant protein 
1 (MCP1) by CD mesenteric fat has also been reported.   
1.10.4 Mesenteric fat as a source of CRP 
CRP is an acute-phase protein marker that is synthesized primarily by the liver. 
It has a key role in innate immunity. Due to its fast response and short half-life, CRP 
has been used as a clinical indicator for assessment of infections and inflammation 
(Henriksen et al., 2008). Although CRP is not considered a specific marker for 
intestinal inflammation in the context of CD, several clinical outcomes reflecting 
disease activity were shown to correspond to CRP levels. For example, CRP level was 
shown to correlate with the CD endoscopic score and with clinical relapse rate (Chang 
et al., 2015). Interestingly, the secretion of CRP by MAT has been recently 
investigated in CD. The mesenteric fat depot can be an important source of CRP in 
CD, which eventually could contribute to the overall status of inflammation. 
Furthermore, recent findings have identified bacterial translocation and local 
inflammation as triggers to CRP production in MAT (Peyrin-Biroulet et al., 2012). 
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1.10.5 Mesenteric fat as a target for bacterial translocation 
Generally, CD is associated with enhanced gut permeability and bacterial 
translocation. However, the association between bacterial translocation and the 
accumulation of mesenteric fat in CD has been recently investigated. Studies have 
shown that adipocytes can respond to bacterial stimuli (Batra et al., 2009). Recent 
findings have shown that bacterial translocation into mesenteric adipocytes results in 
the inflammatory response in CD via CRP synthesis (Peyrin-Biroulet et al., 2012). 
Other findings from animal studies on experimental colitis have shown that the 
accumulation of MAT could protect against bacterial translocation via phagocytosis 
(by adipocytes) and via the increased production of cytokines and infiltration of 
immune cells, thus mediating chronic inflammation in order to act as a defense 
mechanism (Batra et al., 2012). Yet, the various proposed theories regarding the 
involvement of the MAT in CD pathogenesis require further validation.  
1.10.6 Fatty acid profile of mesenteric fat 
Adipose tissue has always been recognized as an important organ in regulating 
lipid storage and metabolism. Adipose tissue acts as an energy reservoir by storing 
lipids. In addition, mesenteric adipocytes that are adjacent to lymph nodes have an 
important role in paracrine interactions. Adipocytes can supply fatty acids to its 
surrounding lymph nodes, which makes the MAT that contains lymph nodes work as 
a link between the human diet and gut epithelial immunity (Pond, 2009). Generally, 
the immune system depends on fatty acids for energy provision and for cell membrane 
functions (especially n-3 and n-6 PUFAs). However, in the case of chronic 
inflammation, studies in animals with experimental colitis have found that the fatty 
acid profile of lymph node-containing MAT is high in PUFA (predominantly n-6 
PUFA) (Acedo et al., 2011). While, another study on human CD tissues showed that 
MAT and the attached lymphoid tissues have more saturated fatty acids and less PUFA 
than controls, the study also found that the ratio of n-6: n-3 fatty acids is high in the 
MAT, while it was low the in the adjacent lymphoid tissues (Westcott et al., 2005). 
The author has suggested that interrupted paracrine interaction between adipose and 
lymphoid tissues in CD is responsible for the abnormal fatty acid composition in 
lymphoid cells. Moreover, similar findings were observed in an earlier study, but with 
a different design, in which the fatty acid profile of plasma phospholipids and 
subcutaneous adipose tissue for CD patients were investigated: a significant reduction 
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in the sum of n-3 and n-6 PUFA was found, and the author speculated that the 
abnormal fatty acid profile in such patients was a result of altered fat metabolism, 
rather than intestinal fat malabsorption (Geerling et al., 1999). Given the fact that there 
are differences in the nature of the disease between human CD and the animal CD 
models, the findings from the above studies should be carefully interpreted. Further 
investigations of the role of CD mesenteric fat in paracrine interaction are warranted. 
Understanding more about such defective lipid metabolism would help in identifying 
the underlying mechanisms between the MAT and intestinal inflammation in CD. 
1.10.7 Therapeutic approaches targeting mesenteric fat in Crohn’s disease 
Interestingly, the presence of hypertrophied mesenteric fat in CD patients is 
currently considered a working model for ongoing IBD research. Some of the current 
applied therapeutic approaches for CD have been investigated in relation to the fat-
wrapping phenomenon. A recent trial has found a relationship between exclusive 
enteral nutrition (EEN) therapy and the alteration of MAT in patients with active CD; 
changes in adipocyte morphology accompanied with a reduced production of TNF-a 
and leptin, and an increased secretion of adiponectin was observed in EEN treated CD 
patients (Feng et al., 2014). However, another study with retrospective design has 
reported a correlation between high visceral fat area and reduced intestinal mucosal 
healing following anti-TNF therapy (infliximab) in CD patients, suggesting  the earlier 
utilization of high doses of anti-TNF therapy among CD patients, especially in those 
with a higher ratio of visceral fat (Shen et al., 2018). Also, other studies have shown 
the effect of steroids, methotrexate, and infliximab therapies on the mesenteric fat 
production of inflammatory markers (Schäffler et al., 2006, Thomaz et al., 2009, 
Clemente et al., 2012). Therefore, drug therapy could modify the inflammatory 
response of mesenteric fat in CD. 
1.11 Intestinal epithelium remodelling by lipids 
The intestinal epithelium, considered the fastest self-renewing tissue in the 
body, is a key player in controlling inflammation. Intestinal stem cells (ISCs) help 
maintain the rate of self-renewal for proper tissue homeostasis in the gut. Digested 
nutrients in the gut can lead to alteration in the circulating factors that stimulate the 
biology of ISCs, which could affect the pattern of tissue remodeling and renewal in 
mucosal epithelium (Luo and Puigserver, 2016). Animal studies have shown that 
animals fed a high fat diet had a significantly higher rate of ISC proliferation, which 
 32 
resulted in an elongation of the crypts (the lower part of the epithelium structure that 
resides in the ISCs), thus predisposing the animals to intestinal cancers (Beyaz et al., 
2016). Interestingly, the resulted changes in the pattern of ISCs were produced by 
specific fatty acids in the interventional high fat diet. Although the findings of such 
studies focused on the effect of dietary fat on the tumorgenicity of the gut, rather than 
the inflammatory response, it does suggest a new mechanism of action of intestinal 
handling of dietary fats, which could be applicable in the aetiopathogenesis of CD. 
1.12 Research gaps 
The findings from previous clinical trials of EN in CD are conflicting, 
regarding which fat composition performs better. Critical analysis and interpretation 
of the available evidence is required to help understand more about the limitations and 
the strengths of each study finding. Moreover, a deep understanding of the 
pathogenesis of CD is lacking. The role of the fat-wrapping phenomenon in CD, and 
whether it is a pre-illness condition or a secondary phenomenon as a consequence of 
the disease, is still not supported by enough evidence. A thorough characterization of 
this type of tissue in CD patients is needed. Moreover, the intestinal epithelium is a 
key player in controlling inflammation. ISCs help maintain the rate of self-renewal for 
proper tissue homeostasis in the gut. Digested nutrients, like lipids, in the gut can lead 
to an alteration in the circulating factors that stimulate the biology of ISCs, which 
could affect the pattern of tissue remodeling and renewal in the mucosal epithelium 
(Luo and Puigserver, 2016). This suggests a new mechanism of action of the intestinal 
handling of dietary fats, which could be applicable in the aetiopathogenesis of CD. 
Overall, the modification of dietary fatty acid intake by CD patients could improve 
their clinical course, via modulation of the hypertrophic MAT and the adjacent 
intestinal epithelium, a proposal that, nevertheless, needs further investigation. 
1.13 Objectives and hypothesis 
The objectives of this research project are to: 
• Critically reanalyze and interpret the evidence and the available RCTs, 
specifically to evaluate the association between the nutrient fat content of 
nutritional feeds and their response rates in CD patients. 
• Characterize the MAT in CD, to investigate the physiological behavior of these 
tissues by identifying and measuring adipogenic and inflammatory gene 
expression and their fatty acid profile. 
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• Investigate the in-vitro effect of different mixtures of fatty acids on the 
adipogenesis of mesenteric pre-adipocytes, using human cultured mesenteric 
pre-adipocytes isolated from CD and control patients. 
• Investigate the in-vitro effect of different fatty acid mixtures on gut epithelial 
physiology in CD and control tissues (e.g. on the proliferation of intestinal 
epithelial cells) by using the human cultured intestinal crypt model. 
 
The hypothesis of this project is that the lipid composition of therapeutic feeds 
has an influence on controlling the inflammatory response in CD. First, this will be 
tested by conducting a systematic review to evaluate the relationship between the fatty 
acid content of enteral feeds and RRs in CD. Secondly, the hypothesis will be tested 
by characterizing and studying the in-vitro effect of fat on the molecular behavior of 
MAT in CD and the adjacent intestinal epithelium. The methodology will be described 
in detail in the following chapters. 
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2 Chapter 2. Effect of fat composition in enteral nutrition for 
Crohn’s disease in adults: a systematic review 
 
 
2.1 Introduction 
2.1.1 Enteral nutrition guidelines in Crohn’s disease 
As well as having a probable role in pathogenesis, nutrition has been identified 
as a key mediator in established CD, such that, in paediatrics at least, defined EN is 
the treatment of first choice for many patients.  However, as is often the case in clinical 
nutrition, the evidence base is not as strong as might be wished.  Several meta-analyses 
have been conducted, but it remains difficult to judge the true effectiveness of EN in 
patients with CD.  The collected evidence supports a superior effect of corticosteroids 
over EN in adults with CD, but many adult clinicians and most paediatricians believe 
that EN is an appropriate and evidence-based primary therapy in CD.  This belief rests 
on the positive results from studies of paediatric and malnourished CD patients, which 
confirm beneficial effects of EN in improving growth and nutritional status, but which 
also indicate mucosal healing, and of course a favourable risk profile compared to 
pharmacological options.   
EN comprises, however, a broad range of options, and the limited comparative 
evidence prevents confidence that the best choice(s) can currently be made.  
Polymeric, protein-based feeds with high fat content have been compared with low 
fat, glucose and amino acid-based feeds, and with oligomeric peptide-based feeds 
(Fernandez-Banares et al., 1995, Griffiths et al., 1995, Messori et al., 1996, Zachos et 
al., 2007a), but without compelling evidence that one is better than another (Zachos et 
al., 2007a).  At present a single EN formula is licenced and marketed specifically for 
inflammatory bowel disease in adults.  This is a casein-based polymeric feed rich in 
transforming growth factor-β (TGF-β), but there is little evidence to support any 
particular efficacy (Triantafillidis et al., 2010, Kanwar et al., 2016).  
2.1.2 Effect of lipid compositions of enteral feed 
Due to the physiological role of lipids in manipulating the inflammatory 
response, some trials have specifically compared the effect of different enteral feeds 
with different fat compositions in CD, which overall generated inconsistent 
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interpretations of the effect of lipids. PUFAs are known to have an anti-inflammatory 
and pro-inflammatory effect in several inflammatory diseases. However, in 
inflammatory intestinal diseases, several mechanisms of action for the impact of 
PUFA have been suggested. This include regulation of pro-inflammatory mediators, 
stimulation of anti-inflammatory cytokines, and restoration of intestinal epithelium 
via enhancing the process of wound healing (Scaioli et al., 2017). 
2.1.3 Research gaps 
Meta-analysis shows a weak and non-significant positive association between 
the protein content of feeds and their associated clinical RR.  One meta-analysis found 
a negative correlation between LCT content and RR (Middleton et al., 1995), and a 
second found comparable but non-significant trends favouring low LCT and low 
overall fat content (Zachos et al., 2007a). Given the potential aetiopathogenic 
relevance of lipids to Crohn's disease (more disease in populations on high fat Western 
diets) and the curious phenomenon of fat wrapping (almost pathognomonic of 
Crohn's), further investigation in this area appears readily justifiable despite and partly 
because of the inability of the other meta-analyses to provide a verdict on this issue.  
2.1.4 Hypothesis 
The available evidence is not clear regarding the effect of fat composition in 
enteral feeds in CD, indicating the need for detailed analysis of the current literature 
in EEN in CD. Such hypothesis will be studied by conducting a systematic review of 
all the available RCTs concerned with EEN in CD, which will be examined in details 
to help elucidate the potential effect of lipid composition on disease outcomes.  
2.1.5 Objectives 
The aim of this systematic review has been to reanalyse the findings of the 
older studies and to combine these with the findings of those more recently published, 
specifically to evaluate the relationship between nutrient fat content and response rates 
in the treatment of patients with CD.  Conscious that currently reported evidence is 
inconclusive and aware that many authorities consider the case for EN so weak as to 
argue robustly against it in the treatment of CD, we have approached this in a different 
and we hope more exploratory fashion than previous reviews. We focus on specific 
fatty acids, not just on lipid class, and on the ratios of individual fatty acids to each 
other, as well as to other macronutrients and to their relative contributions to energy 
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provision. The work of this chapter was originally published as a paper (Ajabnoor and 
Forbes, 2017). 
 
2.2 Materials and methods 
The PRISMA checklist and guidelines were used for this systematic review 
(Appendix 1). The study is registered with the PROSPERO database of systematic 
reviews, registration number: CRD42016033857. 
2.2.1 Search strategy  
A computer-based systematic search was undertaken using the Medline 
database (1946 to present) and the Embase database via OVID.  The search strategy 
was customized for each database and applied to titles and abstracts of papers.  For 
text terms related to enteral nutrition we used: “enteral”, “elemental”, “polymeric”, 
“whole protein”, “amino acid based”, “peptide based”, “low fat”, or “high fat”; these 
terms were all combined with “nutrition”, “feeding”, “diet”, or “feed”.  For disease-
related text terms we used “Crohn’s disease”, or “inflammatory bowel disease”.  Also, 
we searched “enteral nutrition” and “Crohn disease” as index terms (MeSH) and 
exploded them as appropriate.  The searches were limited to studies that involved 
humans, adults (18-plus years), clinical trials, controlled clinical trials, randomized 
controlled trials, meta-analyses, and systematic reviews.  The searches were not 
restricted to the English language.  In addition, a manual search of the reference lists 
of previously published papers was carried out, looking specifically for clinical trials 
investigating the effect of EN in adult patients with active CD. 
2.2.2 Selection criteria 
The selection of studies was determined by two reviewers following set 
criteria.  The studies included were required to be prospective clinical trials in adults 
with CD (including controlled and uncontrolled trials).  The EN intervention was to 
have been given exclusively for a defined period of time without any food intake (only 
water and sugar/milk-free beverages were allowed).  The response rate must have been 
measured as a primary or secondary outcome, according to clearly stated criteria.  The 
enteral feed used had to be clearly defined (i.e. name and type of feed, oil source, and 
fatty acid composition).  Studies were removed from consideration if EN was given 
together with oral food intake, the study was retrospective, or performed in a paediatric 
population.  Trials that did not provide a defined RR for CD, and trials that 
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investigated the effect of EN in combination with other medical therapies (e.g. with 
non-absorbable antibiotics or with erythropoietin) were also excluded.  Studies where 
the full identity of the lipid content was not published were excluded only after 
application to researcher and/or manufacturer had failed to provide this information.  
When studies were published initially as interim reports our analysis used data only 
from the later full article. 
2.2.3 Data extraction 
For each eligible study, a detailed review was undertaken using a report form, 
looking for the type and quantity of fatty acids in the enteral feeds, the RR achieved 
by EN, which was calculated on the basis of a “per protocol” analysis, and selected 
characteristics related to study design (e.g. duration of intervention, criteria for 
remission, geographical location, number of patients).  The gender and age of patients, 
and the anatomical location and duration of their disease were recorded.  Any apparent 
discrepancies in the data extracted were discussed and resolved between the two 
reviewers. 
Most papers did not provide sufficient detail of the fat composition in the 
enteral feeds for our purposes.  These deficits have been addressed as follows.  Where 
the formula was described by a proprietary name the manufacturer’s data sheet has 
been interrogated.  Where no proprietary name was provided a query was sent to the 
primary investigator of the study concerned.  In each case our analysis was based on 
the fatty acid content of the feed used.  In the great majority of cases this information 
was not provided either by authors or by manufacturers.  However, the nature and 
proportion of the oils in the feeds was generally available or possible to estimate from 
the information given.  The fatty acid profile of each oil was then drawn from a 
thorough published analysis (Dubois et al., 2007).  One additional and unexpected 
problem arose from the fact that the composition of some feeds has been modified 
within the last fifteen years.  Care was therefore taken to ensure that the analysis of 
the lipid content referred to that of the feed available at the time of the study. 
2.2.4 Quality assessment   
The quality of the included studies was judged according to the Downs and 
Black quality checklist on reporting, external validity, internal validity (study bias), 
and confounding (selection bias) (Downs and Black, 1998), with Livingston’s 
amendment for assessment of power (Livingston et al., 2012).   This is considered a 
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reliable assessment tool for both randomized and non-randomized clinical trials: the 
higher the score the better the quality of the methods.  
2.2.5 Data synthesis and statistical analysis 
The primary aim of this review has been to review and interpret the available 
evidence in order to test the potential correlation between the fat composition of 
enteral feeds and the resultant RR.  Scatter plots were used to identify trends.  The 
significance of possible relationships was tested by the Pearson correlation test (SPSS 
Statistics for Windows, Version 22.0, released 2013. IBM Corp., Armonk, NY, USA). 
Subgroup analysis was also conducted which stratified RR by the different levels of 
fats in EEN feeds (e.g. low vs. moderate vs. high MCT) and by the different levels of 
response rate (i.e. low RR <70% vs. high RR >70% response rate). 
 
2.3 Results 
2.3.1 Literature search 
The electronic searches yielded 63 articles and the manual search from 
previous meta-analyses and reviews identified an additional 14 articles.  Initial 
screening of the 77 articles comprised examination of title and abstract in the context 
of our selection criteria.  Forty articles were judged relevant and were further assessed 
for eligibility.  In each case the full paper was read (professionally translated if 
necessary) and checked against our selection criteria.  Joint decisions on selection 
were made by the two reviewers, following discussion if any initial discrepancy arose.  
Ultimately our systematic review was based on 29 pertinent papers (Figure 2). 
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Figure 2: PRISMA 2009 flow diagram demonstrating the search and selection 
strategy.  
PRISMA, Preferred Reporting Items for Systematic Reviews and Meta-Analyses. 
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2.3.2 Study characteristics 
From the total of 29 studies, 24 were controlled trials and 5 were uncontrolled. 
Among the controlled trials: 10 compared the efficacy of EN against drug therapy; 2 
compared EN with PN; and 8 investigated the effect of the type of EN by comparing 
elemental feeds with non-elemental feeds (which include polymeric and semi-
elemental, oligomeric feeds).  Only 4 trials specifically addressed the effect of fat 
composition; these trials compared similar types of feeds but with different fat 
composition.  The study design, patient characteristics, and criteria used to measure 
RR in the papers considered by this review are provided in Appendix 2-3. 
2.3.3 Quality of studies 
The quality of the included studies was highly variable.  The study with the 
highest quality (Gassull et al., 2002) scored 26 (out of 28) by the assessment tool 
(Downs and Black, 1998, Livingston et al., 2012), while the lowest quality study 
scored only 10 (Mantzaris et al., 1996). Poor (or unknown) representativeness of study 
subjects and the lack of power calculations were the commonest defects overall, and 
in the controlled trials, there were high risks of performance and detection bias due to 
the lack of blinding, and high risk of selection bias due to the lack of allocation 
concealment during randomization (Appendix 7).  
2.3.4 Characteristics of identified enteral feeds 
No fewer than 29 distinct enteral feeds have been used in the published studies.  
We have excluded one study (Rigaud et al., 1991), and therefore data on two formulae, 
because patients who were randomized to receive polymeric feeding were prescribed 
one or other of the two formulae depending on availability, but the RR was provided 
only as a combined rate for the two formulae.  Therefore, the final number of reviewed 
formulae is 27: 4 elemental formulae and 23 non-elemental preparations.  The fatty 
acid composition of these formulae with reference to RR is demonstrated in Table 1.  
More detailed fat composition data are provided in Appendix 4-6.  
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Table 1: Fat composition and remission rate for enteral nutritional formulas 
Reference  Type of enteral nutrition Energy Kcal/day Fat% of total 
calories 
Source of oil LCT% of total 
calories  
LCT% of 
total fat 
MCT% of total 
calories 
MCT% of 
total fat 
SFA% of total 
calories 
SFA% of 
total fat 
MUFA% of 
total calories  
MUFA% of 
total fat 
PUFA% of 
total calories  
PUFA% of 
total fat 
Total n-6% 
of total 
fatty acids 
Total n-
3% of 
total fatty 
acids 
n-6:n-3 
Ratio 
RR% 
Bamba et al. (2003)(Bamba et al., 
2003) 
Elemental, Low fat (6 packs of Elental + 
6 packs of dextrin) 
2400 1.15 Soybean oil 1.15 100 0 0 1.19 16.8 0.27 23.9 0.68 59.3 0 7.7 6.70 80 
Elemental, Medium fat (6 packs of 
Elental + 3 packs of dextrin+ 3 packs of 
C-1 dextrin) 
2400 6.21 Soybean oil 6.21 100 0 0 1.04 16.8 1.48 23.9 3.68 59.3 51.6 7.7 6.70 40 
Elemental, High fat (6 packs of Elental 
+ 6 packs of C-1 dextrin) 
2400 11.27 Soybean oil 11.27 100 0 0 1.89 16.8 2.69 23.9 6.68 59.3 51.6 7.7 6.70 25 
Gassull et al. (2002)(Gassull et al., 
2002) 
Polymeric, high in n-9 MUFA 2307 32 Synthetic Trioleate 30.17 94.28 1.83 5.71 5.16 16.11 25.28 79 2.56 8 6.5 1.5 4.33 27 
Polymeric, high in n-6 PUFA 2266 32 Corn oil 30.17 94.28 1.83 5.71 7.94 24.8 9.02 28.2 14.91 46.6 45 1.6 28.13 63 
Giaffer et al. (1990)(Giaffer et al., 
1990) 
Elemental (Vivonex) 2500 1.3 Safflower oil 1.3 100 0 0 0.12 9.1 0.18 13.9 1 77.3 76.5 0.8 95.63 86 
Polymeric (Fortison) 2500 36 Vegetable oil (canola & 
sunflower) 
36 100 0 0 3.74 10.4 15.26 42.4 17.55 48.75 43.6 5.2 8.38 42 
Leiper et al. (2001)(Leiper et al., 
2001) 
Polymeric, 5% LCT - 34.8 Soybean & coconut oils 5 13.8 29.8 86.2 30.69 88.2 1.18 3.4 2.92 8.4 7.4 1 7.40 46 
Polymeric, 30% LCT - 34.8 Palm, Canola, and coconut oils 30 84.7 4.8 15.3 18.72 53.8 12.35 35.5 3.72 10.7 9.5 1.2 7.92 45 
Mansfield et al. (1995)(Mansfield et 
al., 1995) 
Elemental (E028) 2250 16 Arachis oil 16 100 0 0 2.72 17 8.96 56 4.16 26 20 1 20.00 42 
Semi-elemental (Pepti-2000 LF liquid) 2250 9 Corn (50%) & MCT oils 4.5 50 4.5 50 5.22 58 0.99 11 2.79 31 28.05 0.5 56.10 42 
Middleton et al. (1995)(Middleton et 
al., 1995) 
Elemental (E028) - 15.6 Arachis oil 15.6 100 0 0 2.65 17.1 8.88 56.9 4.06 26 20 1 20.00 92 
Elemental (E028), High LCT - 35.6 Safflower & canola oils 35.6 100 0 0 3.95 11.1 23.92 67.2 7.73 21.7 17 4.5 3.78 55 
Elemental (E028), High MCT - 31.6 Safflower, canola, and coconut 
oils 
20.5 64.9 11.1 35.1 13.9 44 13.27 42 4.42 14 11 3 3.67 92 
Semi-elemental (Peptide 2+) - 33.2 Corn & coconut oils 21.6 65 11.6 34.9 21.71 65.4 3.88 11.7 7.6 22.9 22.5 0.4 56.25 87 
Park et al. (1991)(Park et al., 1991) Elemental (E028) 2266 16.47 Arachis oil 16.47 100 0 0 3.01 18.3 8.17 49.6 5.07 30.8 30.2 0.4 75.50 50 
Polymeric (Enteral 400) 2289 36 Arachis (75%) & MCT oils 27 75 9 25 14 38.9 13.57 37.7 8.42 23.4 22.9 0.3 76.33 83 
Raouf et al. (1991)(Raouf et al., 
1991) 
Elemental (EO28) - 16.5 Arachis oil 16.5 100 0 0 2.82 17.1 9.39 56.9 4.29 26 20 1 20.00 75 
Polymeric (Triosorbon) - 36 Sunflower (22%) & MCT oils 7.9 22 28.1 78 29.09 80.8 1.76 4.9 5.22 14.5 14.4 0.1 144.00 73 
Rigaud et al. (1991)(Rigaud et al., 
1991) 
Elemental (Vivonex HN) 2286 0.8 Safflower oil 0.8 100 0 0 0.07 9.1 0.11 13.9 0.62 77.3 76.5 0.8 95.63 71 
Royall et al. (1994)(Royall et al., 
1994) 
Elemental (Vivonex-TEN) - 3 Safflower oil 3 100 0 0 0.27 9.1 0.42 13.9 2.32 77.3 76.5 0.8 95.63 84 
Semi-elemental (Peptamen) - 33 Sunflower (30%) & MCT oil 10 30.3 23 69.7 24.37 73.84 2.22 6.72 6.53 19.8 19.68 0.15 131.20 75 
Sakurai et al. (2002)(Sakurai et al., 
2002) 
Elemental, Low fat (Elental) - 1.5 Soybean oil 1.5 100 0 0 0.24 15.7 0.36 24.2 0.9 59.8 52.1 7.8 6.68 67 
Semi-elemental, High MCT (Twinline) - 25 Safflower & MCT oil (tricaprilin) 7 28 18 72 18.64 74.54 0.97 3.89 5.41 21.64 21.42 0.22 97.36 77 
Verma et al. (2000)(Verma et al., 
2000) 
Elemental 2500 17 NS 11.05 65 5.95 35 6.63 39 7.82 46 2.55 15 12  - -  80 
Polymeric 2500 17 NS 11.05 65 5.95 35 6.63 39 7.82 46 2.55 15 12 -  - 67 
Gonzalez-Huix et al. 
(1993)(Gonzalez-Huix et al., 1993) 
Polymeric (Edanec HN) 2800 32 Olive oil (55%) & milk fat 27.8 87 4.2 13 13.12 41 13.12 41 5.76 18  -  -  - 80 
Lindor et al. (1992)(Lindor et al., 
1992) 
Semi-elemental (Vital HN) - 9 Safflower (55%) & MCT (45%) 4.95 55 4.05 45 4.68 52.04 1.1 12.32 3.26 36.3 36.08 0.3 120.27 60 
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Lochs et al. (1991)(Lochs et al., 
1991) 
Semi-elemental (Peptisorb) - 8 Soybean oil (50%) & MCT 4 50 4 50 4.62 57.85 0.97 12.1 2.39 29.9 26.05 3.9 6.68 60 
Malchow et al. (1990)(Malchow et al., 
1990) 
Semi-elemental (Survimed) - 10 Sunflower 10 100 0 0 1.28 12.8 2.24 22.4 6.6 66 65.6 0.5 131.20 96 
Greenberg et al. (1988)(Greenberg et 
al., 1988) 
Polymeric (Precision-Isotonic) - 28 Soybean oil 28 100 0 0 4.4 15.7 6.8 24.2 16.7 59.8 52.1 7.8 6.68 
58 
Kobayashi et al. (1998)(Kobayashi et 
al., 1998) 
Elemental (Elental) - 1.5 Soybean oil 1.5 100 0 0 0.24 15.7 0.36 24.2 0.9 59.8 52.1 7.8 6.68 70  
Polymeric (Clinimeal) - 28 Corn & coconut oils 19.3 69 8.7 31.15 15 53.7 4.8 17.1 8.23 29.5 28.95 0.55 52.64  67 
Mantzaris et al. (1996)(Mantzaris et 
al., 1996) 
Polymeric (Nutrison HE) - 36 Corn, palm, & coconut oils 34.17 94.92 1.9 5.27 13.45 37.41 11.35 31.54 11.35 31.24 30.63 0.61 50.21 
40 
O’moráin et al. (1984)(O'moráin et 
al., 1984) 
Elemental (Vivonex) - 2.5 Safflower 2.5 100 0 0 0.23 9.1 0.35 13.9 1.9 77.3 76.5 0.8 95.63 
100 
Gorard et al. (1993)(Gorard et al., 
1993) 
Elemental (Vivonex TEN) 2100 2.5 Safflower 2.5 100 0 0 0.23 9.1 0.35 13.9 1.9 77.3 76.5 0.8 95.63 
77 
Okada et al. (1990)(Okada et al., 
1990) 
Elemental (Elental) - 1.5 Soybean 1.5 100 0 0 0.24 15.7 0.36 24.2 0.9 59.8 52.1 7.8 6.68 
80 
Bodemar et al. (1991)(Bodemar et 
al., 1991) 
Polymeric (Semper lowfat) - 20 Soybean 20 100 0 0 3 15.7 5 24.2 12 59.8 52.1 7.8 6.68 
90 
Coyle and Sladen (1989)(Coyle and 
Sladen, 1989) 
Polymeric (Enteral 250) 2000-3000 28 Corn oil 28 100 0 0 4 14.8 8 28.1 16 57.1 56.1 1 56.10 
67 
Riordan et al. (1993)(Riordan et al., 
1993) 
Elemental (E028) - 15.6 Arachis oil 15.6 100 0 0 2.82 17.1 9.39 56.9 4.29 26 20 1 20.00 84 
Guo et al. (2013)(Guo et al., 2013) Polymeric (Nutrison Fiber) 1500-2000 34 Sunflower, canola, & MCT oils 29 84.6 5 15.4 8.7 25.6 19.2 56.4 6.12 18  - - -  85 
Zoli et al. (1997)(Zoli et al., 1997) Semi-elemental (Peptamen) - 33 Sunflower (30%) & MCT oil 10 30.3 23 69.7 24.37 73.84 2.22 6.72 6.53 19.8 19.68 0.15 131.20 80 
Hu et al. (2014)(Hu et al., 2014) Semi-elemental (Peptisorb liquid) - 15 Soy oil % MCT oil 7.95 53 7.05 47 8.3 55.3 1.9 12.8 4.8 31.7 27.6 4.1 6.73 71 
Zhu et al. (2013)(Zhu et al., 2013) Polymeric (Nutrison Fibre) 2037 34 Sunflower, canola, & MCT oils 29 84.6 5 15.4 8.7 25.6 19.2 56.4 6.12 18  - -  -  67 
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2.3.5 Correlation between fat composition and remission rate 
2.3.5.1 Total amount of fat 
Eight studies have compared a pair of feeds with different nutrient composition 
(e.g. polymeric versus elemental or semi-elemental versus elemental).  It is difficult 
to determine the effect of fat content from these comparisons, as their composition for 
other nutrients was not standardised.  Only two studies have specifically examined the 
effect of the amount of total fat.  High and low fat feeds (fat mainly in the form of 
LCT) were compared.  The earlier study showed that the feed with a low percentage 
of fats (15.6% of total calories) achieved a higher RR (92%), than the high fat feed 
(35.6% of total calories), which achieved a RR of 55% (Middleton et al., 1995). The 
later study indicated that a very low fat feed (1.15% of total calories) achieved a 
significantly higher RR (80%) than a modest fat feed (11.27% of total calories), which 
achieved a RR of (25%) (Bamba et al., 2003).  It will be noted that the amount of fat 
in this higher fat feed was barely distinguishable from that of the low fat feed of the 
earlier study and yet the clinical effects were hugely different.  Overall we find no 
significant correlation or trend between total fat content and RR (r= 0.176, p= 0.252) 
(Figure 3A). 
2.3.5.2 Medium chain triglycerides (MCT) 
Varying MCT content does not have a consistent strong effect.  A single study 
which compared a feed with added MCT against a feed with no MCT, generated 
significantly different RRs of 77% and 67% respectively (Sakurai et al., 2002).  
However, the high MCT feed was semi-elemental and the low MCT feed was 
elemental, which precludes any firm conclusions about the contribution of the lipid to 
the observed differences.  Our quantitative analysis, which is based on results from all 
studies, finds a weak non-significant positive trend between MCT delivery as a 
percentage of the total energy provision and RR (r = 0.072; p = 0.643) where the range 
was from 0 to 30% of total energy supply (Figure 3B).  The apparent outlier to the 
upper left of the plot comes from Leiper’s study (Leiper et al., 2001) in which there 
was a particularly high concentration of MCT (>86% of all fat) with a high proportion 
of MUFA (29%) and a low n-6:n-3 ratio (see below) amongst the fats that were LCTs.  
2.3.5.3 Long chain triglycerides (LCT) 
The effect of undifferentiated LCTs has been addressed by comparing feeds 
with similar amounts of total fat but with different percentages of LCT. One study 
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(already mentioned above) compared four feeds: elemental, elemental with added 
LCT, elemental with added MCT, and semi-elemental (Middleton et al., 1995). The 
feed with high LCT was associated with the lowest RR (55%), while the elemental 
feed with added MCT performed best, with a RR of 92%. However, a second study 
found no significant difference in RRs between use of feed with 5% LCT and an 
isocaloric feed with 30% LCT (Leiper et al., 2001). Our quantitative analysis of all 
the reported studies of all feedings reveals a non-significant negative trend between 
LCT provision and RR (r = -0.254; p = 0.096) where the range was from 4 to 35% of 
total energy supply and where in most cases the predominant lipids were of the n-6 
class (where not, the relative excess came from n-9 lipid which we also consider 
disadvantageous (Figure 3C and see below). 
2.3.5.4 Saturated fats 
No single study has directly compared feeds with different levels of saturated 
fatty acids.  We found no significant correlation or trend between the amount of 
saturated fat and the RRs (r = -0.007, p = 0.964) where the range was from trace 
amounts to over 30% of total energy supply (Figure 3D). 
2.3.5.5 Olive oil/MUFA 
Only a single study has compared two feeds with the same amount of total fat 
but with different amounts of oleic acid (balanced by linoleic acid) (Gassull et al., 
2002). The feed with higher oleic acid content (79% of total fat) was significantly less 
effective (RR = 27%) than the feed with lower oleic acid (28%) and higher linoleic 
acid (45%), which achieved a RR of 63%. Although there are no other specific studies 
addressing MUFAs, our overall quantitative analysis is concordant, showing 
disadvantage from monounsaturated fatty acids (MUFA) with no statistical 
significance (r = -0.23, p = 0.13) with a range from trace amounts to about 25% of 
total energy supply (Figure 3E). 
2.3.5.6 n-6 and n-3 PUFAs 
Only the study by Gassull et al. has directly investigated the effect of an n-6-
rich feed (specifically linoleic acid), in which a significantly higher RR was achieved 
than with a lower n-6 content (Gassull et al., 2002). No study of non-elemental 
formulae readily allows assessment of the individual effects of an n-3-rich approach.  
In our quantitative analysis a very weak non-significant negative correlation 
was found between the amount and proportion of PUFA (of all types) and the response 
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rates from all feeds (r = -0.157, p = 0.308) (Figure 3F) as was also the case for n-3 
fatty acids (r = -0.166, p = 0.313) (Figure 3H).  
However, there was a weak positive correlation between the total n-6 fatty acid 
content and response rates (r = 0.253, NS) (Figure 3G), statistical significance (r= 
0.378, p = 0.018) which remained significant after correction for multiple tests (Figure 
3I). In the subgroup analysis (Table 2), when RR was stratified by the level of n-6:n-
3, significant difference (p = 0.011) was reported in the pooled RR between EEN feeds 
with moderate n-6:n-3 (58.94% RR) (95% CI 48.99, 68.9) versus feeds with high n-
6:n-3 (79.91% RR) (95% CI 72.31, 87.51). 
When patients exposed to only a single oil are considered (informal subgroup 
analysis) then the use of safflower oil is favoured, with a mean (median) response rate 
of 83.6% (84%) compared to the overall average response of 68.1% and mean 
(median) values for isolated exposure to soybean or arachis oil of 63.7% (68.5%) and 
68.6% (75%) respectively. 
 
 
 
 
 46 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
0
5
10
15
20
25
30
35
40
0 20 40 60 80 100 120
Fa
t%
 o
f T
ot
al
 C
al
or
ie
s
Remission Rate%
(A) Total fat
0
5
10
15
20
25
30
35
0 20 40 60 80 100 120
M
CT
%
 o
f T
ot
al
 C
al
or
ie
s
Remission Rate%
(B) Medium Chain Triglycerides
0
2
4
6
8
10
12
14
16
18
20
0 20 40 60 80 100 120
PU
FA
%
 o
f T
ot
al
 C
al
or
ie
s
Remission Rate%
(F) Polyunsaturated Fatty Acids
0
5
10
15
20
25
30
35
40
0 20 40 60 80 100 120
LC
T%
 o
f T
ot
al
 C
al
or
ie
s
Remission Rate%
(C) Long Chain Triglycerides
0
5
10
15
20
25
30
35
0 20 40 60 80 100 120
Sa
tu
ra
te
d 
Fa
tt
y 
Ac
id
s%
 o
f T
ot
al
 C
al
or
ie
s
Remission Rate%
(D) Saturated Fatty Acids
0
5
10
15
20
25
30
0 20 40 60 80 100 120
M
UF
A%
 o
f T
ot
al
 C
al
or
ie
s
Remission Rate%
(E) Monounsaturated Fatty 
Acids
 47 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
0
10
20
30
40
50
60
70
80
90
0 20 40 60 80 100 120
To
ta
l n
-6
%
 o
f T
ot
al
 F
at
ty
 A
cid
s
Remission Rate%
(G) Total n-6 Fatty Acids
0
1
2
3
4
5
6
7
8
9
0 20 40 60 80 100 120
To
ta
l n
-3
%
 o
f T
ot
al
 F
at
ty
 A
cid
s
Remission Rate%
(H) Total n-3 Fatty Acids
0
20
40
60
80
100
120
140
160
0 20 40 60 80 100 120
To
ta
l n
-6
:n
-3
 R
at
io
Remission Rate%
(I) Total n-6:n-3 Ratio
P-value < 0.05 
Figure 3: The association between fat composition of enteral nutritional feeds and 
remission rates (calculated based on per protocol analysis) in patients with 
Crohn’s disease.  
Pearson correlation test was used to measure the strength of the correlation. (A) Total fat 
percentage (r= -0.176, P-value= 0.252). (B) Medium chain triglycerides (MCT) percentage (r= 
0.072, P-value= 0.643). (C) Long chain triglycerides (LCT) percentage (r= -0.254, P-value= 
0.096). (D) Saturated fatty acids (SFA) percentage (r= -0.007, P-value= 0.964). (E) 
Monounsaturated fatty acids (MUFA) percentage (r= -0.23, P-value= 0.13). (F) 
Polyunsaturated fatty acids (PUFA) percentage (r= -0.157, P-value= 0.308). (G) Total linoleic 
acid (n-6) percentage (r= 0.253, P-value= 0.110). (H) Total linolenic acid (n-3) percentage (r= 
-0.166, P-value= 0.313). (I) Total n-6:n-3 ratio (r= 0.378, P-value= 0.018*).  
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Table 2: Subgrouping analysis for the effect of fat composition of enteral 
nutritional feeds on CD remission rate stratified by the level of lipid class 
Factor assessed Subgroup Number of comparisons 
(compared enteral feeds) 
Pooled RR (95% CI) 
Total fat level Low fat  11 74.09 (63.63, 84.56) 
Moderate fat 21 66.9 (57.53, 76.28) 
High fat 12 64.86 (53.34, 76.38) 
MCT level No MCT 22 69.59 (60.59, 78.59) 
Moderate MCT 10 56.93 (43.8, 70.06) 
High MCT  12 74.83 (67.32, 82.35) 
LCT level  Low LCT 11 74.27 (64.1, 84.45) 
Moderate LCT 22 70.55 (62, 79.09) 
High LCT 11 57.21 (45.35, 69.07) 
SFA level Low SFA 11 77.36 (66.55, 88.18) 
Moderate SFA 22 62.83 (54.36, 71.31) 
High SFA 11 69.55 (57.47, 81.62) 
MUFA level Low MUFA 11 77.45 (70.25, 84.65) 
Moderate MUFA 21 65.29 (56.53, 74.05) 
High MUFA 12 64.61 (50.74, 78.48) 
PUFA level Low PUFA 12 76.83 (70.03, 83.63) 
Moderate PUFA 20 65.17 (56.02, 74.31) 
High PUFA  12 64.42 (50.46, 78.37) 
Total n-6 level Low n-6 11 65.45 (52.23, 78.68) 
Moderate n-6 18 61.11 (51.29, 70.93)* 
High n-6  12 78.83 (70.7, 86.97)* 
Total n-3 level Low n-3  10 72.3 (60.26, 84.34) 
Moderate n-3 19 67.84 (58.07, 77.62) 
High n-3 10 60.7 (45.96, 75.44) 
n-6:n-3 level Low n-6:n-3 10 67.9 (54.06, 81.74) 
Moderate n-6:n-3 18 58.94 (48.99, 68.9)* 
High n-6:n-3 11 79.91 (72.31, 87.51)* 
Low level (lower quartile range); moderate level (interquartile range); high level (upper quartile range); RR (remission rate); 
MCT (medium chain triglycerides); LCT (long chain triglycerides); SFA (saturated fatty acids); MUFA (monounsaturated fatty 
acids); PUFA (polyunsaturated fatty acids); One-way ANOVA with multiple correction test have been used to test the 
significance of difference in RR between the subgroups; *Difference between subgroups is significant (P-value<0.05). 
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Table 3: Subgrouping analysis for the correlation between the fat composition of 
enteral nutritional feeds and CD remission rate stratified by the level of remission 
rates achieved 
Factor assessed Subgroup Number of 
comparisons 
(compared enteral 
feeds) 
r (95% CI) P-value 
RR for total fat correlation Low RR < 70% 20 -0.03 (-0.46, 0.42) 0.91 
High RR ≥ 70% 24 -0.00 (-0.41, 0.40) 0.99 
RR for MCT correlation  Low RR < 70% 20 0.05 (-0.39, -0.48) 0.83 
High RR ≥ 70% 24 -0.28 (-0.62, 0.14) 0.18 
RR for LCT correlation Low RR < 70% 20 -0.05 (-0.49, 0.39) 0.81 
High RR ≥ 70% 24 0.27 (-0.15, 0.60) 0.21 
RR for SFA correlation Low RR < 70% 20 -0.00 (-0.44, 0.44) >0.99 
High RR ≥ 70% 24 -0.21 (-0.57, 0.21) 0.32 
RR for MUFA correlation Low RR < 70% 20 -0.16 (-0.56, 0.31) 0.51 
High RR ≥ 70% 24 0.23 (-0.19, 0.58) 0.29 
RR for PUFA correlation Low RR < 70% 20 0.13 (-0.33, 0.54) 0.57 
High RR ≥ 70% 24 0.24 (-0.18, 0.59) 0.26 
RR for n-6 correlation Low RR < 70% 19 0.19 (-0.29, 0.59) 0.44 
High RR ≥ 70% 22 0.19 (-0.26, 0.56) 0.41 
RR for n-3 correlation Low RR < 70% 18 -0.08 (-0.53, 0.39) 0.74 
High RR ≥ 70% 21 -0.13 (-0.53, 0.32) 0.59 
RR for n-6:n-3 correlation  Low RR < 70% 18 0.30 (-0.19, 0.67) 0.22 
High RR ≥ 70% 21 -0.01 (-0.44, 0.43) 0.98 
r (Pearson correlation coefficient); RR (remission rate); MCT (medium chain triglycerides); LCT (long chain triglycerides); 
SFA (saturated fatty acids); MUFA (monounsaturated fatty acids); PUFA (polyunsaturated fatty acids). 
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2.4 Discussion 
The wide range of patient characteristics, the low number of participants in 
each study, and varying study designs obstruct the route to confident and generalizable 
conclusions.  We deliberately used results taken from observations on patients who 
followed treatment protocols (rather than intention to treat), but although biologically 
justifiable this will be of limited clinical value if a future “optimal” formula is not 
tolerated and thus the treatment plan is not completed.  Fortunately, the 
compliance/acceptance of the many different formulae did not appear systematically 
different according to the particular lipid profiles. This may have been obscured 
however by the range of duration of the intended therapies. The duration of 
intervention in most of the trials examined was between 3 and 8 weeks, 12 weeks in 
one trial (Hu et al., 2014), and only 2 weeks in 3 studies (Bodemar et al., 1991, Riordan 
et al., 1993, Zoli et al., 1997).  
No fewer than eight different sets of criteria have been utilised to define 
response. Some were strict and binary (e.g. complete steroid withdrawal) and 
associated with relatively low response rates (Giaffer et al., 1990, Mansfield et al., 
1995), while others were more qualitative (subjective).  It should not have had a major 
effect on our interpretations since a full analysis performed on this basis provides the 
same qualitative results (data not shown). 
Our methods may not have been sufficient to overcome bias introduced by the 
differing anatomical location of the CD (small bowel, large bowel, or both).  The trials 
with the highest proportions of patients with small bowel CD (50% and 52%) also had 
amongst the highest RRs (86% and 75% respectively)(Giaffer et al., 1990, Royall et 
al., 1994), a linkage already well recognized in the literature, and perhaps a confounder 
despite apparently well-matched controls.    
It has been thought that EN is more effective in those with early, purely 
inflammatory disease.  Although not all evaluated studies provided the duration of the 
disease, the shortest and longest mean disease durations (1.3 and 18 years) were 
associated with similar and very respectable RRs of 90% and 80% respectively, 
suggesting that this effect is not profound (Okada et al., 1990, Bodemar et al., 1991).  
Considerable differences were observed in respect of sex ratio (0-89% male 
(Sakurai et al., 2002), (Park et al., 1991)), but although prognosis of CD may differ 
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between the sexes (Park et al., 1991) a systematic bias could not be detected within 
our analysis (Zelinkova and van der Woude, 2014).  
The divergence between the different types of unsaturated LCTs (n-3, n-6 and 
n-9) and outcome appear at first surprising, but are fully consistent with the negative 
results from supplementary fish oil in CD (Lev-Tzion et al., 2014).  In terms of specific 
oil content, interpretation is clouded by the number of feeds which contain multiple 
oils.  However the numerical advantage to safflower oil is very much in line with the 
overall conclusion that high n-6:n-3 ratio is advantageous and low proportion of 
MUFA could be relatively effective as well, given the relative paucity of MUFA in 
safflower oil (13.9% compared to 23.9% in soy and 56% in arachis oil) and its n-6:n-
3 ratio, which, at over 90, is the highest of all the dietary oils.  It has been more difficult 
still to link interpretation to individual fatty acids, but linoleic acid is favoured, and 
oleic acid as the only n-9 fatty acid in artificial feeds is targeted for avoidance. 
There is a little supportive evidence also for our hypothesised complementary 
combination of safflower oil and MCT.  One of the highest response rates in the 
literature (92% (Middleton et al., 1995)) was in patients on this combination, and only 
the study of Lindor et al appears to point in the opposite direction, this being a small 
study in which the comparator was steroid therapy (Lindor et al., 1992). 
2.5 Conclusions 
The fat content of EN formulae and its influence on controlling the 
inflammation of CD has generated interest, but its true role has remained unclear.  
Given its potential importance it is surprising that most authors have not thought it 
worthwhile or necessary to disclose the lipid analysis of the formulae used in their 
study.  This systematic review has dissected the previously very broad classification 
of lipids in order to try to assess the effects of individual dietary oils and their fatty 
acids.  It is recognised that definitive analysis is not possible given, on the one hand, 
the incomplete comparative information available, and, on the other, the inevitable 
complexity introduced by the replacement of one lipid with another and/or by different 
total fat content in different feeds.  We manifestly lack sufficiently robust clinical trials 
in this area (Forbes et al., 2016). 
However, our results expose significant results from individual studies, and, 
as well as several suggestive trends, support significant advantage from a high n-6 to 
n-3 ratio and perhaps from avoidance of MUFA.  The various trends are, moreover, 
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not mutually exclusive despite the considerable variation in study design and response 
rates.  Aiming for a relatively low total LCT content and proportionately high MCT 
content, with a relative low MUFA and high n-6:n-3 fatty acid ratio can now be argued 
to offer an optimised approach.  This might most easily and effectively be achieved 
by development of feeds based on a combination of safflower oil and MCT.   
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3 Chapter 3. Investigating the fatty acid profile and adipocytokine 
gene expression in mesenteric adipose tissues of Crohn’s disease 
patients and control  
 
 
3.1 Introduction 
3.1.1 Mesenteric adipose tissues as an emerging role in CD 
Chronic inflammation is part of the pathogenesis of many human diseases, 
including intestinal diseases like CD. In the visceral fats (mesenteric adipose tissues - 
MAT), chronic and low-grade inflammation can create a local microenvironment for 
inflammatory diseases as in CD. A potential role for MAT in CD pathogenesis is 
suggested by previous studies (Zulian et al., 2012, Peyrin-Biroulet et al., 2012). In CD, 
the mesentery attached to the inflamed intestines is usually thickened due to unknown 
reasons, the condition being called the “fat-wrapping” phenomenon, which represents 
a hallmark of the disease. Histologic investigations of the mesenteric fat of patients 
with fat wrapping demonstrated alterations in inflammatory markers (adipocytokines). 
Combining these data with the emergence of adipose tissue as an endocrine organ 
suggest a key role of visceral fat in CD pathophysiology.  
3.1.2 Inflammation in mesenteric adipose tissues 
In obesity, the accumulation of visceral adipose tissues stimulates the 
activation of the pro-inflammatory pathway, while in CD the hypertrophied MAT is 
associated with the increased production of both pro-inflammatory and anti-
inflammatory mediators (Kredel and Siegmund, 2014). The complex inflammatory 
profile shown in CD mesenteric fat has been investigated by a few studies with 
inconsistent findings. One study has shown that the MAT in CD demonstrate increased 
M2 macrophages infiltration, which is associated with anti-inflammatory phenotype, 
therefore suggesting a protective function of this type of tissue in CD pathogenesis 
(Kredel et al., 2013).  However, another study has shown that the mesenteric fat depot 
can be a great source of CRP in CD, which eventually could contribute to the overall 
inflammation in CD. Furthermore, bacterial translocation and local inflammation have 
been identified as triggers to CRP production in MAT (Peyrin-Biroulet et al., 2012). 
Yet, it is unknown if the accumulation of mesenteric fat in patients with CD is a pre-
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illness condition or a secondary phenomenon resulting from local inflammation of the 
adjacent intestine. Further characterization of the inflammatory profile of this type of 
adipose tissue is thus required. 
3.1.3 Lipids in mesenteric adipose tissues 
Adipose tissue acts as an energy reservoir by storing lipids, and has always 
been recognized as an important organ in lipid storage regulation and metabolism. The 
cellular uptake and storage of dietary fatty acids in the adipose tissue is controlled by 
adipocytes. In a situation where adipocyte function is disrupted due to impaired 
adipose tissue accumulation and increased pro-inflammatory response, as observed in 
visceral obesity, the release of fatty acids from this tissue will increase, possibly 
leading to insulin resistance (Siegmund, 2012). In CD, the observed MAT hypertrophy 
results in a complex inflammatory response, and one proposed mechanism has 
associated this phenomenon to the abnormal composition of fatty acid in these tissues. 
The MAT contains lymphoid tissues for facilitating triglyceride entry into the blood 
and they are also capable of the uptake and retention of selected fatty acids (Camell 
and Smith, 2013, Pond, 2017). It has be shown that fatty acid precursors levels of 
eicosanoid and docosanoid are reduced in CD MAT lymphoid cells, which could be 
due to the interrupted interaction between the adipocytes and lymphoid cells within 
these tissues leading to defective fatty acid transport (Westcott et al., 2006). 
Understanding more about such defective lipid metabolism would help in identifying 
the underlying mechanisms between MAT and intestinal inflammation in CD. 
3.1.4 Research gaps 
Our understanding of how the intestinal tissues in CD interact with the diet and 
lead to a relapsing inflammatory response is still poorly understood. Dietary fatty acids 
have been suggested to play a key role in modulating intestinal inflammation in CD; 
yet, their mechanism of action is unclear. However, the abnormal accumulation of 
mesenteric fats that is exclusive to CD does provide an aetiopthogenic relevance of 
lipids in the disease’s behavior. Fatty acids are considered important regulators of 
adipose tissue function and have been demonstrated to stimulate adipocytes via innate 
immunity receptors, which subsequently facilitate the secretion of pro-inflammatory 
cytokines (Shi et al., 2006). Characteristics of the fatty acid profile of the mesenteric 
fat depot in CD, in relation to their inflammatory gene expression is poorly 
investigated, thereby warranting further studies in this area. 
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3.1.5 Hypothesis 
An abnormal inflammatory gene expression and fatty acid profile is associated 
with the fat-wrapping phenomenon observed in CD, which could be a key factor in 
controlling chronic intestinal inflammation. This will be tested by measuring fatty 
acids levels in CD against a control. Additionally, the expression levels of 
adipocytokines and genes involved in inflammation and adipogenesis of the MAT in 
CD will be also measured against a control. 
3.1.6 Objectives 
The primary objective of this study is to better characterize the inflammatory 
gene expression profile and the fatty acids composition of the MAT in patients with 
and without CD. 
 
3.2 Methods 
3.2.1 Human mesenteric adipose tissue collection 
Ethical approval for collecting human tissue samples was obtained from the 
Faculty of Medicine and Health Sciences Research Ethics Committee of the 
University of East Anglia (UEA) (Norwich, UK) (reference: 20152016 66 HT). The 
Norwich Biorepository (Norwich and Norfolk University Hospital (NNUH), UK) 
patient information sheet and consent form were used to obtain the participants’ 
consent (Appendix 8). 
Eligible patients were mainly identified from a theatre list of colorectal 
surgeons, which was checked regularly with the help of the surgeons’ secretaries. 
Patients were then approached on the day of surgery. All patients provided informed 
consent prior to surgery at the same day in the admission unit. Information about 
patients’ medical history was collected pre-operatively. This included: disease type, 
surgical procedure, comorbidities, drug history, smoking history, age, gender, BMI, 
Montreal classification data (for IBD patients only), and biochemical data. 
MAT was collected from colorectal surgical patients with confirmed diagnosis 
of either IBD or colorectal cancer (control group) who were having bowel resection 
involving the small bowel. The inclusion criteria for this study were: 1) patients older 
than 18 years, 2) patients diagnosed with moderate to severe CD affecting either the 
small bowel or both, the small and large bowel, and undergoing intestinal resection, 
3) patients undergoing intestinal resection surgery for UC (as it is usual for a small 
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cuff of healthy ileum to be included in the resection specimen) and, 4) patients 
diagnosed with colorectal cancer (CRC) (control group) who were undergoing right 
hemicolectomy, which is a procedure involving resection of the right side of the colon 
and at least 10 cm of the distal terminal ileum – which is the same portion of the small 
bowel mainly affected in CD. The exclusion criteria excluded: 1) patients undergoing 
surgical resection that only involved the colon (e.g. anterior resections), 2) patients 
with multiple or serious comorbidities, 3) pregnant women and 4) patients unwilling 
to provide informed consent.  
Specimens were collected as follows: once the bowel tissue was resected, the 
operating theatre immediately sent the specimen in a sterile pot to the histopathology 
lab, where a specialized GI histopathologist cut the required MAT samples and handed 
them to myself. All specimens were collected from MAT close to the small intestinal 
wall as shown in Figure 4. For this study, two specimens of healthy MAT (100 mg 
each) were collected from CRC patients, while four specimens (two of healthy MAT 
and two of inflamed MAT) were collected from IBD patients, if possible. Specimens 
were collected in sterile cryovials and immediately frozen in liquid nitrogen and stored 
in the Biorepository at -80oC until laboratory analysis, which included RNA extraction 
for gene expression studies and lipid extraction for fatty acid analysis. In addition, one 
separate specimen (2 gm, approximately 4 x 4 cm in size) of fresh MAT was also 
collected if possible and placed immediately in a sterile collection tube, which was 
immediately sent to the lab for pre-adipocyte isolation and culture study (Chapter 4). 
The time between the surgical resection of the bowel and the sample collection was 
variable as this mainly depended on the nature of each surgery. Moreover, tissue 
collection was successful from the majority of morning cases, while collection from 
late afternoon cases was difficult because of the limited service of the histopathology 
lab at that time. 
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Figure 4: A diagram illustrating the intestinal fat-wrapping in Crohn’s disease. 
The surgical specimen show the fold of mesenteric adipose tissue that cover the intestinal 
surface. 
 
3.2.2 RNA extraction and Quantitative real-time PCR (qRT-PCR) 
3.2.2.1 RNA extraction 
For measuring the level of gene expression, RNA was extracted from frozen 
MAT by using the ReliaPrep RNA tissue extraction kit (Promega Z6111). Briefly, 60 
mg of tissue was homogenized in 500 µl of BL+TG lysis buffer with stainless steel 
beads for 10 minutes at 50 Hz using the TissueLyser II (Qiagen). The homogenized 
sample was then centrifuged at 12,000 g for 10 minutes and at room temperature to 
separate the fat layer, which was removed, and the supernatant collected in a 1.5 ml 
centrifuge tube where the required volume of 100% isopropanol was added. The lysate 
was then transferred to the extraction kit mini-column and centrifuged at 14000g for 
30 seconds. RNA Wash solution (500 µl) was added to the mini-column and 
centrifuged at 14000g for 30 seconds. Next, DNase I incubation mix was prepared by 
mixing 24µl of Yellow Core Buffer, 3µl 0.09M MgCl2 and 3µl of DNase I enzyme 
and then added to each mini-column and incubated at room temperature for 15 
minutes. 200µl of column wash solution was then added to the mini-column and 
centrifuged at 14000g for 15 seconds, followed by 500µl of RNA wash solution, which 
was again centrifuged at 14000g for 30 seconds. The mini-column was thereafter 
placed into a new collection tube where 300µl of RNA wash solution was added and 
centrifuged at 14000g for 2 minutes. Finally, the mini-column was transferred to an 
Mesenteric fat 
Mesenteric fat 
Small intestine 
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elution tube, and 15µl nuclease-free water was added directly onto the membrane and 
centrifuged at 14000g for 1 minute to elute the RNA. The extracted RNA was then 
stored at -20°C until further analysis. RNA concentration and purity was measured 
using a NanoDrop 2000 Spectrophotometer (ThermoScientific, UK). RNA solutions 
with a A260/A280 ratio of 1.9-2.1 was considered pure and of acceptable quality.  
3.2.2.2 cDNA synthesis  
The reverse transcription reaction for cDNA synthesis was done using the 
qPCRBIO cDNA synthesis kit (PCR Biosystems, London, UK). To make a 10 µl 
reaction of cDNA, 2 µl of 5x cDNA Synthesis Mix and 0.5 µl of 20x RTase were 
added to 7.5 µl of nuclease-free water that carried up to 100ng RNA in PCR tubes. 
The tubes were then incubated in the Thermocycler (Bio-Rad, Watford, UK) at 42°C 
for 30 minutes and at 85°C for 10 minutes to denature RTase, and then kept at 4°C for 
up to three hours or stored at -20°C. Before performing gene expression by qRT-PCR, 
the cDNA samples were diluted 1:5 or 1:10 in nuclease-free water. 
3.2.2.3 Gene expression using quantitative real-time PCR (qRT-PCR) 
qRT-PCR was done using the qPCRBIO SyGreen Mix (PCR Biosystems, 
London, UK). For a 10 µL reaction, 5 µL of SyGreen Mix and 1 µl of forward and 
reverse primer mix were added to 4 µL of diluted cDNA. All the samples were then 
run in duplicates on a 96-well white PCR plate (STARLAB). In addition, a negative 
control without cDNA sample was prepared along with every assay. The predesigned 
qRT-PCR primers for the selected genes for this study were purchased from Sigma 
(KiCqStart® SYBR® Green Primers) and are listed in Table 4. These primers were 
dissolved in nuclease-free water as specified by the manufacturer’s technical sheet, 
which were then briefly vortexed and stored at -20°C until future use. The cDNA 
samples were run on a LightCycler 480 (Roche Life Science, Burgess Hill, UK) and 
the following cycles were performed: the pre-amplification step (95°C for 2 minutes), 
followed by cDNA amplification over 45 cycles (95°C for 15 seconds, 60°C for 10 
seconds and 72°C for 10 seconds), which was then followed by a melting curve 
analysis step (95°C for 5 seconds, 65°C for 1 minute and 97°C continuous), which 
was performed to confirm product specificity and to detect any formation of primer 
dimers which could give false positives if unidentified. Finally, the reactions were 
cooled at 40°C for 30 seconds.  
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3.2.2.4 qRT-PCR data analysis 
A cycle threshold (Ct) value was measured and generated at the end of each 
qRT-PCR reaction. Data was normalized against the housekeeping genes Ribosomal 
Protein L13a (RPL13a) and Glucuronidase Beta (GUSB) which were selected for their 
most stable gene expression levels amongst the mesenteric MAT samples (Appendix 
9). The mRNA expression level for each sample was calculated using the Delta Ct 
method (Delta Ct = Ct target gene – Ct housekeeping gene), where Ct represents the 
number of cycles required to generate a fluorescent signal above a pre-defined 
threshold in qRT-PCR. All mRNA expression levels for target genes in this study are 
presented as relative to the geometric mean of the housekeeping genes RPL13a and 
GUSB.  However, the Delta Ct method was used for qRT-PCR data analysis in 
Chapter 4, where a change in gene expression was expressed as a fold change relative 
to control groups (equivalent to 2-(Delta Ct treated-Delta Ct control)). 
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Table 4: Primers used for mRNA expression analysis using qRT-PCR 
Gene Forward primer sequence (5’–3’)  Reverse primer sequence (5’–3’) 
ACTB 
(Beta actin) 
GACGACATGGAGAAAATCTG ATGATCTGGGTCATCTTCTC 
RPL13A GTCTGAAGCCTACAAGAAAG TGTCAATTTTCTTCTCCACG 
GUSB ACTGAACAGTCACCGAC AAACATTGTGACTTGGCTAC 
GAPDH ACAGTTGCCATGTAGACC TTGAGCACAGGGTACTTTA 
RN18S1 ATCGGGGATTGCAATTATTC CTCACTAAACCATCCAATCG 
ADIPOQ 
(Adiponectin) 
GGTCTTATTGGTCCTAAGGG GTAGAAGATCTTGGTAAAGCG 
Leptin TCAATGACATTTCACACACG TCCATCTTGGATAAGGTCAG 
PPARG AAAGAAGCCAACACTAAACC TGGTCATTTCGTTAAAGGC 
CEBPA 
(CEBP4) 
AGCCTTGTTTGTACTGTATG AAAATGGTGGTTTAGCAGAG 
FABP4 CCACCATAAAGAGAAAACGAG AGTTGCTTGCTAAATCATGG 
IL-6 GCAGAAAAAGGCAAAGAATC CTACATTTGCCGAAGAGC 
CD68 GTACTGAACCCCAACAAAAC ATGTAGCTCAGGTAGACAAC 
CCL2 (MCP1) AGACTAACCCAGAAACATCC ATTGATTGCATCTGGCTG 
CD163 ATGAGTCCCATCTTTCACTC CTATGTCCCAGTGAGAGTTAC 
MRC1 
(CD206) 
AAATTTGAGGGCAGTGAAAG GGATTTGGAGTTTATCTGGTAG 
IL-10 GCCTTTAATAAGCTCCAAGAG ATCTTCATTGTCATGTAGGC 
ARG1 
(Arginase) 
ACTAGGAAGAAAGAAAAGGC TCTTCTGTGATGTAGAGACC 
Gene name, forward and reverse primer sequences are shown in the table.  
 
3.2.3 Lipid extraction and fatty acid analysis  
3.2.3.1 Total lipid extraction 
Lipid extraction from and fatty acid analysis of the MAT samples were 
conducted in collaboration with James Dick from the Nutrition group at the Institute 
of Aquaculture in the University of Stirling (UK). The method is based on a previous 
protocol by Folch (Folch et al., 1957). First, the total lipid content was extracted from 
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the snap frozen, pre-weighed MAT samples (detailed in section 3.2.1) with 20 
volumes of ice-cold chloroform: methanol mixture (2:1 v/v) in 50 ml Quickfit 
stoppered tubes, and then homogenized using an Ultra-Turrax tissue disrupter (Fisher 
Scientific, Loughborough, UK) in the fume cupboard. To isolate non-lipid impurities, 
potassium chloride (KCl) at 0.88% (w/v) was subsequently added to the homogenized 
sample followed by centrifugation at 1500 rpm for at least 5 minutes; the top (aqueous) 
layer was discarded while the lower solvent layer containing the lipids was transferred 
to a pre-weighed 15 ml Quickfit stoppered tube and filtered through a pre-washed 
(with chloroform/ methanol (2:1 v/v)) Whatman no.1 filter paper. Lipid extracts were 
then dried under a stream of oxygen-free nitrogen on a nitrogen evaporator and 
resuspended in 2:1 v/v chloroform: methanol with 0.01%, w/v butylated 
hydroxytoluene (BHT) (Sigma-Aldrich, Dorset, UK) to a final concentration of 10 
mg/ml and transferred to 2 ml glass vials, which were stored under nitrogen at -20°C 
until further analysis. Two replicates of lipid extractions were performed on each 
tissue sample.  
3.2.3.2 Fatty acid analysis: FAME analysis and Gas Chromatography 
Fatty acid methyl esters (FAMEs) from total lipid extracts were prepared by 
acid-catalyzed transesterification of total lipid according to Christie’s method 
(Christie, 2003). Total lipid samples (normally 1 mg) were placed into a 15 ml Quickfit 
test tube and free fatty acid standard (Heptadecaenoic acid 17:0 at 1 mg/ml in 2:1 v/v 
chloroform: methanol) was added at 10% of the total lipid mass. The organic solvent 
was then evaporated under nitrogen and 2 ml of methylation reagent solution (1% 
sulphuric acid (H2SO4) in methanol) was then added to the samples for overnight 
incubation at 50°C in a heating block. The samples were then cooled to ambient 
temperature the following day and 2 ml of aqueous potassium bicarbonate KHCO3 
(2% (w/v) was added to neutralize the samples. 5 ml of iso-hexane: diethyl ether (1:1, 
v/v) with 0.01% (w/v) BHT was added thereafter and the contents were mixed by 
inverting the tube followed by centrifugation at 1500 rpm for 2 minutes. After 
centrifugation, the upper organic layer was transferred to a clean test tube using a 
Pasteur pipette. A further 5 ml of iso-hexane: diethyl ether (1:1, v/v) with 0.01% (w/v) 
BHT was added to the original tube, mixed and re-centrifuged as previously; the upper 
organic layer was transferred to the other tube as before. The combined organic 
extracts were evaporated under nitrogen and re-dissolved in 100 µl of iso-hexane. The 
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samples were then loaded onto thin layer chromatography (TLC) silica plates (20 x 20 
cm) using a glass Hamilton syringe, not exceeded 1.5 mg/cm per sample. A methyl 
ester standard was also loaded to the left side of every plate. The plate was then 
chromatographed in 90:10:1 iso-hexane: diethyl ether: acetic acid eluent for an hour. 
After the plate was dried in the fume cupboard, they were sprayed with 1% (w/v) 
iodine in chloroform to visualize the FAMEs. The FAME bands were all marked with 
a pencil and scraped from the TLC plates into test tubes using a straight edged scalpel 
blade or razor blade. The FAMEs were then extracted from the silica by adding 10 ml 
of iso-hexane: diethyl ether (1:1, v/v) + 0.001% (w/v) BHT followed by mixing and 
centrifugation at 1500 rpm to sediment the silica, where after the supernatant was 
carefully transferred to a clean test tube with a glass pasteur pipette and the solvent 
was evaporated under nitrogen. The samples then were transferred into 2 ml glass vials 
dissolved in 1 ml iso-hexane. The FAMEs were stored under nitrogen at -20°C or less 
until gas-liquid chromatography (GLC) analysis. 
GLC was performed on a Thermo Fisher Trace GC 2000 (Thermo Fisher, 
Hemel Hempstead, UK) equipped with a fused silica capillary column (ZBWax, 60 m 
x 0.32 x 0.25 mm i.d.; Phenomenex, Macclesfield, UK) with hydrogen as carrier gas 
and using on-column injection. The temperature gradient was from 50 to 150°C at 
40°C/min and then to 195°C at 1.5°C/min and finally to 220°C at 2°C/min. Individual 
methyl esters were then identified according to previously published data (Tocher and 
Harvie 1988). Data were collected and processed using the Chromcard for Windows 
(version 2.00) computer package (Thermoquest Italia S.p.A., Milan, Italy). 
3.2.4 Statistical analysis 
GraphPad Prism software (Version 7.0, GraphPad Software, San Diego, CA, 
USA) was used for statistical analysis. Results are presented as mean ± standard error 
of the mean (SEM). The non-parametric Mann-Whitney U test was used to compare 
differences in the gene expression level and the fatty acid level between IBD and CRC 
MAT samples. For paired IBD samples (i.e. inflamed versus non-inflamed samples) 
the non-parametric Wilcoxon signed-rank test was used.  P < 0.05 was considered 
statistically significant. Moreover, the significance of correlation between fatty acids 
level and level of gene expression was tested by the Pearson correlation test 
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3.3 Results 
3.3.1 Study subjects’ characteristics  
Surgical specimens of MAT were obtained during intestinal resection of 15 
patients with CRC (mean age 78.5 ± 5.24 years, mean BMI 26.65 ± 4.21 kg/m2) and 
8 patients with IBD (6 patients were diagnosed with CD and 2 patients with UC, mean 
age 43.5 ± 6.36 years, mean BMI 25.51 ± 1.22 kg/m2). Patient characteristics are 
shown in Table 5. The mean age and mean BMI were not significantly different 
between CRC and IBD patients (p > 0.05). 
Table 5: Characteristics of study subjects 
 CRC IBD 
n 15 8  
(6 CD; 2 UC) 
Male (%) 6% 12% 
Female (%) 33% 75% 
Age (years) 78.5 ± 5.24 54 ± 18.73 
BMI (kg/m2) 26.65 ± 4.21 25.51 ± 1.22 
Type of surgery: 
Right hemi-colectomy  
Panproctocolectomy  
Ileocecal resection 
Ileal resection  
Small bowel resection 
Open ileorectal anastomosis  
 
14 
1 
 
 
 
2 
3 
1 
1 
1 
Data are presented as percentages mean ± SEM. BMI, body mass index. *p < 0.05 
CRC vs IBD. 
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3.3.2 Expression of adipokines and adipogenesis genes in CRC and IBD 
mesenteric adipose tissues 
Different types of adipokines and adipogenesis genes expressed differently in 
the MAT. As seen in Figure 5, adiponectin was highly expressed in these tissues (1.41 
± 0.27 for CRC and 1.98 ± 0.42 for IBD) compared to leptin (0.19 ± 0.04 for CRC and 
0.18 ± 0.09 for IBD). Also, the gene expression level for FABP4 was the highest 
among the three key markers for adipogenesis (26.49 ± 5.01 for CRC and 16.65 ± 2.81 
for IBD), while the gene expression levels for PPARg and CEPBa were 0.11 ± 0.01 
and 0.21 ± 0.03 for CRC, and 0.12 ± 0.03 and 0.08 ± 0.01 for IBD. 
The difference in gene expression between the different types of MAT samples 
(CRC vs. CD) is shown in Figure 6 and Figure 7. There was a significant difference 
in the leptin mRNA level between CRC (0.19 ± 0.04) and CD (0.05 ± 0.01) MAT (p= 
0.03), but not in adiponectin mRNA levels (CRC 1.41 ± 0.27 and CD 1.68 ± 0.51, p= 
0.89) (Figure 6A-B). Furthermore, adipogenesis specific markers expressed 
differently in the MAT samples. The difference in CEPBa mRNA levels in CRC and 
CD MAT were statistically significant (CRC 0.21 ± 0.03 and CD 0.07 ± 0.01, p= 
0.003) (Figure 7B). However, the difference in gene expression for PPARg and 
FABP4 was not significant in the tissue samples; the relative mRNA level for PPARg 
was 0.11 ± 0.1 in CRC samples and 0.10 ± 0.03 in CD samples (p= 0.38), while the 
mRNA level for FABP4 was 26.49 ± 5.01 in CRC samples and 15.04 ± 3.38 in CD 
samples (p= 0.15) (Figure 7A and C). Overall, these results indicate a trend for reduced 
gene expression of adipocyte specific markers in inflamed CD MAT compared to 
healthy CRC MAT.  
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Figure 5: Bar graphs showing the relative increase in gene expression across 
adipocytokines and adipogenesis genes in CRC and IBD mesenteric fat samples. 
Data is presented as relative quantity of mRNA normalised to the reference genes RPL13a 
and GUSB. Values are expressed as mean ± SEM. n= 12 for CRC and n= 8 for IBD (including 
CD and UC).               
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Figure 6: Bar graphs comparing the difference in the relative gene expression for 
adipocytokines genes between CRC and IBD mesenteric fat samples. 
Data is presented as relative quantity of mRNA normalised to the reference genes RPL13a 
and GUSB. Values are expressed as mean ± SEM. n= 12 for CRC, n= 6 for CD, and n= 2 for 
UC. Differences in the mRNA expression between the CRC and CD groups were tested using 
Mann-Whitney U test. *p < 0.05. 
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Figure 7: Bar graphs comparing the difference in the relative gene expression for 
adipogenesis genes between CRC and IBD mesenteric fat samples.  
Data is presented as relative quantity of mRNA normalised to the reference genes RPL13a 
and GUSB. Values are expressed as mean ± SEM. n= 12 for CRC, n= 6 for CD, and n= 2 for 
UC. Differences in the mRNA expression between the CRC and CD groups were tested using 
Mann-Whitney U test. **p < 0.01. 
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3.3.3 Expression of inflammatory genes in CRC and IBD mesenteric adipose 
tissues 
mRNA expression levels of inflammatory markers (including macrophage-
specific markers) were investigated in MAT samples. According to Figure 8, 
expression levels varied for all the inflammatory markers. For pro-inflammatory 
specific markers, IL-6 mRNA was highly expressed (0.17 ± 0.09 for CRC and 0.11 ± 
0.03 for IBD) compared to CD68 (0.05 ± 0.01 for CRC and 0.04 ± 0.01 for IBD). 
Amongst anti-inflammatory markers, MCP1 mRNA was the most highly expressed 
(0.11 ± 0.06 for CRC and 0.08 ± 0.03 for IBD) followed by CD163 (0.05 ± 0.02 for 
CRC and 0.01 ± 0.006 for IBD) and CD206 (0.03 ± 0.01 for CRC and 0.01 ± 0.002 
for IBD). mRNA levels for IL-10 and arginase were very low (for some samples the 
levels of IL-10 and arginase were under the detection limits of qRT-PCR). Moreover, 
due to technical problems with TNF-α and CRP primers, measurement of their gene 
expression levels in mesenteric fat was not feasible. 
Comparisons between CRC and CD groups revealed no significant difference 
in mRNA expression levels for the pro-inflammatory markers (IL-6 and CD68); the 
relative gene expression level for IL-6 was 0.17 ± 0.09 for CRC and 0.08 ± 0.03 for 
CD (p= 0.75), while the gene expression level for CD68 was 0.05 ± 0.01 for CRC and 
0.04 ± 0.01 for CD (p= 0.35) (Figure 9A-B). However, expression levels of the CD163 
and CD206 anti-inflammatory markers in CD MAT was lower compared to CRC 
MAT, showing a statistically significant difference: CD163 expression in CD was 0.01 
± 0.008 compared to CRC (0.05 ± 0.02, p= 0.04) (Figure 10B); CD206 expression 
level in CD was 0.01 ± 0.003) versus CRC (0.03 ± 0.01, p= 0.01) (Figure 10C). Both 
are specific markers for M2 macrophages. The mRNA expression levels for the other 
investigated anti-inflammatory markers (MCP1, IL-10, and arginase) didn’t show any 
significant difference (Figure 10A, D, and E).  
Overall, these results indicate a trend for reduced gene expression of selected 
anti-inflammatory markers in inflamed CD MAT compared to healthy CRC MAT, 
while no difference was observed in the gene expression of the pro-inflammatory 
markers between the two types of samples investigated in this study. 
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Figure 8: Bar graphs showing the relative increase in gene expression across 
inflammatory genes in CRC and IBD mesenteric fat samples.  
Data is presented as relative quantity of mRNA normalised to the reference genes RPL13a 
and GUSB. Values are expressed as mean ± SEM. n= 12 for CRC and n= 8 for IBD (including 
CD and UC).  
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Figure 9: Bar graphs comparing the difference in the relative gene expression for 
pro-inflammatory genes between CRC and IBD mesenteric fat samples.  
Data is presented as relative quantity of mRNA normalised to the reference genes RPL13a 
and GUSB. Values are expressed as mean ± SEM. n= 12 for CRC, n= 6 for CD, and n= 2 for 
UC. Differences in the mRNA expression between the CRC and CD groups were tested using 
Mann-Whitney U test. 
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Figure 10: Bar graphs comparing the difference in the relative gene expression 
for anti-inflammatory genes between CRC and IBD mesenteric fat samples.  
Data is presented as relative quantity of mRNA normalised to the reference genes RPL13a 
and GUSB. Values are expressed as mean ± SEM. n= 12 for CRC, n= 6 for CD, and n= 2 for 
UC. For some samples the levels of IL-10 and arginase were under the detection limits of the 
qRT-PCR (these samples were taken out from the analysis). Differences in the mRNA 
expression between the CRC and CD groups were tested using Mann-Whitney U test. *p < 
0.05. 
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3.3.4 Expression of adipokines and adipogenesis genes in healthy and inflamed 
IBD mesenteric adipose tissues 
This comparison aimed to better characterise the mesenteric fat depots (normal 
vs. inflamed or hypertrophied tissues) in IBD patients only. Unfortunately, because of 
the insufficient amount of resected normal intestinal tissues after the operation, 
collection of healthy mesenteric fat tissues was not always feasible from all IBD cases, 
which limited this type of analysis. Paired samples were only obtained from 3 CD 
patients and 2 UC patients. These data are presented in Figure 11 as individual and 
mean values of relative mRNA in normal MAT and hypertrophied (inflamed) 
mesenteric fats from the same patients. 
The gene expression for adiponectin (2.1 ± 0.59) and leptin (0.25 ± 0.14) in 
inflamed MAT was higher than those in paired normal mesenteric samples 
(adiponectin 1.11 ± 0.16, leptin 0.07 ± 0.03) from the same IBD patients (Figure 11A-
B). Similarly, PPARg mRNA was upregulated in inflamed samples (0.15 ± 0.04) and 
downregulated in healthy mesenteric samples (0.08 ± 0.01) (Figure 11C). Overall, the 
trend for increased upregulation of these genes seems to be observed mainly in the UC 
samples. All the inflamed MAT of UC cases showed a consistently increased 
expression of adiponectin, leptin, and PPARg with no statistical significance but 
further analysis may validate this, while the inflamed MAT of CD cases didn’t show 
any significant changes in upregulation or downregulation. For CEBPa and FABP4 
gene expression, no significant trends were identified between inflamed MAT and 
normal MAT samples from the same IBD patients (Figure 11D-E). 
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Figure 11: Gene expression level for adipokines and adipogenesis genes in paired 
IBD mesenteric AT.  
Data are individual and mean values (horizontal bars) of relative mRNA in normal mesenteric 
adipose tissues of CD and UC patients and hypertrophied (inflamed) mesenteric adipose 
tissues of CD and UC patients from the same patients. 
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3.3.5 Expression of inflammatory genes in healthy and inflamed IBD 
mesenteric adipose tissues 
Downregulation of both anti-inflammatory and pro-inflammatory markers was 
observed in inflamed MAT compared to their paired normal fat samples in the same 
IBD patients. The gene expression for the anti-inflammatory markers IL-6 and CD68 
was lower in inflamed fat samples (0.14 ± 0.03 and 0.05 ± 0.02) than those in paired 
healthy fat samples (0.33 ± 0.14 and 0.09 ± 0.03) (Figure 12A-B). Similarly, the mean 
expression levels for MCP1, CD163, and CD206 was lower in inflamed MAT (0.12 ± 
0.05, 0.02 ± 0.009, and 0.01 ± 0.003), and higher in normal fat tissues (0.28 ± 0.12, 
0.07 ± 0.02, and 0.04 ± 0.01) (Figure 12C-E). Data on IL-10 expression trends were 
available from the paired inflamed and normal MAT samples of only 2 CD patients, 
as their levels were below qRT-PCR detection limits; lower IL-10 levels were 
observed in inflamed versus normal MAT samples (Figure 12F). Due to the limited 
sample size, further analysis would be needed to validate this observation. Data on 
arginase expression levels could also not be obtained due to the above stated 
limitation. 
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Figure 12: Gene expression level for pro-inflammatory and anti-inflammatory 
genes in paired IBD mesenteric AT.  
Data are individual and mean values (horizontal bars) of relative mRNA in normal mesenteric 
adipose tissues of CD and UC patients and hypertrophied (inflamed) mesenteric adipose 
tissues of CD and UC patients from the same patients. For some samples the levels of IL-10 
and arginase were under the detection limits of the qRT-PCR (these samples were taken out 
from the analysis). 
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3.3.6 Fatty acid composition in mesenteric adipose tissues 
The fatty acid profile was investigated in CRC and IBD mesenteric fat 
samples. Overall, MUFAs constituted the highest percentage of lipids (57%) in the 
mesenteric fat depot, followed by saturated fatty acids (SFAs) and PUFAs at 29% and 
13%, respectively. Table 6 and Figure 13 show the fatty acid composition of the MAT 
for CRC and IBD patients. Statistical analysis showed that the differences in fatty acid 
compositions of CRC and CD MAT samples were not statistically significant. The 
percentage of total SFA was 28.65 ± 0.79% in CRC mesenteric fat and 29.41 ± 2.20% 
in CD (p= 0.84). Total MUFA was 57.90 ± 0.89% in CRC and 57.51 ± 1.19% in CD 
mesenteric fats (p= 0.60). While total PUFA composition was 13.45 ± 0.51% in CRC 
and 13.08 ± 1.11% in CD (p= 0.77). n-6 fatty acids constituted most of the PUFAs in 
MAT (12.11 ± 0.42% for CRC and 11.89 ± 1.02% for CD, p= 0.65), whereas n-3 fatty 
acid levels were 10 times lower (1.34 ± 0.12% in CRC and 1.20 ± 0.17% in CD). EPA 
levels were negligible in MAT samples from both CRC (0.10 ± 0.0%) and CD (0.02% 
± 0.02%), while DHA levels were 0.23% ± 0.04 in CRC and 0.16% ± 0.02 in CD. The 
n-6: n-3 fatty acid ratios were similar for CRC (9.78 ± 0.74) and CD MAT samples 
(10.89 ± 1.53). 
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Table 6: Fatty acid composition (% of total fatty acids) of the mesenteric 
adipose tissues of CRC and IBD patients 
Fatty acid composition  CRC UC CD P-value 
 CRC vs. CD 
Total saturated fatty acids % 28.65 ± 0.79 31.03 ± 1.96 29.41 ± 2.20 0.84 
12:0 0.39 ± 0.05 0.38 ± 0.07 0.65 ± 0.24 0.44 
14:0 2.62 ± 0.17 3.14 ± 0.46 3.12 ± 0.67 0.84 
15:0 0.28 ± 0.02 0.37 ± 0.04 0.28 ± 0.05 0.85 
Iso 16:0 0.08 ± 0.01 0.10 ± 0.01 0.10 ± 0.01 0.26 
16:0 20.99 ± 0.57 21.01 ± 0.73 20.34 ± 1.03 0.44 
Ante Iso 17:0 0.13 ± 0.01 0.20 ± 0.03 0.14 ± 0.03 0.64 
Iso 17:0 0.18 ± 0.01 0.25 ± 0.02 0.18 ± 0.03 0.92 
18:0 3.79 ± 0.24 5.34 ± 0.58 4.43 ± 0.51 0.28 
20:0 0.22 ± 0.02 0.27 ± 0.03 0.21 ± 0.02 0.98 
22:0 0.06 ± 0.0 Nil Nil 0.55 
Total monounsaturated fatty acids % 57.90 ± 0.89 55.85 ± 0.41 57.51 ± 1.19 0.60 
14:1 0.30 ± 0.02 0.28 ± 0.02 0.37 ± 0.09 0.70 
16:1n-9 0.61 ± 0.04 0.45 ± 0.03 0.55 ± 0.03 0.58 
16:1n-7 5.35 ± 0.34 3.80 ± 0.23 4.69 ± 0.57 0.54 
16:1 0.08 ± 0.0 Nil 0.02 ± 0.02 0.98 
17:1 0.29 ± 0.02 0.27 ± 0.02 0.26 ± 0.03 0.28 
18:1n-9 48.11 ± 0.82 47.57 ± 0.47 48.60 ± 1.59 0.90 
18:1n-7 2.19 ± 0.12 2.04 ± 0.12 2.00 ± 0.13 0.34 
18:1 0.11 ± 0.0 0.13 ± 0.03 0.12 ± 0.02 0.41 
20:1n-11 0.13 ± 0.02 0.18 ± 0.04 0.13 ± 0.01 0.64 
20:1n-9 0.86 ± 0.03 1.11 ± 0.09 0.82 ± 0.12 0.26 
22:1n-11 0.01 ± 0.01 Nil Nil 0.99 
22:1n-9cis 0.10 ± 0.01 0.04 ± 0.04 0.10 ± 0.01 0.88 
Total polyunsaturated fatty acids % 13.45 ± 0.51 13.12 ± 1.55 13.08 ± 1.11 0.77 
18:2n-6 (LA) 10.99 ± 0.45 10.60 ± 1.43 10.91 ± 1.00 0.77 
CLA 0.23 ± 0.02 0.27 ± 0.01 0.23 ± 0.05 0.45 
18:3n-6 0.08 ± 0.0 0.05 ± 0.05 0.10 ± 0.01 0.66 
20:2n-6 0.18 ± 0.01 0.22 ± 0.06 0.18 ± 0.03 0.40 
20:3n-6 0.25 ± 0.02 0.24 ± 0.07 0.20 ± 0.04 0.38 
20:4n-6 0.32 ± 0.03 0.31 ± 0.05 0.27 ± 0.03 0.45 
22:4n-6 (AA) 0.15 ± 0.01 0.12 ± 0.12 0.15 ± 0.02 0.64 
Total n-6 PUFA % 12.11 ± 0.42 11.80 ± 1.67 11.89 ± 1.02 0.65 
18:3n-3 (ALA) 0.88 ± 0.07 0.70 ± 0.04 0.86 ± 0.10 0.88 
18:4n-3 0.11 ± 0.01 Nil 0.02 ± 0.02 0.88 
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20:3n-3 Nil Nil 0.06 ± 0.0 0.07 
20:4n-3 0.09 ± 0.0 Nil 0.07 ± 0.0 0.99 
20:5n-3 (EPA) 0.10 ± 0.0 0.05 ± 0.05 0.02 ± 0.02 0.81 
22:5n-3 0.26 ± 0.02 0.33 ± 0.01 0.22 ± 0.04 0.29 
22:6n-3 (DHA) 0.23 ± 0.04 0.25 ± 0.09 0.16 ± 0.02 0.58 
Total n-3 PUFA % 1.34 ± 0.12 1.33 ± 0.12 1.20 ± 0.17 0.99 
n-6:n-3 9.78 ± 0.74 9.08 ± 2.05 10.89 ± 1.53 0.71 
Data are presented as mean ± SEM for n= 14 CRC patients, n= 2 UC patients, and n= 
6 CD patients. Differences in the fatty acid level between the CRC and CD groups 
were tested using Mann-Whitney U test (*p < 0.05). LA, linoleic acid; CLA, 
conjugated linoleic acid; AA, arachidonic acid; ALA, a-linolenic acid; EPA, 
eicosapentaenoic acid; DHA, decosahexaenoic acid. 
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Figure 13: Bar graphs comparing the difference in the fatty acids composition 
between CRC and IBD mesenteric fat samples.  
Values are expressed as mean ± SEM. n= 14 for CRC, n= 6 for CD, and n= 2 for UC. 
Differences in the fatty acid level between the CRC and CD groups were tested using Mann-
Whitney U test. *p < 0.05. 
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3.3.7 Fatty acid composition in healthy and inflamed IBD mesenteric adipose 
tissues 
Table 7 compares the fatty acid composition between paired samples of normal 
and inflamed MAT in IBD patients.  Paired normal and inflamed samples were 
obtained from 3 CD patients and 2 UC patients. The fatty acid profiles for SFAs, 
MUFAs, and PUFAs in both, healthy and inflamed MAT were similar (p > 0.05) for 
total (combined) IBD sample, as well as for CD sample.   
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Table 7: Fatty acid composition (% of total fatty acids) in paired IBD mesenteric adipose tissue sample 
Data are presented as mean ± SEM of fatty acid% in normal mesenteric adipose tissues and hypertrophied (inflamed) mesenteric adipose tissues 
of the same IBD patients. n= 5 for total IBD sample, n=3 for CD sample, and n= 2 for UC sample. Differences in the fatty acid level between 
the paired samples were tested using the non-parametric Wilcoxon signed-rank test (*p < 0.05). NA: not applicable.  
 
 
 
Total IBD CD UC 
Fatty acid composition  Healthy 
mesenteric 
AT 
Inflamed 
mesenteric 
AT 
P-value Healthy 
mesenteric 
AT 
Inflamed 
mesenteric 
AT 
P-value Healthy 
mesenteric 
AT 
Inflamed 
mesenteric 
AT 
P-value 
Total saturated fatty acids 
% 29.83 ± 2.1 29.03 ± 2.55 0.31 28.96 ± 3.68 27.7 ± 4.28 0.5 31.13 ± 0.84  31.03 ± 1.96 NA 
Total monounsaturated 
fatty acids % 56.38 ± 1.06 57.24 ± 1.35 0.62 56.9 ± 1.84 58.18 ± 2.23 0.75 55.61 ± 0.47 55.85 ± 0.4 NA 
Total polyunsaturated fatty 
acids % 13.79 ± 1.31 13.72 ± 1.25 0.99 14.14 ± 2.25 14.13 ± 2.05 0.99 13.27 ± 1.29 13.12 ± 1.55 NA 
Total n-6 PUFA % 12.55 ± 1.22 12.5 ± 1.14 0.99 13.03 ± 1.98 12.97 ± 1.77 0.99 11.84 ± 1.54 11.8 ± 1.67 NA 
Total n-3 PUFA % 1.23 ± 1.19 1.22 ± 1.16 0.99 1.11 ±0.29 1.15 ± 0.29 0.99 1.43 ± 0.25 1.33 ± 0.12 NA 
n-6:n-3 11.04 ± 1.53 10.96 ± 1.46 0.99 12.56 ± 1.64 12.21 ± 1.94 0.99 8.75 ± 2.59 9.08 ± 2.05 NA 
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3.3.8 Mesenteric adipose tissue fatty acid status and inflammatory genes 
expression  
To study the effect of fatty acid enrichment of MAT on the adipogenesis and 
the inflammatory response of this tissue, the correlation between SFA, MUFA, and 
PUFA levels and the expression levels of several adipogenesis and inflammatory 
genes was investigated for all samples using the Pearson’s correlation coefficient. 
%SFA was found to be negatively associated with the expression of the pro-
inflammatory marker CD68 (r = -0.53, p< 0.05) (Figure 14A), while no correlation 
was observed between its composition and the level of expression of adipogenesis and 
anti-inflammatory genes.  %MUFA was positively associated with the expression of 
CD68 (r = 0.51, p < 0.05) (Figure 14B), with no correlation observed with expression 
levels of adipogenesis and anti-inflammatory genes. %PUFA was positively 
correlated with the expression of the anti-inflammatory marker MCP1 (r = 0.49, p < 
0.05); this correlation was also significant for total n-6 PUFA (r = 48, p < 0.05) (Figure 
14C-D). There was no correlation found between total PUFA% and adipogenesis and 
pro-inflammatory markers expression. Total n-3 PUFA correlated negatively with 
mRNA levels of the adipogenesis marker PPARg (r = -0.50, p < 0.05) (Figure 14E), 
and no association was found with the expression of inflammatory or pro-
inflammatory markers. No correlation was found between the n-6: n-3 ratio and the 
expression levels of all the investigated adipogenesis and inflammatory markers. 
Overall, these findings indicate an association of the various fatty acid levels with only 
a few genes involved in the adipogenesis and inflammatory response of CRC and CD 
MAT. 
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Figure 14: Correlation between CD68, MCP1, and PPARg mRNA expression 
levels and fatty acid composition in mesenteric adipose tissues.  
n= 11 for CRC patients and n= 6 for CD patients.  A) Correlation between total SFA% and 
CD68 (r= -0.53, p= 0.03). B) Correlation between total MUFA% and CD68 (r= 0.51, p= 
0.04). C) Correlation between total PUFA% and MCP1 (r= 0.49, p= 0.04). D) Correlation 
between total n-6 PUFA% and MCP1 (r= 48, p= 0.04). E) Correlation between total n-3 
PUFA% and PPARg (r= -0.50, p= 0.03). SFA, saturated fatty acids; MUFA, monounsaturated 
fatty acids; PUFA, polyunsaturated fatty acids.  
 
 
D. 
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3.3.9 Summary of the results 
The level of leptin mRNA was significantly reduced in CD mesenteric samples 
compared to CRC samples, while there was no difference in adiponectin mRNA 
levels. The expression of adipogenesis marker CEBPa was significantly reduced in 
CD mesenteric fat tissues compared to CRC fat tissues, whereas no differences in the 
levels of the other two adipogenesis specific markers (PPARg and FABP4) were 
observed between the two disease cohorts. Regarding the inflammatory profile of the 
MAT, a pattern of significant reduction of selected anti-inflammatory mediators 
(CD163 and CD206) in CD mesenteric samples was identified; both CD163 and 
CD206 are specific markers for M2 macrophages. Nevertheless, no significant 
difference in the gene expression of pro-inflammatory markers (IL-6 and CD68) was 
reported for CD and CRC MAT samples. Results from the paired IBD samples 
(normal versus inflamed mesenteric fats) showed a reduced expression of anti- and 
pro-inflammatory markers (IL-6, CD68, MCP1, CD163, and CD206) in inflamed 
versus normal MAT samples; further analysis would be needed to validate this 
observation. However, differences in the expression of adipocyte markers 
(adiponectin, leptin, and PPARg) between the paired samples were not statistically 
significant. For the fatty acid composition findings, no differences were found 
between MAT fatty acid levels of CRC and CD samples. Also, the level of fatty acid 
was similar between healthy and inflamed MAT from the same IBD patients. 
Interestingly, correlation analysis indicated a relationship between the level of each 
fatty acid and the gene expression levels of selected adipogenesis and inflammatory 
response markers in the MAT:  SFA was associated with reduced gene expression of 
the CD68 pro-inflammatory marker, while MUFAs were associated with its increase. 
Total PUFA and n-6 fatty acid levels were associated with an increased gene 
expression of MCP1. An association was found between n-3 fatty acid levels and the 
reduced expression of PPARg. 
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3.4 Discussion  
This study aimed to characterize the MAT in CD and CRC patients. The 
findings have shown few abnormalities in the gene expression profile of CD 
hypertrophied mesenteric fat, while no differences in the fatty acid profile for this type 
of adipose tissue was found in comparison to the control. Nevertheless, simple 
correlation analysis suggested few associations between fatty acids levels and mRNA 
levels of selected genes related to adipogenesis and inflammatory response in the 
mesenteric fats of CD and CRC patients. 
Abnormal production of adipokines in inflamed mesenteric fats in CD patients 
has been reported by previous studies (Zulian et al., 2012, Yamamoto et al., 2005). In 
this study, the level of leptin mRNA was significantly reduced in CD mesenteric 
samples compared to CRC samples. A previous study by Oliver et al. found similar 
results, where leptin expression was very low in human CD hypertrophied MAT 
compared to the normal mesenteric and subcutaneous fat depots (Olivier et al., 2011). 
The same study also found a similar pattern of a lowered expression of leptin and other 
adipose tissue markers, like hormone-sensitive lipase, perilipin, and adiponectin in 
hypertrophied MAT, using an animal model of colitis. In contrast, an earlier study 
found high levels of leptin being expressed in CD mesenteric fat when compared to 
control (Barbier et al., 2003). Leptin is a protein mainly secreted by adipocytes in 
relation to the size of AT; it has metabolic and endocrine functions as well as immune 
functions (Karmiris et al., 2008), and has both pro-inflammatory and anti-
inflammatory properties. The role of leptin in CD is still not clearly understood. 
Nevertheless, the low expression of leptin in CD mesenteric fats observed in this study 
can be related to the increased number of small adipocytes rather than large 
adipocytes, which is a specific morphology of this type of fat tissue, previously 
reported (Zulian et al., 2012). The secretion and expression of leptin and other 
adipokines was found to be higher with increased adipocyte size. (Skurk et al., 2007). 
Yet, the suggested mechanism leading to the reduced expression of leptin in CD 
hypertrophied mesenteric fat needs further studies. The level of adiponectin mRNA in 
this study was not different between the two sets of patient samples. Adiponectin 
possesses many anti-inflammatory functions. Earlier studies have shown a significant 
upregulation in the level of secreted adiponectin from CD mesenteric fat versus 
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control, which could be related to an inflammatory response in the adjacent inflamed 
intestines (Yamamoto et al., 2005, Paul et al., 2006). 
Consistent with our findings of low leptin expression, the gene expression of 
CEBPa (a key marker of adipogenesis) was significantly reduced in CD mesenteric 
fat tissues when compared to CRC fat tissues. Thus, defective regulation of 
adipogenesis could be a characteristic of CD hypertrophied mesenteric AT. However, 
no published study has yet investigated CEBPa expression in the context of CD MAT.  
Therefore, these findings should be carefully interpreted and further studies are needed 
for validation. In this study, the expression of other relevant markers like PPARg 
(adipogenesis specific marker) and FABP4 (marker for fat metabolism) were not 
altered in CD mesenteric fat, whereas a previous study found an overall reduction in 
lipid metabolism genes in CD mesenteric fat (Zulian et al., 2012). Also, another study 
that used an animal model of colitis characterized the hypertrophied mesenteric fat by 
defective lipolysis and absence of lipid (triglycerides) storage (Olivier et al., 2011). 
The knowledge about lipid metabolism in CD mesenteric fat is still lacking and further 
investigations are required. 
Inflammation of the MAT in CD is a complex process, where the upregulation 
of both pro-inflammatory and anti-inflammatory cytokines is a specific associated 
characteristic. However, the findings of this study indicated a reduction in the 
expression of the M2 macrophage-specific anti-inflammatory markers, CD163 and 
CD206, in CD hypertrophied mesenteric fat. Contrarily, no differences in gene 
expression of the pro-inflammatory markers IL-6 and CD68 were reported between 
CD and CRC MAT. These findings are inconsistent with earlier studies. Previous 
studies have shown an increased expression of anti-inflammatory genes associated 
with CD mesenteric fat, suggesting a protective role of this type of tissue (Zulian et 
al., 2012). M2 subtype macrophage infiltration is a characteristic feature of CD MAT, 
which is highly stimulated by adipokines (leptin and adiponectin), thus counteracting 
local inflammation in CD and possibly offering protection from further systematic 
inflammation (Kredel et al., 2013). Unfortunately, this study was not able to measure 
the gene expression levels of TNFa and CRP. TNFa is one of the main pro-
inflammatory cytokines produced by fat tissues and has been a target for CD treatment 
for many years. Whereas CRP has only recently been investigated in the context of 
CD mesenteric fat, where its release was found to be triggered by bacterial 
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translocation and an inflammatory response (Peyrin-Biroulet et al., 2012). Therefore, 
further research is needed to elucidate the mechanism of action of mesenteric fat 
inflammation and its role in the pathogenesis of CD.  
The contribution of adipose fatty acids to the immune functions of mesenteric 
fat tissue can modulate inflammation in CD. For instance, the fatty acid content in 
adipose tissue can stimulate the production of eicosanoids, molecules that have a direct 
involvement in the inflammatory process.  Moreover, dietary fatty acids have an 
important role in the development of IBD. Epidemiological studies have shown an 
inverse association between dietary n-3 PUFA (DHA) intake and CD development 
(Chan et al., 2014a). This study has shown no difference in the fatty acid composition 
of CD mesenteric fat tissue and CRC. However, a previous study investigating the 
same type of tissue found notable differences in its fatty acid profile, where CD 
mesenteric AT and associated lymphoid tissues were higher in saturated fatty acids 
and lower in PUFA than control tissues (Westcott et al., 2006). The same study also 
showed that the ratio of n-6: n-3 PUFA was higher in CD AT and lower in lymphoid 
cells, when compared to control tissues, suggesting an interrupted physiological 
interaction between the adipocytes and the lymphoid cells, leading to defective fatty 
acid transport. The proposed mechanism still needs more validation as no other studies 
in the literature have yet investigated the role of fatty acid in CD MAT. Furthermore, 
our study was able to show few relationships between the level of fatty acids and the 
gene expression levels of selected markers. Surprisingly, gene expression of the pro-
inflammatory marker CD68 was inversely associated with the SFA levels, while it was 
positively associated with the MUFA levels. This finding is in contradiction to the 
general statement that high levels of SFAs are associated with an increased pro-
inflammatory response. In-vitro studies of adipocytes have shown that treatment with 
palmitic acid resulted in increased gene and protein expression of the pro-
inflammatory cytokine IL-6 (Ajuwon and Spurlock, 2005), while MUFAs were 
characterized by anti-inflammatory properties. The findings of this study also show 
that expression of the anti-inflammatory marker MCP1 was positively correlated with 
the level of total PUFAs and total n-6 fatty acids. Linoleic acid (an n-6 PUFA) is 
considered a precursor in the biosynthesis of the pro-inflammatory arachidonic acid; 
however, the current evidence is still contradictory and not clear about the 
inflammatory potential of n-6 PUFA (Joffe et al., 2013). Lastly, the expression of 
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PPARg in this study was negatively correlated with the level of total n-3 PUFAs. This 
result contradicts the previous finding that fatty acids, particularly PUFAs, are 
considered ligand (activators) for PPARg (Wahli and Michalik, 2012). 
So far, available studies trying to characterize the MAT in CD are limited. This 
study aimed to further characterize the molecular profile of this type of adipose tissue 
in relation to its fatty acid content. The use of human adipose tissue to characterize the 
fat-wrapping phenomenon associated with long-standing CD is considered more 
representative than employing an animal model. However, the restricted number of 
samples, especially for CD patients, presents itself as limitations. Furthermore, this 
study measured only the gene expression level of investigated markers and not the 
protein expression level, which may have omitted any interesting observations of post-
translational regulations of the protein. Another limitation of this study is the 
statistically low number of paired CD samples, which limited the comparison between 
normal and inflamed mesenteric tissues in CD patients. 
In conclusion, proper characterization of CD hypertrophied mesenteric fat is 
still lacking from the current literature. Inconsistent findings between published 
studies is a reason for this lack of knowledge, and so are inconsistencies between 
methodology and control group choices. This study has shown that MAT in CD 
patients is an abnormal type of AT. Unlike typical adipose tissue, this type of fat tissue 
was associated with defective adipogenesis via reduced expression of leptin and 
CEBPa and was associated with a low anti-inflammatory profile via decreased 
expression of M2 macrophages markers (CD163 and CD206). The fatty acid profile 
of CD MAT was observed to be similar to the control. However, the level of fatty 
acids impacted the expression of selected inflammatory and adipogenesis markers, 
which support the involvement of fatty acids in CD pathogenesis. 
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4 Chapter 4. In-vitro Study: Effect of Fatty Acids on Mesenteric 
Adipocyte Differentiation: Identifying Their Role in The 
Pathogenesis of Crohn’s Disease  
 
 
4.1 Introduction 
4.1.1 Adipocyte hyperplasia controls mesenteric fat hypertrophy and 
inflammation 
Generally, one-third of adipose tissue are composed of mature adipocytes, 
while the remaining consist of other types of cells, such as macrophages, fibroblasts, 
pericytes, red blood cells, endothelial cells, smooth muscle cells, mesenchymal stem 
cells (MSCs), and adipose precursor cells (Ruiz-Ojeda et al., 2016, Moreno-Navarrete 
and Fernández-Real, 2017). The type and location of the adipose tissue affect the 
composition and the functional characteristics of these cells (Ruiz-Ojeda et al., 2016). 
For example, a study found that MSCs from the subcutaneous fat depot tend to 
proliferate and differentiate into adipocytes more than MSCs from the visceral fat 
depot after adipogenesis induction in an in-vitro model (Ong et al., 2014). 
The increased number of adipocytes (adipocyte hyperplasia) in the expanding 
adipose tissue observed in some types of inflammation results from the high 
recruitment rate of adipose tissue precursor cells. This is usually influenced by 
signalling factors that initiate the MSCs to convert into pre-adipocytes, which 
eventually differentiate into bigger and mature adipocytes (Tang and Lane, 2012). 
Nevertheless, it seems that the increased expansion of MAT in CD is dependent on 
the increased number of small adipocytes rather than on adipocyte size, which is a 
characteristic of visceral adipose tissue in obesity. Findings from a recent study found 
that adipose precursor cells isolated from MAT derived from a CD patient were more 
highly proliferative than MAT from control patients. It was therefore suggested that 
these cells could be responsible for the expansion of fat-wrapping (Serena et al., 2017). 
Moreover, histological findings from earlier studies found that morphological features 
of the MAT of CD patients differ from other patients. The size of MAT adipocytes 
from CD patients was found to be significantly smaller, and adipocyte numbers were, 
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furthermore, higher compared to MAT adipocytes from control cases (Peyrin-Biroulet 
et al., 2007). 
Adipocytes are considered to be important factors in adipose tissue 
inflammation. Inflammatory mediators are synthesized by these cells. Alteration in 
the balance of pro-inflammatory and anti-inflammatory adipocytokines in mesenteric 
adipocytes has been previously reported (Paul et al., 2006). Smaller adipocytes tend 
to secret higher amounts of adiponectin than larger adipocytes (Yamamoto et al., 
2005). Another inflammatory factor suggested to be involved in the fat-wrapping 
mechanism is the peroxisome proliferator activated receptor (PPAR-g), which is 
specific to adipocytes and considered one of the key regulators in adipogeneis. An 
earlier study found high levels of PPAR-g in MAT, which was suggested to be related 
to fat hypertrophy due to CD (Desreumaux et al., 1999). In addition, infiltration of the 
inflammatory cells is another significant characteristic of the inflamed MAT in CD. 
Compared to non-inflamed MAT, the expression of macrophages and T lymphocyte 
markers (i.e. CD68 and CD3 positive cells) were found to be significantly higher in 
hypertrophied CD MAT (Yamamoto et al., 2005). The evidence is still inconclusive 
on whether adipocyte hyperplasia is primarily responsible for activating inflammation 
in hypertrophied fat in CD, or whether it is a secondary outcome resulting from the 
transmural inflammation of the diseased intestine. According to Schäffler et al. (2005), 
a schematic hypothetical model (Figure 15) demonstrates how the interactions 
between intestinal inflammation, adipocyte hyperplasia, secreted inflammatory 
mediators, and macrophage infiltration could lead to the pathogenesis of fat-wrapping 
in CD.  
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Figure 15: Hypothetical four-step concept of the pathogenesis of creeping fat in 
Crohn’s disease.  
Adopted with permission from “Mechanisms of disease: adipocytokines and visceral adipose 
tissue—emerging role in intestinal and mesenteric diseases”, by Schäffler, A., Schölmerich, 
J. & Büchler, C. 2005, Nature Reviews Gastroenterology and Hepatology, 2, 103. (Schäffler 
et al., 2005). 
 
 
4.1.2 Regulation of adipogenesis via fatty acids 
Adipogenesis is a complex process regulated by a cascade of adipogenic 
transcription factors which eventually lead to the development of mature adipocytes. 
This process first starts with the cellular commitment of MSCs into an adipocyte 
specific lineage, which then terminally differentiates into fully mature adipocytes. 
Activation of the CCAAT/enhancer-binding protein alpha (C/EBPa) and PPAR-a are 
required for this process; both act in growth arrest, which is needed for adipocyte 
differentiation (Vanella et al., 2013). PPAR-g is usually induced in the early stages of 
the adipocyte differentiation process, which also functions as a sensor for fatty acids 
(Warnke et al., 2011). When activated, PPAR-g regulates the expression of other target 
genes that usually are found in the mature adipocyte, such as Fatty acid binding protein 
4 (FABP4 or aP2), lipoprotein lipase (LPL), acyl-CoA synthase, CD36, and 
adiponectin (Moseti et al., 2016, Garin-Shkolnik et al., 2014).  FABP4 is one of the 
master regulatory factors in adipogenesis, acting as a lipid transporter within cells. 
FABP4 helps in pairing intracellular lipids with their biological target molecules 
(Garin-Shkolnik et al., 2014). 
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There are several factors that could either induce or inhibit adipogenesis. For 
example, growth factors, hormones, cytokines, and specific drug compounds have the 
ability to regulate adipogenesis (Moreno-Navarrete and Fernández-Real, 2017). Also, 
dietary fatty acids are important regulators of adipose tissue function. Different fatty 
acids have varying functions in regulating adipogenesis and lipid metabolism. PUFAs 
are considered PPAR-g ligands (activators) (Madsen et al., 2005). Linoleic acid has 
shown both pro-adipogenic and anti-adipogenic effects in pre-adipocyte cell-lines 
(Madsen et al., 2005, Petersen et al., 2003),  while α-linolenic acids can decrease 
adipocyte differentiation and stimulate fatty acid biosynthesis and lipid turnover 
during adipocyte differentiation contributing to lower pro-inflammatory response 
(Polus et al., 2015). Studies investigating the differentiation of pre-adipocytes isolated 
from the MAT are very limited. Only a recent study by Serena 2017 explored the 
differentiation and immune properties of this type of pre-adipocyte.  However, the 
fatty acid effect was not investigated in this study (Serena et al., 2017). The role of 
fatty acids in mesenteric pre-adipocyte differentiation hence requires further 
investigation.  
4.1.3 Research gaps 
Our understanding of how therapeutic lipids and fatty acids could possibly 
reduce intestinal inflammation in Crohn’s disease is still limited. Mesenteric fat 
hypertrophy adjacent to inflamed intestines has been recognized as a specific 
pathological feature in CD patients for decades. However, knowledge of the 
aetiopathogenesis of fat-wrapping in CD is inconclusive about whether it has a leading 
role in regulating intestinal inflammation, or whether it’s just a secondary outcome. 
The increased number of small adipocytes within the MAT results from the high rate 
of pre-adipocyte proliferation and differentiation. Different fatty acids can have 
differing functions in regulating adipogenesis in the adipose tissue. However, the 
impact of fatty acids on mesenteric pre-adipocyte differentiation has not yet 
investigated.  
4.1.4 Hypothesis 
Specific dietary fatty acids have a direct influence on adipocyte differentiation 
in hypertrophied mesenteric adipose tissue in-vitro, which could contribute to chronic 
intestinal inflammation in CD. This will be tested by collecting fresh mesenteric 
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adipose tissue for pre-adipocyte isolation, which will then be incubated with different 
fatty acids to study their differentiation potential. 
4.1.5 Objectives 
To study and compare the effect of fatty acid treatment during mesenteric pre-
adipocyte differentiation, on the expression of key markers for adipocyte 
differentiation, inflammatory adipocytokines, and fatty acid metabolism. 
 
4.2 Methods 
4.2.1 Human tissue collection 
For details regarding human mesenteric adipose tissue collection, please see 
the Methods section in Chapter 3. 
4.2.2 Cell culture 
4.2.2.1 Isolation and culture of human mesenteric pre-adipocytes 
The protocol for primary pre-adipocyte isolation and culture was kindly 
provided by Seema Ali (School of Biological Sciences, UEA), which was described 
earlier, with minor modifications (Sideri et al., 2015, Serena et al., 2017, Dubois et 
al., 2008). Upon arrival, MAT specimens were kept in a sterile tube in a cold tissue 
culture room until ready for use. Tissue culture hoods were sterilized with 2% trigene 
prior to each procedure. 25 ml Digestion medium was prepared by weighing 12.5 mg 
of collagenase (Sigma C9891) and 2.5 mg of DNase (Roche 11284932001) and 
mixing them in a falcon tube containing 25 ml of pre-warmed serum free Dulbecco’s 
Modified Eagle Medium (DMEM) (Thermo Fisher Scientific 21969-035); the solution 
was then filter sterilized through a 0.22 µm sterile filter (Thermo Fisher Scientific 
10268401). For the isolation process, two grams of fresh MAT were transferred into 
a sterile petri dish and were cut into smaller pieces using a sterile blunt-ended scissor. 
Any apparent blood vessels or white fibrous tissues were removed from the MAT 
sample, before it was minced to facilitate the following digestion step (see Figure 16). 
Just enough pre-warmed digestion medium media (2 ml) was added to the minced 
tissues, to help liquefy it so it can be taken up by the sterile 25 ml pipette and 
transferred in the tube containing the whole digestion medium. The tube was then 
sealed with parafilm and placed in a shaking water bath or oven at 37 (100 rpm) for 
30 minutes to allow digestion, after which it was filtered through a 70 µm sterile cell 
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strainer.  (Thermo Fisher Scientific 11597522). Basal medium was added to the 
filtered homogenate, up to the 50 ml mark in a sterile falcon tube (see Figure 17). The 
basal medium was composed of DMEM (with 4.5 g/L glucose and sodium pyruvate) 
(Thermo Fisher Scientific 21969-035), 10% fetal bovine serum (FBS) (Thermo Fisher 
Scientific 10500064), and 0.5% Penicillin-Streptomycin (Thermo Fisher Scientific 
15140148). The tube was then centrifuged at 1500 rpm for 5 minutes to separate the 
stromal-vascular fraction (SVF) (in the form of a cell pellet) from the floating mature 
adipocytes (see Figure 17). 
The pellet was then resuspended in 1 ml of red blood cell (RBC) lysing buffer 
(Sigma R7757) and incubated for 1 minute at room temperature to help remove any 
RBCs. Thereafter, the pellet was washed with 15 ml of phosphate buffered saline 
(PBS) and centrifuged at 1500 rpm for 5 minutes. The supernatant was discarded and 
the pellet was resuspended in 25 ml basal medium and plated onto a T-75 culture flask 
(Greiner Bio-One 658175) and incubated in a humidified culture incubator at 5% CO2 
and 37°C. After 24 hours, cells were washed with 10 ml of warm sterile PBS for 
allowing better cell growth and fed with new 25 ml growth basal medium. The cell 
culture basal medium was changed every 4 days. 
Cells were sub-cultured till they reached 80% confluence, which took 8 to 10 
days. To prepare the cells for sub-culture, the basal medium was removed before 
washing with 10 mL of warm, filter-sterilized PBS. The cells were then trypsinized 
with 2 ml of pre-warmed 0.25% trypsin (Thermo Fisher Scientific 25200056) and 
incubated for 5 minutes in a tissue culture incubator to allow cell dissociation. The 
cells were observed under a light microscope to check for cell detachment from the 
flask (the flask was gently tapped to help detach the cells). Once the cells were 
completely detached, the trypsin was inactivated by adding fresh basal medium with 
10% FBS. Then, the basal medium containing the cell suspension was transferred from 
the flask into a sterile 15 ml falcon tube and centrifuged at 1500 rpm for 5 minutes to 
allow cell separation. The cell pellet was then re-suspended in pre-warmed basal 
medium and cultured at a suitable dilution to reach a sub-culturing ratio of 1:2. The 
cultures were expanded for up to 4 weeks (Figure 18A-C). Passages 2 and 3 where 
used for this study. Previous studies have shown that earlier passages of adipose tissue 
SVF have a heterogeneous cell population. Thus, additional in-vitro passages are 
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required to ensure a homogenous cellular population of adipose tissue MSCs 
(Zamperone et al., 2013).  
 
                  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A) B) 
Figure 16: A diagram demonstrating the mesenteric fat tissue specimen 
collected for the pre-adipocyte isolation.  
A) Before cutting the tissue sample and before removal of any apparent blood vessels or 
white fibrous tissues. B) After mincing the sample into a fine consistency to make it ready 
for the digestion step. 
Figure 17: A schematic demonstrating the digestion and centrifugation steps 
is isolating mesenteric fat pre-adipocytes.  
Picture on left-hand side show the tube containing the digested tissues after digestion 
step. The digested tissue homogenate was filtered through cell strainer into a new tube 
(picture on right-hand side) with basal medium added enough to fill the 50 ml falcon 
tube; this tube was then centrifuged at 1500 rpm for 5 minutes to separate the stromal-
vascular fraction cells pallet from the floating mature adipocytes. 
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4.2.2.2 Pre-adipocyte differentiation and fatty acid treatment  
For fatty acid differentiation experiments, cells at passage 2-3 were plated in 
24-well tissue culture plates (Thermo Fisher Scientific 103809320) at a seeding 
density of 40,000 cells per well. The cell number was counted before plating using the 
haemocytometer counting method, where 10 µl of cell suspension (pre-mixed with 
trypan blue solution in a 1:1 ratio) was pipetted into a Neubauer Haemocytometer 
Counting Chamber. The area of the counting chamber was observed under light 
microscopy and non-blue dye cells were counted as viable cells. Cells in all four 
quadrants of the chamber were counted and averaged. This number was then used to 
calculate the total number of cells in the original cell suspension by multiplying it by 
10,000, times a dilution factor of two. Once the plated cells reached 100% confluence, 
48 hours were allowed to initiate growth arrest before inducing differentiation. The 
differentiation medium consisted of basal growth medium (DMEM with 4.5 g/L 
glucose, 10% FBS, and 0.5% Penicillin-Streptomycin) supplemented with pro-
adipogenic factors that are required for activating the cAMP signalling pathway at the 
early phase of AT expansion; these factors include 100 nM insulin (Sigma I9278), 0.5 
mM 3-isobutyl-1-methylxanthine (IBMX) (Sigma I5879), 1 µM dexamethasone 
(Sigma D1756), and 0.2 mM indomethacin (Sigma I7378). The cells were incubated 
with the differentiation medium for up to 15 days (Figure 18D). 
Oleic acid (Sigma O3008), linoleic acid (Sigma L9530), and α-linolenic acid 
(Sigma L2376) were chosen to study the effect of fatty acids on adipocyte 
differentiation. All the fatty acids were delivered to the cultured pre-adipocytes as 
fatty acid/bovine serum albumin (BSA) complexes, in a 2:1 molar ratio of fatty acid 
to BSA. A range of 50, 100, 200 mM α-linolenic acid stock solutions were prepared 
by dissolving the free fatty acid in dimethyl sulfoxide (DMSO) organic solvent (Sigma 
D2650), and kept frozen at -80°C until use. Oleic acid and linoleic acid in 10% BSA 
solution, and at a 2:1 fatty acid to BSA molar ratio was purchased. The concentrations 
of fatty acids used in this study are considered to be within optimal physiological 
levels to stimulate the adipocyte differentiation response in the cells, as shown in 
previous studies  (Abdelmagid et al., 2015, Polus et al., 2015). When used in a given 
experiment, a desired volume of the stock solution was added to the adipocyte 
differentiation media to reach a final working concentration of 15 µM, 30 µM, or 60 
µM fatty acid, as required by the experiment. α-linolenic acid treated media had to be 
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A) 
supplemented with 10% BSA solution (Sigma A1595) to obtain a molar ratio of 2:1 
fatty acid to BSA. Differentiation medium with 10% BSA was used as the control. 
Also, the DMSO concentration in all fatty acid treatment groups and controls was 
normalised to 0.5% (v/v). Cells were treated with fatty acid enriched differentiation 
medium for 2, 10, and 15 days. Following the treatment, gene expression analyses 
were performed at day 2 and day 10 only, while lipid droplet staining was performed 
at day 15.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
D) 
B) C) 
10x 40x 
10x 
Figure 18: Morphology of isolated/cultured and differentiated mesenteric pre-
adipocytes.  
A, B, & C) Growth of mesenteric adipose tissue pre-adipocytes over a period of 4 weeks. D) 
Differentiated pre-adipocytes after 15 days of adipocyte differentiation. Images were 
acquired by light microscopy. 
10x 10x 
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4.2.3 RNA extraction and Quantitative real-time PCR (qRT-PCR) 
At day 2 and 10 of the above described differentiation experiment with fatty 
acids, RNA was extracted from the cells using the ReliaPrep RNA cell extraction kit 
(Promega Z6011), to measure the gene expression of adipogenic markers. The 
extraction was performed based on the manufacturer’s description. Briefly, culture 
medium was removed and the cells were washed with 1 ml of ice-cold PBS. 250 µl of 
BL+TG lysis buffer was added and the cell suspension was gently mixed by aspiration 
seven times to help lyse the cells, after which the lysate was transferred to a sterile 1.5 
mL eppendorf tube. The required volume of 100% isopropanol was added and the 
lysate was then transferred to an extraction kit minicolumn and centrifuged at 14000g 
for 30 seconds. 500 µl RNA Wash solution was added to the minicolumn and 
centrifuged at 14000g for 30 seconds. Next, DNase I incubation mix was prepared by 
mixing 24µl of Yellow Core Buffer, 3µl 0.09M MgCl2 and 3µl of DNase I enzyme 
and added to each minicolumn and incubated at room temperature for 15 minutes. The 
minicolumn was then washed with 200µl of column wash solution, followed by 500µl 
of RNA wash solution. The minicolumn was placed into a new collection tube and 
washed with 300µl of RNA wash solution. Finally, the minicolumn was transferred to 
an elution tube, where the RNA was eluted with 15µl nuclease-free water. Extracted 
RNA samples were stored at -20°C till further analysis. 
Please refer to the methods section in Chapter 3 for details about nucleic acid 
quantification (sub-section 3.2.2.1), cDNA synthesis (sub-section 3.2.2.2), qRT-PCR 
(sub-section 3.2.2.3), and the primers used (Table 4). 
4.2.4 BODIPY lipid droplet staining and quantification  
To measure lipid accumulation, fatty acid treated cells at day 15 of 
differentiation were stained with neutral lipid-specific BODIPY 493/503 dye (4,4-
difluoro-1,3,5,7,8-pentamethyl-4-bora-3a,4a-diaza-s-indacene) (Thermo Fisher 
Scientific D3922). Live cells were washed with filtered PBS and then stained with 
BODIPY (10 µg/ml) and kept in the tissue culture incubator for 10 minutes. Cells 
were then washed with filtered PBS and sixteen-bit images of the lipid droplets were 
taken with an AxioCam ICm1 monochrome charge-coupled device camera attached 
to the Apotome.2 Imaging System and a confocal microscope,  (Zeiss LSM 800 with 
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Airyscan) using the Axiovision 4.8.2 software (CarlZeiss). Image staining intensities 
were analyzed with the ImageJ software. Images were background subtracted and 
thresholds were manually applied for regions of interest. For each treatment group, at 
least 7-8 images were selected for analysis and their averages were calculated.  
4.2.5 Statistical analysis 
GraphPad Prism software (Version 7.0, GraphPad Software, San Diego, CA, 
USA) was used for statistical analysis. Results of at least 3 independent experiments 
(unless specified otherwise) are presented as mean ± standard error of the mean 
(SEM). The Mann-Whitney U test was used to compare the difference between test 
groups and p < 0.05 was considered statistically significant. 
 
4.3 Results 
4.3.1 Tissue donor characteristics for primary mesenteric pre-adipocytes 
Live MAT was collected from 10 patients. However, the isolation of pre-
adipocytes was successful (without any risk of contamination and infection) only for 
6 cases, of which four were diagnosed with CRC and were admitted for right 
hemicolectomy, and two were diagnosed with CD and were admitted for ileal 
resection. The median age for the patients was 68 (37-86) years and the median BMI 
was 26.03 (24.84-33.39) kg/m2. 
4.3.2 Effect of unsaturated fatty acids on the gene expression of adipogenic 
markers during the differentiation of mesenteric pre-adipocytes at 
different time points 
The effect of oleic acid, linoleic acid, and a-linolenic acid (at 30 µM 
concentrations) on the differentiation of human mesenteric pre-adipocytes was 
assessed by measuring the gene expression level of key markers for adipogenesis. 
Gene expression was assessed during early phase (day 2) and late phase (day 10) 
adipocyte differentiation (Figure 19). The level of PPARg mRNA did not increase 
significantly from control after fatty acid treatments on day 2 of differentiation. This 
is illustrated in Figure 19A, which shows that PPARg mRNA levels increased only by 
1.6-fold, 2.1 fold and 1.4-fold when treated with oleic acid, linoleic acid, and a-
linolenic acid, respectively. Significant changes in PPARg mRNA expression levels 
also did not occur at day 10 of differentiation for all three fatty acid treatments. 
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Conversely, a marked increase in CEBPa mRNA levels was observed at day 2 of 
differentiation, after treatment with all the three fatty acids. Nevertheless; no changes 
to gene expression were observed at day 10. Figure 19B shows that CEBPa mRNA 
levels in mesenteric pre-adipocytes at day 2 increased 3-fold (p = 0.08) when treated 
with oleic acid, 3.1-fold (p < 0.05) when treated with linoleic acid, and 4.1-fold (p < 
0.05) when treated with a-linolenic acid. No significant effect of the fatty acids on 
FABP4 mRNA expression was observed at day 2 and day 10 of differentiation (Figure 
19C). Adiponectin mRNA expression was only measured at day 10 of differentiation 
because it was considered an adipocyte specific marker that only expressed in the late 
phases of adipogenesis. Figure 19D illustrates that adiponectin mRNA expression was 
highly increased (7.3-fold, p > 0.05) only upon linoleic acid treatment. 
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Figure 19: Fold change in adipogenic markers mRNA expression in human 
mesenteric pre-adipocytes treated with oleic, linoleic, and α-linolenic fatty acids 
(30 µM) during differentiation.  
Data are presented as mean fold change over control group and standard error of mean (error 
bars). n=6 (all disease cohort combined). Statistical analysis was done by Mann-Whitney U 
test to test the difference between fatty acid treatment groups at a given time point of 
differentiation. *p < 0.05. All genes of interest have been normalised to the housekeeping gene 
RPL13A.  
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4.3.3 Effect of unsaturated fatty acids on the gene expression of adipogenic 
markers during mesenteric pre-adipocytes differentiation in Crohn’s 
disease and colorectal cancer 
To examine the effect of fatty acids on mesenteric pre-adipocyte 
differentiation in Crohn’s diseases, primary pre-adipocytes isolated from CD-affected 
MAT samples were used. Healthy MAT samples from patients with colorectal cancer 
(CRC) were used as control. PPARg mRNA expression levels following fatty acid 
treatments in both disease cohorts underwent a slight increase, which was nonetheless 
insignificant. Figure 20A shows that PPARg mRNA from CRC and CD mesenteric 
pre-adipocytes at day 2 of differentiation increased 1.9-fold in CRC and 1.3-fold in 
CD when treated with oleic acid, and 2-fold in CRC and 2.3-fold in CD when treated 
with linoleic acid, and 1.6-fold in CRC and 1.04-fold in CD when treated with a-
linolenic acid (p < 0.05). PPARg mRNA levels at day 10 were unchanged in both CRC 
and CD mesenteric pre-adipocytes. Comparatively, expression levels of CEBPa 
mRNA were highly increased at day 2 in CRC pre-adipocytes (3.9-fold, 3.7-fold, and 
5.6-fold when treated with oleic acid, linoleic acid, and a-linolenic acid respectively, 
p < 0.05) while in CD pre-adipocytes CEBPa mRNA levels underwent a moderate 
increased of 1.8-fold, 2-fold, and 1.2-fold, when treated with oleic acid, linoleic acid, 
and a-linolenic acid respectively (Figure 20B). However, CEBPa mRNA levels at 
day 10 of differentiation were unaltered in both CRC and CD mesenteric pre-
adipocytes. For the FABP4, Fatty acid treatment did not alter FAB4 mRNA levels in 
CRC and CD mesenteric pre-adipocytes at the indicated time points (Figure 20C). For 
adiponectin mRNA, a 10.6-fold change (p > 0.05) was observed at day 10 in CRC pre-
adipocytes, treated with linoleic acid, whereas CD pre-adipocytes showed no 
alteration in adiponectin mRNA levels in response to any of the fatty acids (Figure 
20D). 
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Figure 20: Fold change in adipogenic markers mRNA expression in Crohn’s 
disease (CD) and colorectal cancer (CRC) isolated mesenteric pre-adipocytes 
treated with oleic, linoleic, and α-linolenic fatty acids (30 µM) during 
differentiation.  
Data are presented as mean fold change over control group and standard error of mean (error 
bars). n=4 for CRC group and n=2 for CD group. Statistical analysis was done by Mann-
Whitney U test to test the difference between fatty acid treatment groups at a given time point 
of differentiation. *p < 0.05. Due to the very limited number of mesenteric samples for Crohn’s 
diseases no statistical analysis was applied to compare the differences in the gene expression 
level for the adipogeneic markers between the two disease cohorts. All genes of interest have 
been normalised to the housekeeping gene RPL13A.  
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4.3.4 Effect of different doses of unsaturated fatty acids on the gene expression 
of adipogenic markers during mesenteric pre-adipocytes differentiation 
To further examine the role of oleic, linoleic, and a-linolenic acids on gene 
expression levels of adipogenic markers, mesenteric pre-adipocytes were treated with 
varying doses of the fatty acids (15, 30 and 60 µM), in a dose response experiment 
(Figure 21). Oleic acid stimulated an increase, albeit non-significant, in PPARg 
mRNA and CEBPa mRNA levels with all doses tested on day 2 of differentiation 
(Figure 21A). While on day 10, oleic acid stimulated a non-significant increase in 
PPARg, CEBPa, and adiponectin mRNA expression only at the lowest dose (15 µM) 
and highest dose (60 µM) (Figure 21B). For linoleic acid, a similar trend was 
observed, where there was a non-significant increase in PPARg mRNA and CEBPa 
mRNA expression levels with all doses tested on day 2 of differentiation (Figure 21C). 
However, on day 10, linoleic acid treatment resulted in a small, but non-significant 
reduction in PPARg, CEBPa, FABP4, and adiponectin mRNA levels with all doses 
tested (Figure 21D). For a-linolenic acid, a sharp increase in CEBPa mRNA levels at 
60 µM concentration was observed at day 2 of differentiation, which was not 
statistically significant, while the other genes shown a modest increase (Figure 21E). 
a-linolenic acid treatment also did not show any noticeable and significant changes in 
adipogenic marker expression levels at day 10. (Figure 21F). 
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Figure 21: Effect of increasing concentrations of oleic, linoleic, and α-linolenic 
fatty acids on gene expression of adipogenic markers in mesenteric pre-
adipocytes.  
Data are presented as mean fold change over control group and standard error of mean (error 
bars). n=3. Statistical analysis was done by Mann-Whitney U test to test the difference 
between the effect of different concentrations for each fatty acid at a given time point of 
differentiation. All genes of interest have been normalized to the housekeeping gene RPL13A. 
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4.3.5 Effect of unsaturated fatty acids on lipid droplet formation during 
mesenteric pre-adipocyte differentiation  
To examine the effect of fatty acids on lipid droplet formation during 
adipogenesis, BODIPY staining of differentiated mesenteric adipocytes was 
performed by measuring the fluorescence of BODIPY-stained lipid droplets after 15 
days of differentiation with fatty acid treatment. As hypothesized, lipid accumulation 
was potentially increased in pre-adipocytes that were treated with adipocyte 
differentiation medium, with or without fatty acids (as in control, oleic acid, linoleic 
acid and a-linolenic acid groups), compared to cells that were treated with basal 
medium only (Figure 22A). A 7-fold increase in lipid accumulation was observed for 
cells treated with linoleic acid, while a-linolenic acid treated cells demonstrated a 34-
fold increase, which was not statistically significant. Oleic acid has showed a non-
significant inhibitory effect on lipid accumulation (Figure 22B). 
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Figure 22: Effect of fatty acids on lipid droplet formation at day 15 of adipocyte 
differentiation.  
A) Live cells at day 15 of fatty acid differentiation treatment were stained for lipid droplets 
by using BODIPY. B) Data are presented as fold change of the mean fluorescent intensity 
calculated over control group (differentiation medium only) and standard error of mean (error 
bars). n=3. Images were analysed with ImageJ. Statistical analysis was done by Mann-
Whitney U test to test the difference between fatty acid treatment groups.  
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4.3.6 Results Summary 
Oleic acid, linoleic acid and a-linolenic acid all seemed to cause an increase 
in adipogenesis in the early phase of differentiation, mainly via elevating CEBPa 
mRNA, while in late phase, only linoleic acid was observed to continue upregulation 
of adipogenesis via increasing adiponectin mRNA levels (non-significant). The effect 
of all three fatty acids on elevating CEBPa mRNA levels, was more potent in CRC 
mesenteric pre-adipocytes compared to CD pre-adipocytes, during the early phase of 
differentiation. A similar trend was also observed in the late phase of differentiation 
for linoleic acid, but only on adiponectin mRNA. The effect of fatty acids on CEBPa 
mRNA expression was observed to be relatively dose dependent, especially during the 
early phase of differentiation. Finally, linoleic acid and a-linolenic acid, both 
demonstrated increased lipid accumulation, which was dose-dependent, while oleic 
acid relatively downregulated lipid droplet formation. These results were, however, 
statistically non-significant. 
 
4.4 Discussion  
The results in this study have shown that unsaturated fatty acids generally 
induced a pro-adipogenic effect in mesenteric pre-adipocytes by varying degrees. This 
increasing effect on adipogenesis was mainly regulated by CEBPa, which is a key 
adipogenic transcription factor during the early stages of adipogenesis. This effect was 
relatively more potent in CRC derived mesenteric pre-adipocytes than those derived 
from CD patients. Furthermore, the observed pro-adipogenic effect was further 
confirmed by increasing lipid droplet formation in the fully differentiated mesenteric 
pre-adipocytes, an effect that was enhanced only for linoleic and a-linolenic acids but 
not for oleic acid. 
Previous studies consistently reported an increased expression of PPARg and 
CEBPa in differentiated pre-adipocytes that were treated with fatty acids (Regassa et 
al., 2017). In the present study, dietary fatty acids seemed only to significantly increase 
the expression of CEBPa in mesenteric pre-adipocytes. The level of PPARg mRNA 
was insignificantly elevated, while no changes occurred in FABP4 expression. PPARg 
and CEBPa are both induced during the early phases of adipogenesis, which 
subsequently regulate the expression of later adipogenesis target genes (Madsen et al., 
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2005). While further research is required, it is proposed that the high expression of 
CEBPa reported here, in response to fatty acids, could be specific to mesenteric pre-
adipocytes. The effect of oleic acid and linoleic acid on adipogenic gene expression 
reported in this study is consistent with previous findings, which demonstrated their 
upregulating effect on PPARg, as well as CEBPa expression (Madsen et al., 2005). 
However, the pro-adipogenic effect of a-linolenic acid reported in this study is 
inconsistent with the current evidence, which reports a reduction in adipogenesis when 
pre-adipocytes were treated with a-linolenic acid (Siriwardhana et al., 2013). 
Moreover, the expression of the adipocyte specific marker (adiponectin) was 
relatively elevated only with linoleic acid, indicating that the pro-adipogenic effect at 
later stages of adipogenesis could be enhanced with linoleic acid. 
Only very few studies have investigated the role of mesenteric adipose tissues 
in CD. However, the effect of dietary fatty acids on CD mesenteric pre-adipocyte 
differentiation is not yet investigated. This study is the first to look at the adipogenic 
potential of mesenteric pre-adipocytes in response to fatty acid exposure, where the 
findings have demonstrated an increase in adipogenesis only in CRC mesenteric pre-
adipocytes treated with unsaturated fatty acids, whereas adipogenesis was very 
modestly upregulated in CD mesenteric pre-adipocytes. The pro-adipogenic effect 
was reflected by the significant increase in CEBPa mRNA expression. Nevertheless, 
these findings should be carefully interpreted as a small sample size due to very 
limited surgical samples, especially for CD patients, is one of the limitations of this 
study. Therefore, future studies are needed with larger sample sizes to elucidate the 
role of fatty acids on the adipogenesis of CD MAT. 
Accumulation of intracellular lipids is an important characteristic during the 
process of adipogenesis. The degree of formation of lipid droplets will consequently 
determine the size of adipocytes and its adipocytokine profile; the bigger the 
adipocyte, the more pro-inflammatory mediators will be secreted, and so its anti-
inflammatory potential will be lower (Skurk et al., 2007, Polus et al., 2015). Therefore, 
lipid droplet formation in differentiating mesenteric adipocytes was also investigated 
in later phases of differentiation in this study. Oleic acid was observed to relatively 
down-regulate lipid droplet formation, as indicated by the low lipid droplet fluorescent 
intensity. This result is relatively consistent with earlier animal studies, that reported 
an inhibitory effect of oleic acid on the degree of adiposity (Hsu and Huang, 2006, 
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García-Escobar et al., 2008). However, linoleic acid and a-linolenic acid have both 
shown an increasing effect on lipid droplet accumulation. Similar results for linoleic 
acid have been observed in a recent study using human subcutaneous pre-adipocytes, 
whereas linoleic acid precursor (arachidonic acid) significantly reduced lipid 
accumulation within treated cells by 25% compared to control cells (Polus et al., 
2015). However, for a-linolenic acid our results are inconsistent with previous 
evidence that consistently reported decreased lipid droplet formation in pre-adipocyte 
cell-lines treated with a-linolenic acid (or its derivative EPA) (Warnke et al., 2011, 
Manickam et al., 2010). The disagreement in this data with the existing literature could 
be related to the fact that the types and origins of pre-adipocytes used in previous 
studies are different to what we have used for our investigation. In this study, primary 
human mesenteric pre-adipocytes were used, while only very few studies have started 
to investigate this type of pre-adipocyte. Therefore, these findings should be carefully 
interpreted as cells from different origins could behave differently to the influence of 
fatty acids. Moreover, the reported differences between the effect of oleic acid and the 
two PUFAs might suggest an opposing effect of unsaturated fatty acids on the 
inflammation of mesenteric fat. The anti-inflammatory effect of oleic acid on MAT 
has been previously investigated in-vivo; the level of anti-inflammatory markers 
specific for M2 macrophages was increased after supplementation of oleic acid in the 
animals’ diet for three days, while no changes occurred after palmitic acid 
supplementation (Camell and Smith, 2013). Unfortunately, there is no available 
evidence for the suggested pro-inflammatory effect of PUFAs on mesenteric fat. 
Unlike previous studies, this study has used a primary human mesenteric pre-
adipocyte model to investigate the effect of dietary fatty acids, which is more 
representative than using cell-lines. One of the limitations of this study is the shortage 
of human mesenteric tissue samples: the number of CD patients undergoing intestinal 
surgical resection was very low, which limited the power of the study. Moreover, the 
risk of contamination and infection associated with the use of primary human cells 
further limited the number of successfully isolated mesenteric pre-adipocytes. Another 
limitation in this study is the absence of measuring the protein level of the investigated 
adipogenic markers, to account for any post-translation modifications of these markers 
in protein form. 
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Pre-adipocytes are a major cellular component of AT and are found to strongly 
control the secretion of inflammatory adipocytokines associated with the 
pathophysiology of chronic disorders (O’Hara et al., 2012). Hypertrophied MAT is a 
key phenomenon in CD as it is predominantly involved in the intestinal inflammation. 
Therefore, understanding the role of dietary fatty acids on MAT cellular function has 
an important clinical implication. Collectively, the findings of this study can guide 
future researches to identify the most optimal proportion of fatty acids in therapeutic 
diets prescribed for CD patients, that might beneficially modulate adipogenesis and 
MAT inflammation. Interestingly, other similar dietary constituents have also been 
identified as modulators of adipogenesis. Although not investigated in this study, 
curcumin is another potential dietary supplement that has been reported to have an 
anti-adipogenic effect in in-vitro studies, in addition to its reported anti-inflammatory 
effect in an IBD therapeutic diet (Siriwardhana et al., 2013, Alhagamhmad et al., 
2017). More investigations are required to elucidate the modulatory effect of these 
nutrients in the context of CD adipogenesis. 
In conclusion, this study has shown that mesenteric pre-adipocytes have an 
increased adipogenic response to unsaturated fatty acids. This effect was 
predominantly modulated via CEBPa, a key marker in the early stages of 
adipogenesis. Moreover, an increase in lipid droplet accumulation was observed in 
differentiated mesenteric pre-adipocytes treated with linoleic and a-linolenic acids, 
while oleic acid relatively reduced lipid accumulation. However, differences in the 
effect of the fatty acids on CD versus CRC mesenteric pre-adipocytes could not be 
concluded in this study as a larger sample size was required. Recent observations 
introduced mesenteric pre-adipocytes as a novel cellular population with immune 
functions that are likely to be involved in controlling intestinal inflammation in IBD 
(Sideri et al., 2015). Given the complexity of the MAT in CD, future studies targeting 
the potential interaction between dietary fats and the inflammatory responses 
produced by pre-adipocytes and immune cells present in hypertrophied MAT, and 
epithelial cells located in the adjacent inflamed intestinal mucosa are required.  
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5 Chapter 5. Preliminary in-vitro studies: impact of lipids on 
human intestinal crypt proliferation  
 
 
5.1 Introduction 
CD is characterised by transmural inflammation, that penetrates the intestinal 
wall, leading to serious complications. Transmural inflammation in CD is linked to 
mesenteric fat hypertrophy (Kruis et al., 2014). Impaired gut barrier function and 
increased gut permeability have been found to be associated with increased visceral 
fat deposition (Gummesson et al., 2011). Therefore, achieving transmural healing in 
CD patients is associated with better long-term outcomes, rather than achieving 
mucosal healing alone (Fernandes et al., 2017). Interestingly, diet has an important 
role in modulating the intestinal inflammatory response in CD. Enhancement of the 
gut mucosal barrier function is one of the mechanisms of action of nutritional therapy 
in CD (Ioannidis et al., 2011).  
The alteration in tissue remodeling of intestinal epithelium by high fat intake 
is a newly suggested and plausible cellular mechanism for intestinal diseases. 
Intestinal epithelium is a key player in controlling inflammation, and is considered the 
fastest self-renewing tissue in the body. Intestinal stem cells (ISC) help maintain the 
rate of self-renewal for adequate tissue homeostasis in the gut. Digested nutrients in 
the gut can lead to an alteration in  circulating factors that stimulate the biology of 
ISC, which could in turn affect the pattern of tissue remodeling and renewal in the 
mucosal epithelium (Luo and Puigserver, 2016). A recent study has shown that 
animals fed a high-fat diet have a significantly higher rate of ISC proliferation, which 
resulted in elongation of the crypts (the lower part of the epithelium in which ISCs are 
found), thus predisposing the animals to intestinal cancers (Beyaz et al., 2016). 
Interestingly, the resulting changes in the pattern of ISCs were produced by specific 
fatty acids in the interventional high-fat diet. Although the findings of this study focus 
on the effect that dietary fat has on tumorgenicity of the gut, rather than inflammatory 
response, it does suggest a new mechanism of action for the intestinal handling of 
dietary fats, which could be applicable to the understanding of CD aetiopathogenesis. 
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5.1.1 Intestinal epithelium in health and Crohn’s disease 
The intestinal epithelium is a highly renewable tissue in our body and has an 
important physiological function in regulating gut homeostasis. It consists of epithelial 
cells that stimulate interactions between the intestinal mucosa immune response and 
intestinal contents, which is an important mechanism in regulating intestinal 
homeostasis (Turner, 2009). Generally, the intestinal lining is comprised of 
proliferative crypts, consisting of ISCs that are responsible for epithelial tissue 
renewal, and villi, which have varying differentiated enterocytes. Both, the villi and 
the crypts aid in the absorption of nutrients, water, and electrolytes. Contrarily, the 
colon epithelium consists only of crypts, where water is primarily absorbed with ions 
and bile salts. 
There are five types of epithelial cells located in intestinal crypts: enterocytes, 
which are the most abundant epithelial cells with major functions in nutrient and 
electrolyte absorption; enteroendocrine cells, which produce hormones; goblet cells, 
which secrete mucus that acts as a gut barrier against luminal bacteria; tuft cells, which 
are thought to have secretory functions, and ISCs which are located at the base of the 
crypt, and are constantly self-renewing. The communication between intestinal 
epithelial cells, luminal microbes and gut immune cells is considered to be an 
important characteristic of gut homeostasis; such interactions are crucial for 
maintaining normal homeostasis, as well as for enhancing the protective immune 
response against pathogens. (Maloy and Powrie, 2011).  
The inner lining of the intestines plays an important role as a barrier against 
luminal bacteria, its metabolites and other toxic molecules. However, an abnormal 
immune response to gut antigens may occur in genetically predisposed individuals, 
which would consequently lead to intestinal inflammation, thereby causing symptoms 
characteristic of CD. It is proposed that an aspect of CD pathogenesis involves the 
impairment of gut barrier functions and the enabling of bacterial translocation into the 
inner lining of the gut. In addition, the disturbed immune response associated with the 
disease can result in an increased rate of immune cell recruitment and an increased 
expression of pro-inflammatory cytokines, with reduced levels of anti-inflammatory 
cytokines (Manuc et al., 2016). 
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5.1.2 Crypt proliferation and mucosal healing 
Generally, achieving mucosal healing requires a dynamic balance between the 
three cellular mechanisms of restoration, proliferation, and differentiation of epithelial 
cells in the injured gut epithelium. Dysregulation in these cellular mechanisms that 
affect the rate of crypt proliferation will allow the development of mutation. Several 
signalling pathways are involved in regulating the function of intestinal crypts; the 
Wnt/β-catenin signalling pathway is mainly responsible for directing crypt 
proliferation. Thus, an active mutation in the Wnt pathway would lead to disturbances 
in intestinal homeostasis and, consequently, influence the development of CRC (Van 
Der Flier and Clevers, 2009). However, cellular mechanisms are less clearly 
understood for IBD. Restoring the barrier functions and immune functions of 
epithelial cells are essential for achieving mucosal healing in IBD, as crypt 
proliferation is required for mucosal tissue repair. Interactions between the 
intracellular signalling pathways, stimulated by pro-inflammatory cytokines, or by 
growth factors, or by intrinsic proliferative signals, can result in tissue repair in IBD 
(Okamoto and Watanabe, 2016). Other factors, such as diet, have also been suggested 
to play a role in regulating mucosal healing. 
5.1.3 Role of dietary lipids in crypt proliferation  
The association between obesity (related to high-fat diets) and intestinal 
tumours has been suggested for many years. A mechanism for the effect of dietary fat 
on intestinal tumour development, via excessive ISC proliferation in the crypt was 
recently proposed (Figure 23) (Beyaz et al., 2016). In this animal study, the long-term 
intake of a high-fat diet led to intestinal changes, such as intestinal villi shortening and 
increased proliferation of ISCs within intestinal crypts. Moreover, PPARd (a nuclear 
receptor transcription factor which can bind to fatty acids) was suggested to act as a 
signalling component, which could link the role of a high fat-diet in intestinal tumour 
initiation. On the other hand, epidemiological studies have identified fat intake, 
independent of obesity, as a risk factor for IBD disease development. Gruber et al. 
found that a high-fat diet can modulate gut inflammation in an animal model of CD, 
via enhanced gut permeability and impaired gut barrier functions, resulting in a high 
rate of cellular recruitment of dendritic cells, and a high rate of immune cell infiltration 
into the lamina propria (Gruber et al., 2013). Nevertheless, further studies are still 
needed to validate the precise role of dietary lipids in intestinal disease development. 
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5.1.4 Research gap 
The cellular mechanism behind mucosal healing in CD is not yet clear. The 
role of dietary factors in modulating gut epithelium function has been investigated, 
and a newly proposed mechanism of action suggests that dietary fat can remodel the 
intestinal epithelium in CRC via crypt proliferation (Beyaz et al., 2016). However, fat 
composition of the diet was found to regulate inflammatory cytokines in IBD studies 
using IBD organ culture, suggesting an anti-inflammatory effect of fish oil enriched-
nutritional feeds (Meister and Ghosh, 2005). Another study found that an elemental 
diet administered to animals reduced the rate of crypt proliferation, while the addition 
of fat emulsion to the same elemental feed was found to increase absorption via the 
distal jejunum, suggesting that fat intake might enhance the mucosal integrity of the 
gut (Kawano et al., 2010). As dietary fat intake is linked to CD incidence rate, the role 
of fat on crypt proliferation and in controlling mucosal tissue repair in CD has been 
suggested to be a working model for future investigations. 
5.1.5 Hypothesis  
Dietary fat has an effect on the intestinal epithelial cellular function via 
regulating the rate of crypt proliferation, which could contribute to mucosal healing in 
CD. This effect will be investigated in this study using a human crypt culture model 
Figure 23: Dietary fats remodel the intestine.  
Adopted with permission from LUO, C. & PUIGSERVER, P. 2016. Stem cells: Dietary fat 
promotes intestinal dysregulation. Nature, 531, 42-43 (Luo and Puigserver, 2016). 
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isolated from colonic and small bowel mucosa, which will also be treated with 
different concentrations of lipid mixture to test their proliferative effect. 
5.1.6 Objectives 
The main objective of this study is to compare the effect of fatty acid 
treatment on the rate of colonic and small bowel epithelial crypt proliferation.  
 
5.2 Methods 
5.2.1 Human tissue collection  
For details regarding ethical approval and patient eligibility for human tissue 
collection, please consult the Methods section in Chapter 3. For this study, mucosal 
tissue samples (normal colonic mucosa and normal small bowel mucosa) were 
collected from some of the recruited patients. For specimen collection, a 3 cm x 3 cm 
full thickness portion of fresh normal mucosa was collected. In CRC cases, mucosal 
samples were taken with more than a 10 cm tumor margin, while in IBD cases, 
mucosal samples were taken from non-ulcerated/non-inflamed regions as much as 
possible. 
5.2.2 Isolation and culture of crypt from intestinal epithelium  
Cultured crypts were kindly supplied by Dr. Mark Williams and Dr. Alyson 
Parris (School of Biological Sciences, UEA), who also performed crypt isolation.  
The protocol for crypt isolation was described earlier by Williams and 
colleagues (Parris and Williams, 2015, Reynolds et al., 2014, Reynolds et al., 2007). 
During tissue collection, the mucosal sample was washed in Hepes-buffered saline 
(HBS; 140 mM NaCl, 5mM KCl, 10 mM HEPES, 5.5 mM D-glucose, 1 mM Na2HPO4 
1, 0.5 mM MgCl2, 1 mM CaCl2), and placed in a 25ml screw top plastic bottle 
(Universal) containing HBS without Ca+2 and Mg+2, and supplemented with 
diaminoethanetetraacetic acid disodium salt (EDTA; 1mM), and incubated for 1 hour 
at room temperature. The crypts were then liberated by serial rounds of vigorous 
shaking, crypt sedimentation and collection. Sedimented crypts were collected and 
mixed in Matrigel (BD Bioscience), and a 20 µl droplet containing 50-100 crypts was 
placed onto a no. 0 glass coverslip (VWR), contained within a 12-well cell culture 
plate. After polymerization at 370C for 5-10 minutes, crypts were flooded with 0.5 mL 
of human crypt culture medium, which contained advanced F12/DMEM 
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supplemented with B27 and N2 (Invitrogen), n- acetylcysteine (1 mM), HEPES (10 
mM), penicillin/ streptomycin (100 U/ml), L-Glutamine (2mM), Wnt-3A (100 ng/ml) 
(R&D systems), IGF-1 (50 ng/ml) (Sigma), Noggin (100 ng/ml) (Peprotech), RSPO-
1 (500 ng/ml) (Sino Biological or R&D Systems), and the ALK 4/5/7 inhibitor, A83-
01-01 (0.5 µM) (R&D systems). The human crypt culture medium was changed every 
two days and was modified further, depending on the stated experiments. The 
morphology of isolated and cultured human colonic crypt is shown in Figure 24. 
 
 
 
 
 
 
 
5.2.3 Lipids and fatty acid treatment  
On day 1-2 after isolation, cultured crypts were treated with a lipid mixture 
supplement (Sigma L0288), containing 10 µg/mL each of linoleic, linolenic, myristic, 
oleic, palmitic, and stearic acids, and only 2 µg/ml of arachidonic acid. The lipid 
mixture was added directly to the standard human crypt culture medium (with 100% 
growth factors). Only in one separate set of experiments on colonic crypts, the lipid 
mixture was added directly to a 20% growth factor supplemented human crypt culture 
medium, to help lower the high proliferation rates associated with high concentrations 
of growth factors. Lipid was added at 0.1% and 1% concentrations. Concentration 
choices were based on a previous study that used a similar lipid mixture at up to 2% 
concentration (Beyaz et al., 2016). The incubation time with lipids was up to 48 hours. 
Additionally, the effect of individual fatty acids (linoleic acid) was also tested. Pre-
conjugated linoleic acid (Sigma L9530) was added to the medium, which was pre-
dissolved in 10% bovine serum albumin (BSA) solution, giving a final fatty acid to 
Figure 24: Morphology of isolated and cultured human colonic 
crypt.  
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albumin molar ratio of 2:1. Linoleic acid supplement was added directly to the culture 
medium at 0.1% working concentration. 
5.2.4 Proliferation (EdU) assay  
The Click-iT 5-ethynyl-2′-deoxyuridine (EdU) Alexa Fluor cell proliferation 
assay kit (Invitrogen) was used in experiments assessing cell proliferation rates. 
Briefly, this assay uses a nucleoside analog of thymidine, called EdU, which 
efficiently incorporates itself into cells with newly synthesized DNA (cells in the S 
phase of the cell cycle), and then fluorescently labels these cells with the Alexa Fluor 
dye, which can be detected by using a fluorescence microscope. 
After stimulating the crypt culture with selected concentrations of lipids, 
crypts where incubated with EdU (10 µM) for 2 hours in a cell culture incubator; this 
was done by replacing the spent culture medium with a fresh medium supplemented 
with EdU. Thereafter, crypts were immediately processed for fixation and 
permeabilization. Media was removed and 4% paraformaldehyde (PFA) solution was 
added (about 200 µl) to each cover slip containing the crypts, and incubated for 1 hour 
at room temperature. The fixative was then removed and the crypts were washed two 
times with phosphate buffered saline (PBS); this was done by aspirating away the PFA 
from the coverslips, and pipetting a sufficient amount of PBS to cover the Matrigel in 
each coverslip. To help permeabilize crypt cell membranes, ammonium chloride 
(NH4Cl2) was added for 13 minutes and 1% Sodium dodecyl sulphate (SDS) for 5 
minutes, each step followed by 2-5 PBS washes. Then, a 1% Triton X-100 solution in 
PBS was added to the fixed crypts, and incubated for 30 minutes at room temperature, 
followed by two washes with 3% BSA solution in PBS.  
The Click-iT reaction was subsequently induced by replacing the wash 
solution with a freshly prepared reaction mix, according to the kit manufacture’s 
instructions. For a 1 ml reaction mixture, 860 µl reaction buffer, 40 µl CuSO4 solution, 
2.5 µl Alexa Fluor azide, and 100 µl reaction buffer additive were mixed. The Click-
iT reaction cocktail was protected from light and used within 15 minutes. About 40 µl 
of the reaction cocktail was added to each coverslip and incubated for 35 minutes at 
room temperature (protected from light). The reaction mix was then removed with two 
3% BSA solution washes. After this step, crypts were ready to be mounted on a glass 
microscope slide for florescence imaging. Crypts were mounted as follows: aspirating 
away all the wash solution from the previous step; lifting each coverslip from the 
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culture plate using a tweezer and putting it on a clean tissue paper to drain off any 
excess fluids; adding a drop of mounting media (Vectashield containing nuclear stain 
DAPI (marker for nucleus (DNA)); inverting the coverslip on a clean glass microscope 
slide, sealing the edges with a transparent nail varnish to help prevent mounting media 
leakage; finally, the slides were stored in a light-protected slide box in a fridge, before 
fluorescence imaging.  
Depending on the experiment, immunolabeling with primary and secondary 
antibodies was additionally performed. This process simply involved extending the 
EdU proliferation assay by immunostaining the EdU-labeled crypts with primary 
antibodies and a suitable, species-specific Alexafluor-conjugated secondary antibody, 
which were raised in donkey. The primary antibodies mainly used were against ki67 
and E-cadherin, which are considered to be markers for proliferation and the plasma 
membrane, respectively.  
Briefly, after the final step in the EdU protocol (just before mounting the 
coverslips), serum block solution with 10% secondary antibody serum and 1% BSA 
was added to each coverslip for 2 hours at room temperature (protected from light) to 
help block non-specific binding. The blocking solution was then removed, followed 
by two PBS washes. The required combination of primary antibodies was diluted in 
PBS (1:100 dilution); these were rabbit anti-ki67 (R&D) and goat anti-E-cadherin 
(R&D). 50 µl of the primary antibody working solution was added to each coverslip 
and the culture plate was wrapped with wet tissue paper and cling film to minimize 
water evaporation, and stored overnight at 4ºC. The following day, the primary 
antibody solution was removed, followed by two washes with cold PBS. Fluorophore-
conjugated secondary antibodies were prepared at half the dilution of primary 
antibodies (1:200); these were donkey anti-rabbit Alexa Fluor 488 (green) and donkey 
anti-goat Alexa Fluor 647 (red) (Thermo Fisher Scientific); 50 µl of secondary 
antibody working solution was added to each coverslip followed by 2 hours of 
incubation on ice (protected from light). The secondary antibodies solution was 
removed and washed once with PBS.  Fresh PBS solution was added again and left 
for 1 hour (about 1 ml in each coverslip). The microscope slide was now prepared for 
fluorescence imaging, and mounted as described earlier. 
Reagents used in this assay were either prepared fresh for immediate use, or 
were prepared earlier and aliquoted by Dr Mark Williams’s team (School of Biological 
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Sciences, UEA). Reagents used include: PBS solution (1 tablet (Oxoid BR0014G) 
dissolved in 100 ml deionized water which was then autoclaved); 4% PFA solution, 
which was prepared weekly by dissolving 4 g of PFA powder (Sigma P6148) in 100 
ml PBS solution with gentle warming for up to 4 hours till the solution was clear and 
stored in aliquots at -80°C); 1% TritonX (Roche) solution in PBS, which was prepared 
for immediate use; 100 mM Ammonium chloride NH4Cl2 solution  (Sigma A9434) in 
PBS; 1% SDS solution (Melford B2008), in PBS; 10% donkey serum (sigma 9663); 
1-3% BSA solution, which was prepared by dissolving 0.1-0.3 gm of BSA (Sigma 
A2153) in 10 ml PBS at room temperature; coverslip mounting media with nuclear 
counterstain Hoechst “VectashieldTM” (Vector labs H1000, H1200 or H1300); and 
coated microscope slides (PolysineTM VWR). 
5.2.5 Epifluorescence/confocal imaging 
Following EdU assay and immunolabeling treatment, slides of mounted crypts 
were imaged by epifluorescence microscopy (Nikon Ti) or confocal microscopy 
(Zeiss 510 META). Usage of the fluorescence microscopy facility was supervised by 
Dr. Paul Thomas (Henry Wellcome Laboratory for Cell Imaging, UEA), Dr. Alyson 
Parris, and Victoria Jeffery (School of Biological Sciences, UEA). For 
epifluorescence microscopy, a 40x objective lens was used to acquire images of crypts 
at the equatorial plane.  
5.2.6 Data analysis  
5.2.6.1 Image analysis 
Acquired images of crypts were analysed using the Fiji ImageJ software. The 
total number of DAPI-positive nuclei was counted at the crypt equatorial plane. The 
number of EdU-positive cell nuclei was then counted. The percentage of EdU-positive 
cells was calculated from the number of DAPI-positive nuclei. Counting for colonic 
crypts was divided into four regions (base, supra base, mid, and top) along the crypt 
axis, each region containing an equal number of nuclei; the percentage of EdU-
positive cells was calculated for each region. However, for small bowel crypt, 
counting was done for the whole crypt region. For each experiment, at least four 
representative crypts were analysed for each treatment group, to give the mean rate of 
proliferation in each case.  
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5.2.6.2 Statistical analysis  
Prism software (Version 7.0, GraphPad Software, San Diego, CA, USA) was 
used to analyze the data. The statistical difference between the treatment groups was 
determined by using one-way analysis of variance (ANOVA) and to correct for 
multiple comparisons, Tukey’s post-hoc test was performed. A p-value < 0.05 was 
considered as significant. Results were expressed as mean ± standard error of the mean 
(SEM) of three or more independent experiments.  
 
5.3 Results 
5.3.1 Characteristics of tissue donors 
Between April 2016 and February 2017, mucosal tissue samples from small 
and large bowels were collected from a total of 21 patients (2 were diagnosed with 
Crohn’s disease, 2 were diagnosed with ulcerative colitis, and 17 were colorectal 
cancer patients). However, crypt isolation was successful in only 12 cases, of which 
only 10 were investigated in this study (the other two were used for training purposes). 
These were all patients diagnosed with CRC, confirmed by histopathology. Two 
patients had right hemicolectomy, one had small bowel resection, one had 
panproctocolectomy, and six had anterior resections. 
Successful isolation of intestinal crypts was limited due to several factors, 
including: 1) a limited amount of non-ulcerated mucosa in IBD cases; 2) the long 
durations of surgical operations, typically > 5 hours, which affected the viability of 
live tissues due a limited blood supply to intestinal tissues; 3) the duration of tissue 
transportation from the surgical theatre to the histopathology lab and to the cell culture 
lab for isolation, which was long enough to affect tissue viability; 4) and on three 
occasions, infected tissue. 
 
5.3.2 Effect of different concentrations of lipids on colonic crypt proliferation 
This sub-section reports the results of experiments investigating the effect of 
various lipid mixtures on colonic crypt proliferation (as measured by the percentage 
of EdU positive cells). 
In the first set of experiments, stimulating the colonic crypts with different 
concentrations of lipids (in a standard human crypt culture medium with 100% growth 
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factors) resulted in no difference in proliferation rates in the base of the crypt; the 
mean rates of proliferation for the control, 0.1% lipid, and 1% lipid groups were 30.6 
± 2.35, 31.5 ± 1.94, and 28.33 ± 2.73, respectively. A similar pattern was observed in 
the supra base region as well. In the mid region of the crypt, lipid treatment resulted 
in a numerically increased proliferation rate that did not reach statistical significance. 
The mean proliferation rate was 20.49 ± 2.4 for the 0.1% lipid group, 18.23 ± 3.32 for 
1% lipid group, and 12.52 ± 2.18 for the control (p = 0.09). In the uppermost region 
of the crypts, proliferation was only increased when crypts were treated with 1% lipid 
(13.42 ± 3.92) compared to control (6.15 ± 1.71), however, this was not statistically 
significant (p = 0.11) (Figure 25 A-B). 
In the second set of experiments, stimulating the colonic crypts with 0.1% and 
1% lipid solution (in a reduced-growth factor crypt culture medium with only 20% 
growth factors) resulted in a difference in proliferation rates across all crypt regions. 
At the base of the crypt, both concentrations of lipids resulted in a lowered percentage 
of proliferative cells compared to control, however this difference was not statistically 
significant: 21.67 ± 4.08 (0.1% lipids), 24.67 ± 4.36 (1% lipids), versus 33.57 ± 3.52 
(control). In the supra base region, treatment with 0.1% lipid solution also reduced 
proliferation (9.44 ± 3.27) compared to control (17.25 ± 2.97) and the 1% lipid 
solution (22.54 ± 3.86); the difference was statistically significant after adjusting for 
multiple comparison (Tukey’s test) between the 0.1% lipid group and 1% lipids group 
(p < 0.05). Similarly, in the mid region, 0.1% lipid treatment achieved the lowest 
percentage of proliferation (3.61 ± 2.2) compared to 1% lipid treatment (11.44 ± 3.82) 
and control (18.05 ± 3.26); the difference was statistically significant between the 
control and the 0.1% lipid treatment group (p < 0.05). In the uppermost region, 
treatment with 0.1% lipid only numerically reduced cell proliferation (2.68 ± 1.81) 
compared to the 1% lipid treatment group (5.87 ± 4.69) and control (6.48 ± 2.23) (p = 
0.65) (Figure 26 A-B). 
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Figure 25: Effect of lipids on human colonic crypt proliferation. 
A) Confocal image showing the immunolabeling for lipids stimulated colonic crypts for 48 
hours (in this experiments lipids added to a standard human crypt culture medium with 100% 
growth factors), EdU (pink), E-cadherin (red), and blue (nuclei). B) Histogram showing the 
cell proliferation rate (expressed as mean percentage of EdU positive cells and standard error 
of mean (error bars)) in the different regions of colonic crypts that have been stimulated with 
0.1% and 1% lipids in a standard human crypt culture medium (with 100% growth factors) 
for up to 48 hours (n=4 CRC). Statistical analysis was done by one-way ANOVA and to 
correct for multiple comparisons Tukey’s post-hoc test was performed. *p < 0.05.   
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Figure 26: Effect of lipids on human colonic crypt proliferation.  
A) Epifluorescence image showing EdU labeling for lipids stimulated colonic crypts for 48 
hours (in this experiments lipids added to a reduced growth factors (20%) human crypt culture 
medium), EdU (pink) and blue (nuclei). B) Histogram showing the cell proliferation rate in 
the different regions of colonic crypts that have been stimulated with 0.1% and 1% lipids in a 
reduced growth factors (20%) human crypt culture medium for up to 48 hours (n=3 CRC). 
Data are presented as mean ± standard error of mean (error bars). Statistical analysis was done 
by one-way ANOVA to test the significance between the three treatment groups in each region 
across the crypt axis and Tukey’s test was used to correct for multiple comparisons. *p < 0.05. 
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5.3.3 Effect of different lipid concentrations on small bowel crypt 
proliferation 
The effect of lipid mixtures on small bowel crypt proliferation was also 
investigated in this study. The proliferation rate per crypt (quantified in the whole 
region of the small bowel crypt) was not significantly different between treatment 
groups. Compared to the proliferation rate achieved by the control group (20.37 ± 
3.57), treatment with 0.1% lipid slightly reduced proliferation to 14.73 ± 1.86 
compared to the control, while treatment with 1% lipid showed no difference in 
proliferation rate versus control (21.38 ± 3.8) (Figure 27 A-B). 
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Figure 27: Effect of lipids on human small bowel crypt proliferation. 
A) Epifluorescence image showing EdU labeling for lipids stimulated small bowel crypts for 
48 hours (in this experiments lipids added to full growth factors human crypt culture 
medium), EdU (pink) and blue (nuclei). B) Histogram showing the cell proliferation rate 
(expressed as percentage of EdU positve cells) in the whole region of small bowel crypts that 
have been stimulated with 0.1% and 1% lipids in a standard human crypt culture medium 
(with 100% growth factors) for up to 48 hours (n=3 CRC). Data are represented as mean ± 
SD. Statistical analysis was done by one-way ANOVA to test the significance between the 
three treatment groups and Tukey’s test was used to correct for multiple comparisons. *p < 
0.05. 
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5.3.4 Effect of linoleic acid on colonic crypt proliferation 
According to the results from only a single representative experiment, 
treatment with linoleic acid (0.1%) and a reduced concentration of growth factors 
(20%) for 48 hours did not show any significant difference in the number of EdU 
positive cells compared to the control (Figure 28). 
 
 
 
Figure 28: Effect of linoleic acid on human colonic crypt proliferation.  
Histogram showing results from a single representative experiment (n=1 CRC). Bars represent 
the mean cell proliferation rate (expressed as percentage of EdU positve cells) in the different 
regions of colonic crypts that have been stimulated with linoleic acid (0.1%) in a reduced 
growth factors (20%) human crypt culture medium for 48 hours. Four crypts counted in each 
treatment group.  
 
 
5.3.5 Effect of different concentration of lipids on the rate of Ki67-positive 
cells in colonic and small bowel crypts 
A technical problem with Ki67 immunolabeling, related to high background 
staining, did not allow the quantification of Ki67-positive cells in culture crypts. 
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5.3.6 Summary of results 
This study has shown that low concentrations of lipids reduced the rate of 
proliferation in mostly all regions within the colonic crypt, and was statistically 
significant only in supra base and mid regions; this is proposed to be attributed to the 
lower growth factor concentration used in the experiment. At higher lipid 
concentrations, a numerically increased rate of proliferation in the upper regions of 
the colonic crypt was observed. The different concentration of lipids did not 
significantly affect proliferation in small bowel crypts. Reduced proliferation in the 
small bowel crypts was only observed at low concentrations of lipid. This study was 
unable to find any differences in crypt proliferation rates between treatment groups 
after linoleic acid treatment.  
 
5.4 Discussion  
The dynamic crosstalk between intestinal epithelial cells is essential for 
maintaining gut homeostasis in health and disease, which balance between 
epithelial cell proliferation, differentiation, and apoptosis. The different subsets of 
intestinal epithelial cells have a potential role in controlling intestinal inflammation, 
which is a result of the loss of gut homeostasis between epithelial cells, the immune 
response, and gut microbes. In this study, we have investigated the effect of lipids 
on epithelial cell proliferation using the human cultured crypt model that helped in 
determining the epithelial cellular response to dietary fat. The main findings of this 
study have shown that a low concentration of lipids reduced the rate of proliferation 
in mostly all regions of the colonic crypt and was significant only in the supra base 
and mid regions; this was mainly achieved when lipids were added to a culture 
medium with a lower concentration of growth-factors. 
The role of dietary fat in CD has long been recognized. Epidemiological 
studies on the western diet have identified high-fat diets as a risk factor in rising 
CD incidence rates (Hou et al., 2011). This indicates a potential role of low-fat diets 
in preventing CD. The findings of this study have shown that lower lipid 
concentrations significantly reduced intestinal crypt proliferation rates in CRC, but 
not in CD. Unfortunately, due to the very limited availability of CD mucosal tissue 
samples, the findings from this study were not able to identify the effect of lipid 
treatment on crypt proliferation in a CD context. Similar to chronic intestinal 
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inflammation, the development of intestinal tumors is induced by dysregulations in 
the cellular processes of the epithelium. CRC is induced by enhanced crypt 
proliferation, which forms into a cluster of irregular crypts resulting in a localized 
adenoma, that can consequently form into a carcinoma (Humphries and Wright, 
2008). Moreover, as with CD, a high-fat western diet has also been identified as a 
risk factor for CRC. Our findings are relatively consistent with previous studies that 
indicate a negative effect of high-fat diets on increasing intestinal crypt proliferation 
and consequently, enhancing intestinal tumour formation (Tuominen et al., 2013, 
Dermadi et al., 2017, Beyaz et al., 2016).  
While a low-fat diet is recommended for reducing the risk of CD development, 
a high-fat diet in established disease could offer a possible therapeutic potential in CD 
treatment. In active CD, destruction of crypts and reduced proliferation is a 
morphological characteristic of the disease leading to mucosal atrophy. The effect of 
enhanced crypt proliferation on disease pathogenesis and outcomes might differ 
between CRC and IBD. In CRC, increased crypt proliferation is characteristic of 
tumorigenesis. While increased cellular proliferation in the gut epithelium is 
considered a tissue renewing process, which could help in healing mucosa that were 
damaged due to inflammation (Shaw et al., 2012). Therefore, patients with active CD 
may benefit from using dietary factors that stimulate gut epithelial proliferation and 
turnover. The findings of this study indicate that at high concentration, lipids have 
numerically (but not statistically) increased the rate of proliferation in intestinal 
crypts; however, this was only observed in CRC and not CD samples. To our 
knowledge, the role of fat in enhancing mucosal integrity via cellular proliferation 
in CD is not yet investigated. 
The importance of the type of fat in CD has also gained attention over the 
past years. Different types of fatty acids could modify the synthesis of inflammatory 
eicosanoids by altering the rate of conversion of fatty acid derivatives like EPA, 
DHA, and arachidonic acid. In this study, the difference in crypt proliferation rate in 
response to specific fatty acid treatment (i.e. n-6 PUFA) was unable to be measured. 
However, the low proliferation rate observed in this study, after treatment with low 
concentrations of lipids in both, colonic and small bowel crypts, might suggest a 
protective effect of selected fatty acids at low ratios. There might be a threshold for 
certain fatty acids to induce their inhibitory effect on crypt proliferation. The effect of 
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specific fatty acids on intestinal epithelium remodelling has been investigated 
previously; LCT fats were found to enhance ISC function, resulting in higher rates of 
crypt proliferation (Beyaz et al., 2016). 
A limitation of this study is the risk of contamination and infection 
accompanied with the use of primary human cell culture, which limited the number of 
successfully isolated crypt cultures, and consequently, limited the findings in this 
study. However, the study has used a primary human crypt culture as a model to 
investigate the effect of dietary fat, which is considered more representative of the 
human gut than using epithelial cell-lines.  
Collectively, the results in the study show that reduced crypt proliferation after 
treatment with low concentration of lipids could be one mechanism of action of how 
a low-fat diet can be protective against CRC development, and possibly against CD. 
Nonetheless, the fatty acid(s) that promoted such protective cellular effects needs to 
be determined. Although, the findings of this study could not address the effect of fat 
on intestinal epithelial cell proliferation in CD, that might lead to inflammation, it does 
provide a working model for future research investigating the mechanism of action of 
dietary fat in CD. Further studies are required to determine the generalizability of these 
findings in a more diverse patient population.  
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6 Chapter 6: General discussion 
 
 
6.1 Overview 
The overall aim of this thesis was to investigate the effect of dietary fat 
composition on the treatment and aetiopathogenesis of CD via a systematic review 
and meta-analysis of RCTs, also via an observational study to characterize mesenteric 
adipose tissue (MAT) in human CD, and in-vitro studies to investigate the effect of 
fatty acids on the behaviour of mesenteric pre-adipocytes and on gut epithelial 
physiology. Novel observations have been made that show effect of dietary fat on the 
adipogenic potential of mesenteric pre-adipocytes and on the crypt proliferation of gut 
epithelium in CD. 
The treatment of CD is complex and challenging. The use of enteral nutrition 
(EN) as primary therapy in adult patients with CD is not yet supported by high quality 
evidence. The current evidence is inconclusive regarding what, how, and why specific 
types of enteral feed perform better than others. The fat composition of EN feeds has 
been suggested to be a key factor in controlling inflammation in CD. As part of this 
research, a systematic review was initially conducted to reanalyse the findings of 
previous clinical trials, and to focus on evaluating the relationship between EN fat 
content and remission rate (RR) in CD patients. The quality of the included studies 
was highly variable. However, a few trends were identified between disease response 
rate and the percentage of long chain triglycerides (LCTs) and polyunsaturated fatty 
acids (PUFA) of total calories. 
Moreover, a deep understanding of disease pathogenesis is also lacking. In CD, 
the mesentery attached to the inflamed intestines is usually thickened due to unknown 
reasons, a condition known as the “fat-wrapping” phenomenon. Additionally, the 
alteration in tissue remodeling of the intestinal epithelium due to high fat intake is a 
newly suggested, plausible cellular mechanism for intestinal diseases. Therefore, this 
research project aimed to determine the effects of lipids on the cellular and molecular 
environment of hypertrophied MAT and its adjacent intestinal epithelium. The results 
of this work form the basis of a human clinical trial investigating the effects that EN 
fat composition may induce in CD patients, with a focus on the alteration of the MAT. 
Lipids are, thus, an interesting and important dietary factor for future IBD research.  
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Altogether this thesis aims to contribute to our understanding of the potential 
mechanisms through which lipids could modulate disease treatment and pathogenesis. 
6.2 Relevance of dietary fat in CD treatment 
The relationship between lipids and CD has long been recognized. The current 
guidelines for CD state that an increased intake of n-3 PUFA and a  reduced intake of 
saturated fats and n-6 PUFA should be recommended to reduce the risk of developing 
CD (Forbes et al., 2017). Fat could also modulate disease outcomes via their action on 
eicosanoid synthesis, which can alter the immune response. Therefore, the efficacy of 
nutritional therapy in CD has been considered to correlate with the content of dietary 
fat. The fat composition of EN feeds has gained interest over the years. In the 
systematic review presented in this thesis, a significant positive correlation was found 
between n-6 PUFA intake and remission rates in adult CD patients, while only a 
positive, non-significant trend was found between medium chain triglyceride (MCT) 
composition and remission rates, and a negative trend was reported for the intake of 
monounsaturated fatty acids (MUFA). The practice of recommending or prescribing 
a specific type of fat for patients with active CD remains a matter of debate and an 
existing challenge. The choices are many, and would consist of deciding between 
increasing MCT or MUFA proportions, or rebalancing the ratio of different PUFAs. 
The delivery of MCT in the diet is considered less inflammatory than LCT. Studies 
using animal models of colitis have demonstrated that a reduction in inflammatory 
cytokines levels occurred in animals that were fed with an enteral diet high in MCT 
(Papada et al., 2014). MCT can control intestinal inflammation and mucosal damage. 
Previous studies have suggested that the beneficial effect shown with MCT 
administration in CD is related to its efficient absorption in the small intestine and 
colon, and its reduced pro-inflammatory action (Andoh et al., 2000). For MUFA 
composition, although it is considered anti-inflammatory, one high quality RCT in this 
context found that EN feeds with a high MUFA content are less effective than a high-
PUFA feed in controlling inflammation in CD patients (Gassull et al., 2002). 
However, a recent updated meta-analysis found no significant difference in remission 
rates of CD patients who were treated with enteral feeds with varying degrees of fat 
composition (Narula et al., 2018). Only the very low fat feeds and the very low LCT 
feeds showed a higher remission rate. It is remains challenging to elucidate the 
individual effect of each fatty acid within a given feed; it could be that the whole fatty 
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acid profile of the enteral feed is responsible for the immunomodulatory effect rather 
than a particular fatty acid itself (Gassull et al., 2002). Therefore, the inconsistency in 
current evidence can be better validated by future studies investigating the effect of 
different fatty acid profiles in the diet of CD patients.  
6.3 Dietary fat has various effects on adipose tissues in CD  
Hypertrophied MAT associated with CD has long been recognized as a 
manifestation of the disease. Over the past years, several studies were conducted to 
understand the pathophysiology of the fat-wrapping phenomenon and its relevance in 
CD. As part of my research, a study (detailed in chapter 3) was preformed to 
characterise MAT by investigating its inflammatory gene expression profile and fatty 
acid composition. An in-vitro study was also conducted (detailed in chapter 4) to 
examine the effect of fatty acid treatment on the differentiation of mesenteric pre-
adipocytes.  
Dietary fat can influence the pathogenesis of MAT in CD via three proposed 
mechanisms. First, certain fatty acids could modify the expression of inflammatory 
markers in adipose tissues. Secondly, dietary fat could have an impact on altering the 
fatty acid profile of the MAT, which is found to be abnormal in CD patients (Westcott 
et al., 2006). Thirdly, dietary fat can control the process of adipogenesis in MAT. The 
findings from chapter 3 have demonstrated a few associations between fatty acids 
levels and the mRNA levels of selected genes related to adipogenesis and the 
inflammatory response in the MAT of CD and colorectal cancer (CRC) patients, while 
the fatty acid profile for MAT was not significantly different between CD and control 
tissues. The findings reported in chapter 4 showed that unsaturated fatty acids induced 
a pro-adipogenic effect in mesenteric pre-adipocytes, which was mainly regulated by 
CEBPa. This effect was relatively more potent in CRC derived mesenteric pre-
adipocytes than CD mesenteric pre-adipocytes. These findings were first to be 
reported in CD mesenteric pre-adipocytes. Previous studies in this field only reported 
the effect of fatty acids on cell-lines or on pre-adipocytes derived mainly from 
subcutaneous fats or from visceral fats of non-CD patients. Therefore, this study was 
able to use a more representative cell culture model. Overall, the combined results of 
this work have provided new insights for MAT characterisation, and for investigating 
the role of dietary fat in CD pathogenesis. 
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6.4 Dietary fat can modulate gut epithelium physiology: a relevant 
mechanism for CD 
The gut epithelium forms an important platform for handling nutrients by the 
body. It is considered one of the most rapid, self-renewing tissue in the body, which 
comprises specialised intestinal stem cells (ISCs) that reside in the crypt structure of 
the epithelium. Yet, the role of dietary fat and other dietary factors in regulating the 
ISCs’ function and crypt proliferation is not clear. In this thesis, it was hypothesised 
that intestinal epithelial cells can respond to dietary fat provision. The alteration in 
tissue remodelling of intestinal epithelium by dietary fat is a newly suggested plausible 
cellular mechanism for intestinal diseases (Beyaz et al., 2016). Our work in chapter 5 
aimed primarily to study the role of dietary lipids on ISCs function in CD via 
assessing the rate of crypt proliferation. Earlier in-vitro studies in CD mainly 
focused on measuring pro-inflammatory markers as outcomes rather than intestinal 
epithelial cellular function which is an important factor contributing to CD 
aetiopathogenesis. In the methodology, we have used a highly sophisticated 3D 
human cell culture model to investigate the effect of lipids on epithelial cell 
proliferation (detailed in chapter 5), where an alteration in the rate of crypt 
proliferation after lipid treatment was observed. The model used in this study is 
unlike the model applied by previous studies which used cell-lines that only mimic 
the characteristics of intestinal cells.  The crypt culture model used here is able to 
display all the different types of cells present in human intestine which make it a 
near-native culture system.  
In this study, low concentration of lipids resulted in a statistically significant 
lower rate of colonic crypt proliferation compared to a higher concentration. 
Unfortunately, due to limited availability of CD mucosal tissue samples the findings 
could not be employed to elucidate differences in the level of crypt proliferation in 
response to lipid treatment in CRC versus CD tissues.  
A mechanism whereby dietary fat induces intestinal tumour development via 
ISC proliferation in crypts was recently proposed. Recent studies using animal models 
have demonstrated a change in proliferation rate, where a high fat diet promoted a 
significantly higher rate of ISC proliferation, which resulted in elongation of the 
crypts, thus predisposing the animals to intestinal cancers (Beyaz et al., 2016). 
However, in the context of CD, although there is a well-established association 
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between high fat diet and increased disease risk, the mechanism of fat in controlling 
mucosal tissue repair in CD is yet to be identified. A high fat diet can modulate gut 
inflammation via enhanced gut permeability and impaired gut barrier functions, 
resulting in a higher rate of cellular recruitment of dendritic cells and immune cell 
infiltration into the lamina propria (Gruber et al., 2013). Additionally, the different 
types of fat in the diet can impact the physiology of gut epithelium in different ways. 
For example, supplementing the diet with n-3 PUFA, in addition to other nutrients like 
curcumin and pectin has been shown to reduce colonic tumorigenesis, via promotion 
of apoptosis in damaged ISCs, and by suppressing proliferation (Kim et al., 2016, 
Hong et al., 2015).  Nevertheless, the current evidence still needs further validation to 
clarify the role of dietary nutrients in regulating gut epithelial physiology. 
6.5 Other approaches to investigate EN efficacy in CD 
6.5.1 A plausible effect of dietary emulsifiers on intestinal inflammation  
It is also suggested that dietary agents related to fat formation in processed 
foods could be involved in the mechanism of action of disease pathogenesis. 
Emulsifiers, such as polysorbate 80, are suggested to be potential dietary agents in this 
context and are found in most commercial food products. Recent studies have found 
that dietary emulsifiers can physiologically impact the gut epithelium in mice by 
enhancing bacterial overgrowth and translocation and, consequently, promoting 
intestinal inflammation (Chassaing et al., 2015). Another study found a strong positive 
association between dietary emulsifiers intake and CD incidence rate in Japan 
(Roberts et al., 2013). Therefore, it is also possible that CD patients’ response to EN 
therapy could be related to the emulsifier composition of the feed. The use of 
emulsifiers is important for the stabilization of feed lipid emulsion.  
A few years ago, a group of researchers hypothesized that high intake of 
emulsifiers could be associated with increasing CD incidence, suggesting that 
patients’ response to EN feeds might be affected by the emulsifiers’ content, rather 
than the fat content of the feed (Roberts et al., 2013). Thereafter, the same group tested 
the in-vitro effect of emulsifiers on the translocation of E coli bacteria isolated from 
CD patients, and found that translocation increased significantly across Caco2-cl1 
cell-line and M-cells (Roberts et al., 2010). These findings indicated a need to study 
the clinical effect of food emulsifiers in enteral feeds on CD outcomes.  
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In the systematic review presented in this thesis (detailed in Chapter 2), it was 
attempted to analyse the possible correlation between, both, emulsifier composition 
and fat composition in enteral feeds on CD outcomes. However, not all feed 
manufacturing companies reported the type and amount of emulsifiers, which limited 
the amount of data available. Where emulsifier contents were disclosed, lecithin and 
polysorbate 80 were found to be the main dietary emulsifiers present in the 
investigated enteral feeds. Future research is needed in this area to clarify the impact 
of emulsifiers in CD pathogenesis and treatment. 
6.6 Clinical implications and future directions of research  
The main objective of this research was to better understand the impact of 
dietary fat in CD treatment and pathogenesis. The evidence is currently inconclusive 
and this study helped to clarify the relevance of dietary fat composition in influencing 
CD clinical outcomes, pertaining to mesenteric inflammation regulation, and in 
modulating the gut epithelium repair mechanism. This study suggests that optimizing 
the fatty acid composition of enteral feeds for CD patients could promote better 
disease outcomes via their action on adipogenesis and MAT inflammation regulation, 
and on the gut epithelium repair mechanism. 
In terms of understanding disease aetiopathogenesis, further research should 
work to better characterize MAT in CD. Characterization studies related to 
histological, immunological, and molecular analysis of MAT are still limited. In 
addition, investigating the association between disease behaviour, clinical 
manifestations, and mesenteric fat characteristics will help in clarifying the 
significance of the fat-wrapping phenomenon on CD pathogenesis. Future prospective 
studies based on investigating different depots of MAT from the same CD patient 
would help in better characterization. A key limitation of this study was the limited 
availability of paired inflammed and non-inflammed MAT samples from CD patients; 
also, the availability of surgically resected healthy mesenteric tissues was limited and 
varied across patients. Additionally, assessing nutritional status and food intake (via 
food frequency questionnaires) before MAT samples collection would have been 
helpful in determining the association between nutrient intake and fatty acid 
composition of MAT in CD patients. 
The current evidence supporting the effect of individual dietary oils and fatty 
acids in enteral feeds for CD is still limited.  Robust, randomized control trials (RCTs) 
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of exclusive enteral nutrition in CD are still needed. Future work in CD should focus 
on investigating the effect of enteral feeds with different fat composition on the 
physiological alteration of mesenteric fat (i.e. histological, biochemical, and 
inflammatory changes). Also, investigating the role of fat in modulating the gut 
epithelial cells in CD would help in elucidating its mechanism of action.  
Based on the findings in this thesis, the next step in evaluation of future RCTs 
of enteral nutrition should aim to compare the effect of at least two feeds with 
relatively comparable amounts of total calories, carbohydrate, protein, and fat but with 
different fatty acid profiles. The effect of the feed will best be investigated among 
presurgical CD patients. The reason for this first choice of patient group is partially 
pragmatic because studying the mesenteric adipose tissue (MAT) directly is 
challenging as its collection is highly invasive and non-routine in clinical practice, 
surgery being the only way for researchers to gain access to it. Therefore, CD patients 
undergoing intestinal resection would be the only eligible candidates for such a 
clinical investigation. Nonetheless a pertinent RCT can be devised which would apply 
four arms of intervention so the intervention feed given exclusively would be 
compared against the standard feed (control) also given exclusively, and the same 
intervention feed but given as a part of a regular diet will be compared again against 
a control supplement to regular diet. The intervention would be given for a period of 
four to six weeks before surgery. Because compliance to an intervention like exclusive 
enteral nutrition is potentially a major issue in adult CD patients, minimizing the 
period of such an intervention should be considered: the duration of exclusive enteral 
nutrition in most of the previous trials was between 3 and 8 weeks. The primary 
outcome measure would be the degree of adipogenesis in MAT and its association 
with inflammation. This thesis suggests a couple of potential biomarkers that can be 
investigated in the future RCTs to study the role of fat in CD. For example, the level 
of adipogenic markers like CEBPa are important in showing the effect of intervention 
on the degree of adipogenesis in MAT in CD. Also, adipokines levels such as those of 
leptin in MAT and serum are considered important for studying MAT function in 
association with inflammation. Moreover, it will be interesting to obtain radiological 
quantification of mesenteric fat (acquired from CT and MRI scans) which will help in 
showing the degree of mesenteric fat hypertrophy before and after the intervention. 
Other biological markers include assessing the level of mucosal healing, transmural 
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healing, and mucosal tissue crypt proliferation in association with mesenteric tissue 
alterations, which would be useful in identifying a novel mechanism of action of 
enteral feeding in CD. 
There are still many gaps in the knowledge on the relationships between CD 
phenotype, dietary fat, mesenteric adiposity, and inflammation, to determine disease 
risk and outcomes.  Many clinical, scientific, and environmentally relevant questions 
need to be addressed in future research. 
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Appendix 1: PRISMA 2009 Checklist 
1. Section/topic  # Checklist item  
Reported 
on page 
# 
TITLE   
Title  1 Identify the report as a systematic review, meta-analysis, or both.  1 
ABSTRACT   
Structured summary  2 Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility 
criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; 
conclusions and implications of key findings; systematic review registration number.  
2 
INTRODUCTION   
Rationale  3 Describe the rationale for the review in the context of what is already known.  4 
Objectives  4 Provide an explicit statement of questions being addressed with reference to participants, interventions, 
comparisons, outcomes, and study design (PICOS).  
4-5 
METHODS   
Protocol and registration  5 Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, 
provide registration information including registration number.  
5 
Eligibility criteria  6 Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years 
considered, language, publication status) used as criteria for eligibility, giving rationale.  
5-6 
Information sources  7 Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify 
additional studies) in the search and date last searched.  
5 
Search  8 Present full electronic search strategy for at least one database, including any limits used, such that it could 
be repeated.  
5 
Study selection  9 State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if 
applicable, included in the meta-analysis).  
5-6 
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Data collection process  10 Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any 
processes for obtaining and confirming data from investigators.  
6-7 
Data items  11 List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions 
and simplifications made.  
6-7 
Risk of bias in individual 
studies  
12 Describe methods used for assessing risk of bias of individual studies (including specification of whether this 
was done at the study or outcome level), and how this information is to be used in any data synthesis.  
7 
Summary measures  13 State the principal summary measures (e.g., risk ratio, difference in means).  6-7 
Synthesis of results  14 Describe the methods of handling data and combining results of studies, if done, including measures of 
consistency (e.g., I2) for each meta-analysis.  
7 
 
Page 1 of 2  
Section/topic  # Checklist item  Reported on page # 
Risk of bias across studies  15 Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, 
selective reporting within studies).  
7 
Additional analyses  16 Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, 
indicating which were pre-specified.  
7 
RESULTS   
Study selection  17 Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for 
exclusions at each stage, ideally with a flow diagram.  
8 &22 
Study characteristics  18 For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up 
period) and provide the citations.  
8-7 
Risk of bias within studies  19 Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12).  9 
Results of individual studies  20 For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each 
intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.  
22-23 
Synthesis of results  21 Present results of each meta-analysis done, including confidence intervals and measures of consistency.  20-21 
Risk of bias across studies  22 Present results of any assessment of risk of bias across studies (see Item 15).  App.B(p.11) 
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Additional analysis  23 Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see 
Item 16]).  
20-21 
DISCUSSION   
Summary of evidence  24 Summarize the main findings including the strength of evidence for each main outcome; consider their 
relevance to key groups (e.g., healthcare providers, users, and policy makers).  
12-15 
Limitations  25 Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete 
retrieval of identified research, reporting bias).  
14 
Conclusions  26 Provide a general interpretation of the results in the context of other evidence, and implications for future 
research.  
14-15 
FUNDING   
Funding  27 Describe sources of funding for the systematic review and other support (e.g., supply of data); role of 
funders for the systematic review.  
15 
 
From:  Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 6(7): 
e1000097. doi:10.1371/journal.pmed1000097  
For more information, visit: www.prisma-statement.org.  
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Appendix 2: Study design and criteria for measuring remission rate 
Study Type of intervention Trial design Duration of 
intervention 
(weeks)  
Remission rate criteria  Study 
geographical 
location 
Bamba et al. (2003)14 Three elemental feeds with different fat levels were 
compared 
Randomized controlled, not 
double-blinded (multicentre) 
4 Organization of Inflammatory Bowel Disease (IOIBD) rating > 2 and at least one 
abnormal inflammatory marker 
Japan 
Gassull et al. (2002)11 Polymeric feed high in n-9 vs. polymeric feed high in n-
6 vs. steroids 
Randomized double-blinded 
(multi-centre) 
4 Van Hees activity index (VHAI)< 120 Spain, UK, 
Germany 
Giaffer et al. (1990)21 Elemental feed vs. polymeric feed Randomized, not double-
blinded 
4 Control of symptoms, avoidance of complications, complete withdrawal of all medication 
including steroids, and CDAI<150 
UK 
Leiper et al. (2001)16 Polymeric feed low in LCT vs. polymeric feed high in 
LCT 
Randomized controlled, 
double-blinded (two centres) 
3 CDAI of <150 UK 
Mansfield et al. (1995)22 Semi-elemental feed vs. elemental feed Randomized controlled, not 
double-blinded 
4 Reduction in CDAI of 100 points or 40% of the initial value, control of symptoms, and 
withdrawal of all treatment including corticosteroids. 
UK 
Middleton et al. (1995)7 Elemental feed vs. elemental feed with added MCT vs. 
elemental feed with added LCT vs. semi-elemental 
feed 
Randomized, not double-
blinded 
3 Harvey & Bradshaw Index (HBI)<3 within 3 weeks of commencing enteral feed UK 
Park et al. (1991)25 Elemental feed vs. polymeric feed Randomized controlled, 
double-blinded 
4 Harvey-Bradshaw simple CDI<2 after 28 days of treatment UK 
Raouf et al. (1991)30 Elemental feed vs. polymeric feed Randomized controlled, not 
double-blinded 
3 Harvey-Bradshaw simple CDI<4 after 21 days of treatment UK 
Rigaud et al. (1991)13 Elemental feed vs. polymeric feed Randomized controlled, not 
double-blinded (two centres) 
4 CDAI<150 during the last 7 days France 
Royall et al. (1994)23 Elemental feed vs. semi-elemental feed Randomized controlled, 
double-blinded 
3 CDAI<150 after 21 days of treatment Canada 
Sakurai et al. (2002)15 Elemental low fat feed vs. semi-elemental high MCT 
feed 
Randomized controlled, not 
double-blinded 
6 Reduction of CDAI by at least 40% or by 100 or more after 42 days of treatment Japan 
Verma et al. (2000)31 Elemental feed vs. polymeric feed Randomized, double-blinded 4 Amelioration of bowel symptoms, reduction in the CDAI to < 150 or by at least 100 
points from baseline level, and normal CRP 
UK 
Gonzalez-Huix et al. (1993)32 Polymeric feed vs. steroids Randomized controlled, not 
double-blinded 
4 VHAI < 120 after 28 days of treatment Spain 
Lindor et al. (1992)28 Steroids vs. semi-elemental feed vs. both Randomized, not double-
blinded 
4 Reduction in CDAI of 100 points or more of the initial value after 30 days US 
Lochs et al. (1991)33 Semi-elemental feed vs. drug therapy (sulfasalazine 
and 6-methyl-prednisolone) 
Randomized, not double-
blinded 
6 Reduction in CDAI of 100 points or 40% of the initial value after 42 days Austria & 
Germany 
Malchow et al. (1990)34 Semi-elemental feed vs. drug therapy (sulfasalazine 
and 6-methyl-prednisolone) 
Randomized, not double-
blinded (multi-centre) 
6 Reduction in CDAI of 100 points or 40% of the initial value after 42 days Europe 
Greenberg et al. (1988)35 TPN vs. polymeric feed vs. partial PN with oral diet Randomized controlled, not 
double-blinded (multi-centre) 
3 CDAI<150 after 21 days of treatment Canada & US 
Kobayashi et al. (1998)36 TPN vs. elemental feed vs. polymeric feed Randomized controlled, not 
double blinded 
4 IOIBD < 1 and normal inflammatory markers (CRP, ESR) Japan 
Mantzaris et al. (1996)12 Polymeric feed vs. steroids vs. both Randomized, not double-
blinded 
4 Reduction in CDAI of 100 points or CDAI < 150 Greece 
O'moráin et al. (1984)37 Elemental feed vs. steroids Randomized controlled, not 
double blinded 
4 Harvey-Bradshaw simple CDI UK 
Gorard et al. (1993)38 Elemental feed vs. steroids Randomized, not double-
blinded, multi-centre 
4 Harvey-Bradshaw simple CDI UK 
Okada et al. (1990)24 Elemental feed vs. steroids Controlled (not randomized), 
not double-blinded. 
6 Harvey-Bradshaw simple CDI Japan 
Bodemar et al. (1991)18 Polymeric feed only Uncontrolled trial 2 Harvey-Bradshaw simple CDI Sweden 
Coyle and Sladen (1989)39 Polymeric feed only Uncontrolled trial 4 Harvey-Bradshaw simple CDI UK 
Riordan et al. (1993)19 Elemental feed only Uncontrolled trial, multi-centre 2 HBI < 3 UK 
Guo et al. (2013)40 Polymeric feed only Uncontrolled trial 4 CDAI < 150 + CRP < 10 mg/L China 
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Zoli et al. (1997)20 Semi-elemental feed vs. steroids Randomized controlled, not 
double blinded 
2 HBI Italy 
Hu et al. (2014)17 Semi-elemental feed only Uncontrolled trial 12 More than 70 points reduction of CDAI score China 
Zhu et al. (2013)41 Polymeric feed vs. drug therapy (infliximab) Randomized, Not double 
blinded, multi-centre 
8 CDAI of <150 China 
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Appendix 3: Patients characteristics 
Study Type of enteral nutrition Number of 
participants 
Males% 
  
Females% 
  
Age 
(mean) 
  
CD location Mean of 
disease 
duration 
(years) 
Small 
bowel% 
Large 
bowel% 
Both% 
Bamba et al. (2003)14  Elemental, Low fat (6 packs of Elental + 6 packs of dextrin) 10 50% 50% 27 10% 10% 80%  - 
Elemental, Medium fat (6 packs of Elental + 3 packs of dextrin+ 3 packs of C-1 dextrin) 10 60% 40% 31 40% 0% 60%  - 
Elemental, High fat (6 packs of Elental + 6 packs of C-1 dextrin) 8 75% 25% 26 38% 38% 25%  - 
Gassull et al. (2002)11  Polymeric, high in n-9 MUFA 20 45% 55% 31.1 35% 25% 40% 2.41 
Polymeric, high in n-6 PUFA 23 43% 57% 30.8 35% 17% 48% 2.05 
Giaffer et al. (1990)21 Elemental (Vivonex) 16 25% 75% 34 50% 19% 31%  - 
Polymeric (Fortison) 14 29% 71% 42 29% 36% 36%  - 
Leiper et al. (2001)16  Polymeric, 5% LCT 27 -  -  36.9 33% 22% 44%  - 
Polymeric, 30% LCT 27 -  -  35.6 22% 33% 44%  - 
Mansfield et al. (1995)22 Elemental (E028) 22 50% 50%  - 32% 18% 50% 8.6 
Semi-elemental (Pepti-2000 LF liquid) 22 23% 77%  - 41% 14% 45% 8.7 
Middleton et al. (1995)7  Elemental (E028) 17 41% 59% 34 24% 35% 41% 8.6 
Elemental (E028), High LCT 22 50% 50% 35 32% 36% 32% 4.6 
Elemental (E028), High MCT 19 26% 74% 30 37% 21% 42% 4.7 
Semi-elemental (Peptide 2+) 18 33% 67% 32 22% 22% 56% 9.1 
Park et al. (1991)25 Elemental (E028) 7 14% 86% 33 14% 29% 57% 5.8 
Polymeric (Enteral 400) 7 0% 100% 38 14% 14% 71% 2.4 
Raouf et al. (1991)30  Elemental (EO28) 13  - -  -  -  -   -  - 
Polymeric (Triosorbon) 11  - - -  -  -   -  - 
Rigaud et al. (1991)13 Elemental (Vivonex HN) 15 60% 40% 33 0% 67% 33% 5.9 
Royall et al. (1994)23  Elemental (Vivonex-TEN) 19 53% 47% 31.5 26% 11% 63% 9.5 
Semi-elemental (Peptamen) 21 62% 38% 31.4 52% 10% 38% 6.8 
Sakurai et al. (2002)15 Elemental, Low fat (Elental) 18 78% 22% 26.3 28% 17% 56%  - 
Semi-elemental, High MCT (Twinline) 18 89% 11% 25.3 28% 17% 56%  - 
Verma et al. (2000)31 Elemental 11 36% 55% 38 18% 9% 64% 6.9 
Polymeric 10 40% 70% 33 30% 50% 30% 4.3 
Gonzalez-Huix et al. (1993)32 Polymeric (Edanec HN) 15 47% 53% 31.1 20% 20% 60%  - 
Lindor et al. (1992)28 Semi-elemental (Vital HN) 9 44% 56% 34.6 33% 33% 33% 3.2 
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Lochs et al. (1991)33 Semi-elemental (Peptisorb) 55 40% 60% 27.5 15% 16% 69%  - 
Malchow et al. (1990)34 Semi-elemental (Survimed) 51 41% 59% 30.1 12% 27% 53% 4 
Greenberg et al. (1988)35 Polymeric (Precision-Isotonic) 19 57.90% 42.10% 31.6  - 21% -  5.5 
Kobayashi et al. (1998)36  Elemental (Elental) 10 -  -  21.6 30% 20% 50% 2.2 
Polymeric (Clinimeal) 
9  - - 19.2 33% 22% 44% 1.8 
Mantzaris et al. (1996)12 
Polymeric (Nutrison HE) 10  - -  -  -  -   -  - 
O'moráin et al. (1984)37 Elemental (Vivonex) 11 82% 18% 31.9 18% 27% 55%  - 
Gorard et al. (1993)38 Elemental (vivonex TEN) 22 55% 45% 31.6 32% 18% 50%  - 
Okada et al. (1990)24 Elemental (elental) 10 50% 50% 21 40% 20% 40% 1.28 
Bodemar et al. (1991)18 Polymeric (Semper lowfat) 10 70% 30% 46.6 20% 10% 70% 18 
Coyle and Sladen (1989)39 Polymeric (Enteral 250) 12 42% 58% 38.5 33% 42% 25%  - 
Riordan et al. (1993)19 Elemental (E028) 136 -  -  -  -  -   -  - 
Guo et al. (2013)40 Polymeric (Nutrison Fibre) 13 69% 31% 26.1 15% 8% 77% 1.4 
Zoli et al. (1997)20 Semi-elemental (Peptamen) 10 60% 40% 33.5 20% 0% 80%  - 
Hu et al. (2014)17 Semi-elemental (Peptisorb liquid) 59 71% 29% 32.3 41% 17% 42%  - 
Zhu et al. (2013)41 Polymeric (Nutrison Fibre) 52 - - 31.4 8% 4% 69% - 
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Appendix 4: Saturated fatty acids profile for enteral nutritional formulas 
Study Type of enteral nutrition Total Saturated Fatty Acids 
C6:0 C8:0 C10:0 C12:0 
Lauric acid 
C14:0 C16:0 Palmitic 
acid 
C18:0 
Stearic 
acids 
C20:0 C22:0 C24:0 
Bamba et al. (2003)14  Elemental, Low fat (6 packs of Elental + 6 packs of dextrin) 0 0 0 0 0 12.4 4.4 0 0 0 
Elemental, Medium fat (6 packs of Elental + 3 packs of dextrin+ 3 packs of 
C-1 dextrin) 
0 0 0 0 0 12.4 4.4 0 0 0 
Elemental, High fat (6 packs of Elental + 6 packs of C-1 dextrin) 0 0 0 0 0 12.4 4.4 0 0 0 
Gassull et al. (2002)11  Polymeric, high in n-9 MUFA 0 4.7 0.8 0.31 3.7 3.3 3.3 0 0 0 
Polymeric, high in n-6 PUFA 0 7 1 0 0.4 10.9 5.5 0 0 0 
Giaffer et al. (1990)21 Elemental (Vivonex) 0 0 0 0 0 6.1 2.3 0.4 0.3 0.1 
Polymeric (Fortison) 0 0 0 0.25 0.1 5.7 3.1 0.45 0.55 0.2 
Leiper et al. (2001)16  Polymeric, 5% LCT 0.1 51 35 0.1 0 1.5 0.5 0 0 0 
Polymeric, 30% LCT 0.1 9 6 0.2 0 34.5 4 0 0 0 
Mansfield et al. (1995)22 Elemental (E028) 0 0 0 1 1 10 3 1 3 1 
Semi-elemental (Pepti-2000 LF liquid) 0.05 32.5 17.5 0.05 0 6.15 0.95 0.2 0.05 0.05 
Middleton et al. (1995)7  Elemental (E028) 0 0 0 1 1 10 3 1 3 1 
Elemental (E028), High LCT 0 3 2 0 1 4 1 1 1 0 
Elemental (E028), High MCT 1 21 15 1 0 3 2 0 1 0 
Semi-elemental (Peptide 2+) 0 27.9 6.7 15 15 8.1 2.1 0 0 0 
Park et al. (1991)25 Elemental (E028) 0 0 0 0 0.1 10.4 3 1.2 2.3 1.4 
Polymeric (Enteral 400) 0 16.3 8.75 0 0 7.9 2.3 0.9 1.7 1.1 
Raouf et al. (1991)30  Elemental (EO28) 0 0 0 1 1 10 3 1 3 1 
Polymeric (Triosorbon) 0.1 50.7 27.3 0.2 0 1.4 1 0.1 0.2 0 
Rigaud et al. (1991)13 Elemental (Vivonex HN) 0 0 0 0 0 6.1 2.3 0.4 0.3 0.1 
Royall et al. (1994)23  Elemental (Vivonex-TEN) 0 0 0 0 0 6.1 2.3 0.4 0.3 0.1 
Semi-elemental (Peptamen) 0.07 45.5 24.5 0.22 0 1.92 1.35 0.09 0.24 0.06 
Sakurai et al. (2002)15 Elemental, Low fat (Elental) 0 0 0 0 0.1 10.8 3.9 0.3 0.2 0.3 
Semi-elemental, High MCT (Twinline) 0.07 46.8 25.2 0.07 0 1.7 0.64 0.11 0.08 0 
Verma et al. (2000)31 Elemental - - - - - - - - - - 
Polymeric - - - - - - - - - - 
Gonzalez-Huix et al. (1993)32 Polymeric (Edanec HN) - - - 13 - 28 - - - - 
Lindor et al. (1992)28 Semi-elemental (Vital HN) 0.05 29.25 15.75 0.35 0.05 3.52 2.48 0.17 0.5 0.1 
Lochs et al. (1991)33 Semi-elemental (Peptisorb) 0.5 32.5 17.5 0.05 0.05 5.4 1.95 0.15 0.1 0.15 
Malchow et al. (1990)34 Semi-elemental (Survimed) 0 0 0 0.5 0.1 6.4 4.5 0.3 0.8 0.2 
Greenberg et al. (1988)35 Polymeric (Precision-Isotonic) 0 0 0 0 0.1 10.8 3.9 0.3 0.2 0.3 
Kobayashi et al. (1998)36  Elemental (Elental) 0 0 0 0 0.1 10.8 3.9 0.3 0.2 0.3 
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Polymeric (Clinimeal) 0 3.8 3.25 24.1 9.25 10.5 2.3 0.25 0.05 0.05 
Mantzaris et al. (1996)12 Polymeric (Nutrison HE) 0 0.66 0.57 4.04 1.99 26.51 3.11 0.33 0.1 0.1 
O'moráin et al. (1984)37 Elemental (Vivonex) 0 0 0 0 0 6.1 2.3 0.4 0.3 0.1 
Gorard et al. (1993)38 Elemental (vivonex TEN) 0 0 0 0 0 6.1 2.3 0.4 0.3 0.1 
Okada et al. (1990)24 Elemental (elental) 0 0 0 0 0.1 10.8 3.9 0.3 0.2 0.3 
Bodemar et al. (1991)18 Polymeric (Semper lowfat) 0 0 0 0 0.1 10.8 3.9 0.3 0.2 0.3 
Coyle and Sladen (1989)39 Polymeric (Enteral 250) 0 0 0 0 0 12.3 1.9 0.4 0.1 0.1 
Riordan et al. (1993)19 Elemental (E028) 0 0 0 1 1 10 3 1 3 1 
Guo et al. (2013)40 Polymeric (Nutrison Fibre) - - - - - - - - - - 
Zoli et al. (1997)20 Semi-elemental (Peptamen) 0.07 45.5 24.5 0.22 0 1.92 1.35 0.09 0.24 0.06 
Hu et al. (2014)17 Semi-elemental (Peptisorb liquid) 0.5 30.5 16.45 0.05 0.05 5.7 2.07 0.16 0.1 0.16 
Zhu et al. (2013)41 Polymeric (Nutrison Fibre) - - - - - - - - - - 
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Appendix 5: Monounsaturated fatty acids profile for enteral nutritional formulas 
Study Type of enteral nutrition Total Monounsaturated Fatty acids 
C16:1 n-7 C16:1 n-9 C17:1 n-7 C18:1 n-9 
Oleic acid 
C18:1 n-7 C20:1 n-9 C20:1 n-7 C22:1 n-9 C24:1 n-9 
Bamba et al. (2003)14  Elemental, Low fat (6 packs of Elental + 6 packs of dextrin) 0 0 0 23.9 0 0 0 0 0 
Elemental, Medium fat (6 packs of Elental + 3 packs of dextrin+ 3 packs 
of C-1 dextrin) 
0 0 0 23.9 0 0 0 0 0 
Elemental, High fat (6 packs of Elental + 6 packs of C-1 dextrin) 0 0 0 23.9 0 0 0 0 0 
Gassull et al. (2002)11  Polymeric, high in n-9 MUFA 0 0 0 79 0 0 0 0 0 
Polymeric, high in n-6 PUFA 0 0 0 28.2 0 0 0 0 0 
Giaffer et al. (1990)21 Elemental (Vivonex) 0.1 0 0 13.4 0 0.2 0 0 0.2 
Polymeric (Fortison) 0.15 0 0 41.05 0 0.8 0 0.25 0.15 
Leiper et al. (2001)16  Polymeric, 5% LCT 0 0 0 3.4 0 0 0 0 0 
Polymeric, 30% LCT 0 0 0 35.5 0 0 0 0 0 
Mansfield et al. (1995)22 Elemental (E028) 0 0 0 58 0 1 0 0 0 
Semi-elemental (Pepti-2000 LF liquid) 0.05 0 0 13.85 0 0.15 0 0 0 
Middleton et al. (1995)7  Elemental (E028) 0 0 0 58 0 1 0 0 0 
Elemental (E028), High LCT 0 0 0 66 0 1 0 1 0 
Elemental (E028), High MCT 0 0 0 42 0 0 0 0 0 
Semi-elemental (Peptide 2+) 0 0 0 11.7 0 0 0 0 0 
Park et al. (1991)25 Elemental (E028) 0.2 0 0.1 47.9 0 1.3 0 0.1 0 
Polymeric (Enteral 400) 0.15 0 0.08 36.4 0 0.98 0 0.08 0 
Raouf et al. (1991)30  Elemental (EO28) 0 0 0 58 0 1 0 0 0 
Polymeric (Triosorbon) 0 0 0 4.9 0 0 0 0 0 
Rigaud et al. (1991)13 Elemental (Vivonex HN) 0.1 0 0 13.4 0 0.2 0 0 0.2 
Royall et al. (1994)23  Elemental (Vivonex-TEN) 0.1 0 0 13.4 0 0.2 0 0 0.2 
Semi-elemental (Peptamen) 0 0 0 6.63 0 0.06 0 0 0 
Sakurai et al. (2002)15 Elemental, Low fat (Elental) 0.2 0 0 23.9 0 0.1 0 0 0 
Semi-elemental, High MCT (Twinline) 0 0 0 3.75 0 0.05 0 0 0.05 
Verma et al. (2000)31 Elemental 0 0 0 45 0 0 0 0 0 
Polymeric 0 0 0 45 0 0 0 0 0 
Gonzalez-Huix et al. (1993)32 Polymeric (Edanec HN) 0 0 0 41 0 0 0 0 0 
Lindor et al. (1992)28 Semi-elemental (Vital HN) 0.06 0 0 12.16 0 0.1 0 0.06 0 
Lochs et al. (1991)33 Semi-elemental (Peptisorb) 0.1 0 0 11.95 0 0.05 0 0 0 
Malchow et al. (1990)34 Semi-elemental (Survimed) 0.1 0 0 22.1 0 0.2 0 0.1 0 
Greenberg et al. (1988)35 Polymeric (Precision-Isotonic) 0.2 0 0 23.9 0 0.1 0 0 0 
Kobayashi et al. (1998)36  Elemental (Elental) 0.2 0 0 23.9 0 0.1 0 0 0 
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Polymeric (Clinimeal) 0.05 0 0 16.85 0 0.2 0 0 0 
Mantzaris et al. (1996)12 Polymeric (Nutrison HE) 0.14 0 0 31.2 0 0.2 0 0 0 
O'moráin et al. (1984)37 Elemental (Vivonex) 0.1 0 0 13.4 0 0.2 0 0 0.2 
Gorard et al. (1993)38 Elemental (vivonex TEN) 0.1 0 0 13.4 0 0.2 0 0 0.2 
Okada et al. (1990)24 Elemental (elental) 0.2 0 0 23.9 0 0.1 0 0 0 
Bodemar et al. (1991)18 Polymeric (Semper lowfat) 0.2 0 0 23.9 0 0.1 0 0 0 
Coyle and Sladen (1989)39 Polymeric (Enteral 250) 0.1 0 0 27.7 0 0.3 0 0 0 
Riordan et al. (1993)19 Elemental (E028) 0 0 0 58 0 1 0 0 0 
Guo et al. (2013)40 Polymeric (Nutrison Fibre) 0 0 0 56.4 0 0 0 0 0 
Zoli et al. (1997)20 Semi-elemental (Peptamen) 0 0 0 6.63 0 0.06 0 0 0 
Hu et al. (2014)17 Semi-elemental (Peptisorb liquid) 0.1 0 0 12.7 0 0.05 0 0 0 
Zhu et al. (2013)41 Polymeric (Nutrison Fibre) 0 0 0 56.4 0 0 0 0 0 
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Appendix 6: Polyunsaturated fatty acids for enteral nutritional formulas 
 
Study Type of enteral nutrition Total Polyunsaturated Fatty acids 
C18:2 n-6 
Linoleic 
acid 
C18:3 n-3 
Linolenic 
acid 
C18:3 
n-6 
C18:4 n-3 C20:2 n-6 C20:3 n-6 C20:4 n-6 
Arachidonic 
acid 
C20:5 n-3 C22:2 n-6 C22:4 n-6 
Bamba et al. (2003)14  Elemental, Low fat (6 packs of Elental + 6 packs of dextrin) 51.6 7.7 0 0 0 0 0 0 0 0 
Elemental, Medium fat (6 packs of Elental + 3 packs of dextrin+ 3 packs 
of C-1 dextrin) 
51.6 7.7 0 0 0 0 0 0 0 0 
Elemental, High fat (6 packs of Elental + 6 packs of C-1 dextrin) 51.6 7.7 0 0 0 0 0 0 0 0 
Gassull et al. (2002)11  Polymeric, high in n-9 MUFA 6.5 1.5 0 0 0 0 0 0 0 0 
Polymeric, high in n-6 PUFA 45 1.6 0 0 0 0 0 0 0 0 
Giaffer et al. (1990)21 Elemental (Vivonex) 76 0.3 0 0 0 0 0.5 0.5 0 0 
Polymeric (Fortison) 43.55 5.2 0 0 0.05 0 0 0 0 0 
Leiper et al. (2001)16  Polymeric, 5% LCT 7.4 1 0 0 0 0 0 0 0 0 
Polymeric, 30% LCT 9.5 1.2 0 0 0 0 0 0 0 0 
Mansfield et al. (1995)22 Elemental (E028) 20 1 0 0 0 0 0 0 0 0 
Semi-elemental (Pepti-2000 LF liquid) 28.05 0.5 0 0 0 0 0 0 0 0 
Middleton et al. (1995)7  Elemental (E028) 20 1 0 0 0 0 0 0 0 0 
Elemental (E028), High LCT 17 4.5 0 0 0 0 0 0 0 0 
Elemental (E028), High MCT 11 3 0 0 0 0 0 0 0 0 
Semi-elemental (Peptide 2+) 22.5 0.4 0 0 0 0 0 0 0 0 
Park et al. (1991)25 Elemental (E028) 30.2 0.4 0 0 0 0 0 0 0 0 
Polymeric (Enteral 400) 22.9 0.3 0 0 0 0 0 0 0 0 
Raouf et al. (1991)30  Elemental (EO28) 20 1 0 0 0 0 0 0 0 0 
Polymeric (Triosorbon) 14.4 0.1 0 0 0 0 0 0 0 0 
Rigaud et al. (1991)13 Elemental (Vivonex HN) 76 0.3 0 0 0 0 0.5 0.5 0 0 
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Royall et al. (1994)23  Elemental (Vivonex-TEN) 76 0.3 0 0 0 0 0.5 0.5 0 0 
Semi-elemental (Peptamen) 19.68 0.15 0 0 0 0 0 0 0 0 
Sakurai et al. (2002)15 Elemental, Low fat (Elental) 52.1 7.8 0 0 0 0 0 0 0 0 
Semi-elemental, High MCT (Twinline) 21.28 0.08 0 0 0 0 0.14 0.14 0 0 
Verma et al. (2000)31 Elemental 12 - - - - - - - - - 
Polymeric 12 - - - - - - - - - 
Gonzalez-Huix et al. (1993)32 Polymeric (Edanec HN) - - - - - - - - - - 
Lindor et al. (1992)28 Semi-elemental (Vital HN) 36.08 0.3 0 0 0 0 0 0 0 0 
Lochs et al. (1991)33 Semi-elemental (Peptisorb) 26.05 3.9 0 0 0 0 0 0 0 0 
Malchow et al. (1990)34 Semi-elemental (Survimed) 65.6 0.5 0 0 0 0 0 0 0 0 
Greenberg et al. (1988)35 Polymeric (Precision-Isotonic) 52.1 7.8 0 0 0 0 0 0 0 0 
Kobayashi et al. (1998)36  Elemental (Elental) 
52.1 7.8 0 0 0 0 0 0 0 0 
Polymeric (Clinimeal) 28.95 0.55 0 0 0 0 0 0 0 0 
Mantzaris et al. (1996)12 
Polymeric (Nutrison HE) 
30.63 0.61 0 0 0 0 0 0 0 0 
O'moráin et al. (1984)37 
Elemental (Vivonex) 
76 0.3 0 0 0 0 0.5 0.5 0 0 
Gorard et al. (1993)38 
Elemental (vivonex TEN) 
76 0.3 0 0 0 0 0.5 0.5 0 0 
Okada et al. (1990)24 
Elemental (elental) 
52.1 7.8 0 0 0 0 0 0 0 0 
Bodemar et al. (1991)18 
Polymeric (Semper lowfat) 
52.1 7.8 0 0 0 0 0 0 0 0 
Coyle and Sladen (1989)39 
Polymeric (Enteral 250) 
56.1 1 0 0 0 0 0 0 0 0 
Riordan et al. (1993)19 
Elemental (E028) 
20 1 0 0 0 0 0 0 0 0 
Guo et al. (2013)40 
Polymeric (Nutrison Fibre) 
- - - - - - - - - - 
Zoli et al. (1997)20 
Semi-elemental (Peptamen) 
19.68 0.15 0 0 0 0 0 0 0 0 
Hu et al. (2014)17 
Semi-elemental (Peptisorb liquid) 
27.6 4.1 0 0 0 0 0 0 0 0 
Zhu et al. (2013)41 
Polymeric (Nutrison Fibre) 
- - - - - - - - - - 
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Appendix 7: Downs and Black quality assessment checklist for included trials 
 
Reference  Reporting (11) External validity 
(3) 
Internal validity 
(bias) (7) 
Internal validity 
(confounding-
selection bias) 
(6) 
Power 
(1)* 
Overall score 
(28) 
Bamba et al. (2003)14 10 1 5 4 0 20 
Gassull et al. (2002)11 11 2 7 5 1 26 
Giaffer et al. (1990)21 9 2 5 5 0 21 
Leiper et al. (2001)16 10 1 5 4 1 21 
Mansfield et al. (1995)22 9 1 5 5 1 21 
Middleton et al. (1995)7 9 2 3 3 0 17 
Park et al. (1991)25 9 1 6 3 0 19 
Raouf et al. (1991)30 10 1 3 2 0 16 
Rigaud et al. (1991)13 9 1 5 3 0 18 
Royall et al. (1994)23 11 1 6 3 0 21 
Sakurai et al. (2002)15 9 1 5 3 0 18 
Verma et al. (2000)31 10 2 7 5 0 24 
Gonzalez-Huix et al. (1993)32 11 2 5 4 1 23 
Lindor et al. (1992)28 10 1 4 4 0 19 
Lochs et al. (1991)33 10 2 4 2 1 19 
Malchow et al. (1990)34 10 1 4 3 1 19 
Greenberg et al. (1988)35 10 1 5 5 0 21 
Kobayashi et al. (1998)36 9 1 4 4 0 18 
Mantzaris et al. (1996)12 4 1 3 2 0 10 
O'moráin et al. (1984)37 9 1 4 2 0 16 
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Gorard et al. (1993)38 9 1 4 3 0 17 
Okada et al. (1990)24 9 1 4 3 0 17 
Bodemar et al. (1991)18 9 1 5 2 0 17 
Coyle and Sladen (1989)39 9 1 4 2 0 16 
Riordan et al. (1993)19 9 2 4 3 0 18 
Guo et al. (2013)40 10 2 5 4 0 21 
Zoli et al. (1997)20 8 2 4 4 0 18 
Hu et al. (2014)17 10 1 5 3 0 19 
Zhu et al. (2013)41 10 2 5 4 0 21 
                                                         176 
 
Appendix 8: The Norwich Biorepository information sheet and consent form 
for patients  
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Appendix 9: qRT-PCR data normalization  
 
 
 
GeNorm M graph presenting the average expression stability of the 
housekeeping candidate genes. The geNorm M graph shows the ranking of the 
reference candidate genes according to their stability, expressed in geNorm M values, 
from most unstable genes at the left (high M value) to the best reference genes at the 
right (low M value). The threshold value for M is 0.5, with values ≤ 0.5 indicating a 
high expression stability. Three from the five screened housekeeping genes (18S 
rRNA gene (18S), B-actin, and glyceraldehyde-3phosphate dehydrogenase 
(GAPDH)) had M values higher than 0.5, indicating poor expression stability. 
Whereas RPL13a and GUSB had M values lower than 0.5 indicating high expression 
stability.  
 
 
 
 
GeNorm V graph indicating the optimal number of housekeeping  genes. 
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